UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, ~~2024~~2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission File Number: 001-39294

ASSERTIO HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware			85-0598378
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)			(I.R.S. EMPLOYER IDENTIFICATION NUMBER)


100 South Saunders Road, Suite 300, Lake Forest, Illinois (Address of Principal Executive Offices)			60045 (Zip Code)

Registrant’s telephone number, including area code: (224) 419‑7106

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol(s):

Name of each exchange on which registered:

Common Stock, $0.0001 par value

ASRT

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☐

Accelerated Filer

☒

Non-accelerated Filer

☐

Smaller reporting company

☒

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Act). Yes ☐ No ☒

The aggregate market value of the shares of common stock held by non‑affiliates of the registrant, computed by reference to the closing price as reported on the Nasdaq Capital Market as of June 30, ~~2024~~2025, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $~~116~~60.17 million.

The number of shares outstanding of the registrant’s common stock, $0.0001 par value, as of March 79, ~~2025~~2026 was 956,~~773~~445,~~083~~161.

Documents Incorporated by Reference`

Part III of this Annual Report on Form 10-K incorporates by reference portions of the registrant’s Proxy Statement for its 2026 Annual Meeting of Stockholders, which Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the registrant’s 2025 fiscal year.

ASSERTIO HOLDINGS, INC.

FORM 10‑K FOR THE FISCAL YEAR ENDED DECEMBER 31, ~~2024~~2025

TABLE OF CONTENTS



Forward-Looking Statements

PART I
Item 1.			Business
Item 1A.			Risk Factors
Item 1B.			Unresolved Staff Comments
Item 1C.			Cybersecurity
Item 2.			Properties
Item 3.			Legal Proceedings
Item 4.			Mine Safety Disclosures

PART II
Item 5.			Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities
Item 6.			[Reserved]
Item 7.			Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A.			Quantitative and Qualitative Disclosures about Market Risk
Item 8.			Financial Statements and Supplementary Data
Item 9.			Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A.			Controls and Procedures
Item 9B.			Other Information
Item 9C.			Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

PART III
Item 10.			Directors, Executive Officers and Corporate Governance
Item 11.			Executive Compensation
Item 12.			Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters
Item 13.			Certain Relationships and Related Transactions, and Director Independence
Item 14.			Principal Accountant Fees and Services

PART IV
Item 15.			Exhibits and Financial Statement Schedules
Item 16.			Form 10-K Summary
			Signatures

Unless otherwise noted or required by context, use of “Assertio,” the “Company,” “we,” “our” and “us” refer to Assertio Holdings and/or its applicable subsidiary or subsidiaries. Reference to “Assertio Specialty” refers to Assertio Specialty Pharmaceuticals, LLC and “Spectrum” refers to Spectrum Pharmaceuticals, Inc. and/or its applicable subsidiary or subsidiaries. Both Assertio Specialty and Spectrum are wholly-owned subsidiaries of the Company. Additionally, the use of “Assertio Therapeutics” ~~or “Depomed”~~ refers to Assertio Therapeutics, Inc., and/or its applicable subsidiary or subsidiaries. Assertio Therapeutics was divested on May 9, 2025.

Assertio®, Zyla®, Spectrum®, ROLVEDON®, INDOCIN®, Otrexup®, Sympazan®, SPRIX®, and CAMBIA® are trademarks owned by or licensed to Assertio. All other trademarks and trade names referenced in this Annual Report on Form 10-K are the property of their respective owners. Such terms, when first mentioned in this Annual Report on Form 10-K, appear with the trade name, trademark or service mark notices and then throughout the remainder of this Annual Report on Form 10-K without the trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense. Unless otherwise indicated, all statistical information provided about our business in this report is as of December 31, ~~2024~~2025.

CAUTIONARY NOTE REGARDING FORWARD‑LOOKING STATEMENTS

Statements made in this Annual Report on Form 10‑K that are not statements of historical fact are forward‑looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements can in some cases be identified by words such as “anticipate,” “approximate”,” “believe,” “could”,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “opportunity,” “plan,” “potential,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “will” and other similar expressions, or the negative of these words and phrases. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to, and depend on, among other things, events, competitive dynamics and industry change, and economic or other circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report on Form 10-K. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report on Form 10-K, they may not be predictive of results or developments in future periods.

Examples of forward-looking statements in this Annual Report on Form 10-K include, but are not necessarily limited to, those relating to:

•our ability to grow sales and the commercial success and market acceptance of ROLVEDON and our other products, including the coverage of our products by payors and pharmacy benefit managers;

•our ability to successfully develop and execute our sales, marketing and ~~promotion~~promotional strategies ~~using our sales force and omni-channel promotion model capabilities~~, including developing and maintaining relationships with customers, physicians, payors and other constituencies;

•the entry and sales of generics of our products and/or other products competitive with any of our products, including, but not limited to, biosimilars and indomethacin suppositories compounded by hospitals and other institutions and a 503B compounder which we believe is violating certain provisions of the Federal Food, Drug and Cosmetic Act;

•the timing and impact of additional generic approvals and uncertainty around the recent approvals and launches of generic INDOCIN products, which are not patent protected and now face generic competition, on our future results of operations, financial condition, and cash flows;

•our ability to execute the planned simplification of our corporate structure, which includes the May 2025 divestiture of Assertio Therapeutics and ongoing efforts to consolidate operations and align ROLVEDON and other products under a single entity, while ensuring uninterrupted product supply for patients that achieves the anticipated operating efficiencies in a timely manner and complies with applicable legal and regulatory requirements;

•our ability to successfully identify and execute business development and other strategic transactions;

•our ability to achieve the expected financial performance from products we acquire, as well as delays, challenges and expenses, and unexpected liabilities and costs associated with integrating and operating newly-acquired products, including our expectations around our ability to grow the sales and profitability of ROLVEDON;

•our expectations regarding changes in product volume and mix and the impact those changes may have on our operating results;

•our ability to achieve the expected financial performance from product candidates and/or products we acquire, as well as delays, challenges and expenses, and unexpected liabilities and costs associated with obtaining regulatory approval and launching or integrating, as applicable, and operating newly-acquired product candidates and/or products, including our expectations around our ability to grow the sales and profitability of ROLVEDON;

•our expectations regarding changes in product volume and mix and the impact those changes may have on our operating results;

•our expectations regarding the recoverability of long-lived assets;

•our expectations regarding industry trends, including pricing pressures and managed healthcare practices;

•our ability to retain executive leadership and key employees;

•the ability of our third-party manufacturers to manufacture adequate quantities of commercially salable inventory and active pharmaceutical ingredients for each of our products on commercially reasonable terms and in compliance with their contractual obligations to us, and our ability to maintain our supply chain which relies on single-source suppliers;

•the outcome of, and our intentions with respect to, any ~~litigation or government investigations, including~~ pending and potential future ~~shareholder~~disputes, litigation ~~relating to the Spectrum Merger and/~~or ~~the recent approval and launch of generic indomethacin suppositories, opioid-related~~ government investigations ~~and opioid-related litigation~~, Spectrum’s legacy shareholder and other litigation, and other disputes and litigation including our antitrust and unsealed qui tam litigation for which settlements in principle were reached in the third and fourth quarters, respectively, of 2024, as well as the costs and expenses associated therewith;

•the timing, cost, results and ~~results~~impact of our clinical studies and other research and development efforts, including the extent to which data from the ROLVEDON same-day dosing trial, which was completed in the fourth quarter of 2024 and published in the January 2026 issue of the peer-reviewed journal, The Oncologist, may be subsequently included in the National Comprehensive Cancer Network guidelines in support of our ongoing commercialization efforts;

•our compliance or non-compliance with, or being subject to, legal and regulatory requirements related to the development or promotion of pharmaceutical products in the United States (“U.S.”);

•the extent to which the current U.S. federal administration may impose or seek to impose leadership, rule and/or policy changes impacting our business, including the Centers for Medicare & Medicaid Services’ (“CMS”) recently proposed new drug payment models to lower drug prices for Medicare beneficiaries under which CMS would explore potential adjustments to Medicare drug inflation rebate calculations by comparison to international drug pricing information, as well as legal challenges and uncertainty around the funding, functioning, regulatory and policy priorities of U.S. federal regulatory agencies;

•the potential impacts of future outbreaks of epidemics, pandemics or other diseases on our liquidity, capital resources, operations and business and those of the third parties on which we rely, including suppliers and distributors;

•our ability to obtain and maintain intellectual property protection for our products and operate our business without infringing the intellectual property rights of others;

•our ability to generate sufficient cash flow from our business to fund operations and to make payments on our indebtedness, our ability to restructure or refinance our indebtedness, if necessary, and our compliance with the terms and conditions of the agreements governing our indebtedness;

•our ability to raise additional capital or refinance our debt, if necessary;

•our intentions or expectations regarding the use of available funds and any future earnings or the use of net proceeds from securities offerings;

•our commitments and estimates regarding future obligations, contingent consideration obligations and other expenses, future revenues, capital requirements and needs for additional financing;

•our counterparties’ compliance or non-compliance with their obligations under our agreements;

•variations in revenues obtained from commercialization agreements, which may include contingent milestone payments, royalties, license fees and other contract revenues, including non-recurring revenues, and the accounting treatment with respect thereto;

•the estimation, projection or availability of net operating losses or tax credit carryforwards;

•the potential impacts of adverse business and economic conditions including inflationary pressures, economic slowdown or recession, relatively high interest rates, changes in monetary policy, potential U.S. federal government shutdowns, geopolitical conflicts and financial institution instability;

•the potential impacts of ~~changes~~adverse tobusiness ~~U.S.~~and ~~policy~~economic conditions, ~~especially~~including ininflationary ~~light of recent comments made by the new U.S. federal administration~~pressures, ~~which~~economic ~~may~~slowdown ~~result~~or ~~in changes to existing trade agreements~~recession, ~~the~~relatively ~~imposition~~high ofinterest ~~new tariffs (including potential tariffs on imported pharmaceuticals into the U.S.) and greater restrictions on trade generally~~rates, asgovernment ~~well~~shutdowns ~~as support for protectionism~~ and ~~rising~~changes ~~anti-globalization sentiment~~ in ~~the~~monetary ~~U.S. and other countries that may slow global growth~~policy;

•the potential impacts of changes to U.S. and international trade policies, especially in light of the tariffs announced or imposed by the U.S. federal administration, including announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals, subject to certain exceptions, and tariffs and other retaliatory actions, including legal challenges, taken by other countries, which may be followed by further changes to trade agreements, the imposition of further tariffs and greater restrictions on trade generally, as well as support for protectionism and rising anti-globalization sentiment in the U.S. and other countries that may slow global growth;

•the potential impacts of cybersecurity breaches on our compliance with applicable laws, our intellectual property protection and our operations; and

•our common stock ~~regaining and~~ maintaining compliance with The Nasdaq Capital Market’s ~~minimum~~continued ~~closing~~listing ~~bid requirement of at least $1~~standards.~~00 per share in light of the deficiency notification received on January 22, 2025.~~

Please refer to “Item 1A. Risk Factors” and elsewhere in this Annual Report on Form 10‑K for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. While the list of factors presented in this Annual Report on Form 10‑K are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements are made as of the date of this report. Except as required by law, we assume no obligation to update or revise any forward-looking statement after the date of this Annual Report on Form 10‑K, whether as a result of new information, future events, changes in assumptions or otherwise. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in any such forward‑looking statement.

PART I

ITEM 1. BUSINESS

Overview

WeUnless ~~are~~otherwise anoted ~~pharmaceutical~~or ~~company~~required ~~with~~by ~~comprehensive~~context, ~~commercial~~use ~~capabilities~~of ~~offering~~“Assertio,” ~~differentiated~~the ~~products~~“Company,” ~~designed~~“we,” “our” and “us” refer to ~~address~~Assertio ~~patients’~~Holdings ~~needs~~and/or its applicable subsidiary or subsidiaries. ~~Our~~Reference ~~focus~~to is“Assertio onSpecialty” ~~supporting~~refers ~~patients~~to byAssertio ~~marketing~~Specialty ~~products~~Pharmaceuticals, inLLC, ~~oncology~~and “Spectrum” refers to Spectrum Pharmaceuticals, ~~neurology~~Inc. and/or its applicable subsidiary or subsidiaries. Both Assertio Specialty and Spectrum are wholly-owned subsidiaries of the Company. Additionally, the use of “Assertio Therapeutics” refers to Assertio Therapeutics, Inc., and/or ~~pain~~its ~~management~~applicable subsidiary or subsidiaries. Assertio Therapeutics was divested on May 9, 2025.

We ~~have~~are ~~built our product portfolio through the acquisition or licensing of approved products, including our lead product, ROLVEDON, which we acquired on July 31, 2023, through~~ a ~~merger~~pharmaceutical ~~with~~company ~~Spectrum Pharmaceuticals, Inc. (“Spectrum”, and the merger~~ with ~~Spectrum~~comprehensive ~~the~~commercial ~~“Spectrum~~capabilities ~~Merger”).~~offering ~~ROLVEDON~~differentiated isproducts ~~the~~designed first, long-acting myeloid growth factor that has a unique molecular structure that combines a granulocyte colony-stimulating factor (“G-CSF") analog with a Fc fragment of human immunoglobulin G4 (IgG4). ROLVEDON is indicated to ~~decrease~~address ~~the incidence of infection, as manifested by febrile neutropenia, in adult~~ patients ~~receiving anti-cancer drugs. We believe that ROLVEDON~~’s ~~profile provides opportunities in both hospitals and community oncology clinics~~needs. WeOur ~~are~~focus ~~working~~is toon ~~identify~~supporting ~~further~~patients ~~opportunities~~by ~~for~~marketing ~~ROLVEDON~~products ~~commensurate~~primarily ~~with the successful completion of our same-day dosing clinical study, which was completed~~ in the ~~fourth~~oncology ~~quarter of 2024~~market.

~~Sympazan~~We have built our product portfolio through the acquisition or licensing of approved products, including our lead product, ROLVEDON, which we acquired inon ~~October~~July of31, ~~2022~~2023, ~~utilizes~~through ~~clobazam~~a ~~and~~merger iswith ~~indicated~~Spectrum ~~for~~(the “Spectrum Merger”). ROLVEDON is the ~~adjunctive~~first, ~~treatment~~long-acting ofmyeloid ~~seizures~~growth ~~associated~~factor ~~with~~that ~~Lennox~~has a unique molecular structure that combines a granulocyte colony-~~Gastaut~~stimulating ~~Syndrome~~factor (“~~LGS”~~G-CSF") ~~for~~analog ~~patients~~with ~~older~~an ~~than~~Fc ~~two~~fragment ~~years~~ of ~~age.~~human ~~Sympazan~~immunoglobulin ~~differentiates~~G4. ~~itself~~ROLVEDON ~~from~~is ~~other~~indicated ~~clobazam~~to ~~products~~decrease ~~through~~the ~~its~~incidence ~~use~~ of ~~PharmFilm®~~infection, ~~technology~~as tomanifested ~~provide~~by ~~clobazam~~febrile neutropenia, in aadult ~~convenient~~patients ~~film~~receiving anti-cancer drugs. We believe that ~~adheres~~ROLVEDON’s profile provides opportunities in both hospitals and community oncology clinics, and we are working to identify further opportunities for ROLVEDON. For example, we presented the ~~tongue~~results of our same-day dosing trial in December 2024 and ~~which~~March ~~may~~2025. beIn ~~beneficial~~January 2026, the full manuscript was accepted for ~~patients~~publication ~~that~~in ~~experience~~the ~~trouble~~peer-reviewed ~~swallowing~~journal, ~~traditional~~The ~~oral~~Oncologist, ~~clobazam.~~and the data is widely available via open access.

Our other products include ~~Otrexup~~Sympazan, which was acquired in ~~December~~October ~~2021~~2022, SPRIX and INDOCIN, which were acquired through a merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”), and CAMBIA, which was acquired in December 2013. Prior to July 2025, our other products included Otrexup, which was acquired in December 2021. We ceased commercialization of Otrexup in July 2025.

Our commercial capabilities include marketing through a sales force for ROLVEDON, both a sales force and omni-channel promotional model for Sympazan and an omni-channel promotional model for our other products. This omni-channel sales platform supports Sympazan and our other products through a non-personal promotion model that blends digital channels, remote virtual representatives, and machine learning (“ML”). Key aspects of our commercial model include (i) a patient-centric approach, (ii) differentiated products in oncology, neurology, and pain management that set us apart in a competitive market, (iii) patient/provider services to improve adoption of our products and enhance the overall patient experience, and (iv) increased accessibility, which is vital to reaching a broader patient population. Additionally, our executive leadership team has extensive commercial execution and business development experience that supports our commercial capabilities and our sales force.

Our primary marketed products are:

ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use			A long-acting ~~granulocyte colony-stimulating factor (~~“G-CSF”) with a novel formulation that is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Sympazan® (clobazam) oral film			A benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (“LGS”) in patients aged two years of age or older. Sympazan is the only product to offer clobazam in a convenient film with PharmFilm® technology. Sympazan is taken without water or liquid, adheres to the tongue, and dissolves to deliver clobazam.
INDOCIN® (indomethacin) Suppositories			A suppository and oral solution of indomethacin used both in hospitals and out-patient settings. Both products are nonsteroidal anti-inflammatory drugs (“NSAIDs”), indicated for:
			• Moderate to severe rheumatoid arthritis including acute flares of chronic disease
			• Moderate to severe ankylosing spondylitis
INDOCIN® (indomethacin) Oral Suspension			• Moderate to severe osteoarthritis
			• Acute painful shoulder (bursitis and/or tendinitis)
			• Acute gouty arthritis
Otrexup® (methotrexate)injection for subcutaneous use			A once weekly single-dose auto-injector containing methotrexate. Otrexup is a folate analog metabolic inhibitor indicated for the:
			• Management of patients with severe, active rheumatoid arthritis (“RA”) and polyarticular juvenile idiopathic arthritis (“pJIA”), who are intolerant of or had an inadequate response to first-line therapy.
			• Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.
SPRIX® (ketorolac tromethamine) Nasal Spray			A prescription NSAID indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at an opioid level. SPRIX is a non-narcotic nasal spray that provides patients with moderate to moderately severe short-term pain relief through a form of ketorolac that is absorbed rapidly but does not require an injection administered by a healthcare provider.
CAMBIA® (diclofenac potassium for oral solution)			A prescription NSAID indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. CAMBIA can help patients with migraine pain, nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). CAMBIA is not a pill; it is a powder, and combining CAMBIA with water activates the medicine in a unique way.

~~Results~~2025 ~~Overview~~Transactions

InOn ~~2024~~May 9, 2025, we ~~generated~~transferred ~~$120.8~~all ~~million~~the ofequity ~~net~~interests ~~product~~in ~~sales,~~Assertio ~~compared~~Therapeutics ~~with~~to ~~$149.5~~an ~~million~~established inpurchaser ~~2023~~of legacy litigation matters, ~~with~~resulting ~~ROLVEDON~~in ~~contributing~~Assertio ~~$60.1~~Therapeutics ~~million~~being ofowned ~~net~~by ~~product~~the ~~sales.~~purchaser’s ~~INDOCIN~~related company, ~~which~~ATIH ~~prior~~Industries, toLLC ~~2024~~(the ~~was~~“Therapeutics ~~our~~Transaction”). ~~highest~~At ~~selling~~the ~~product~~closing of the Therapeutics Transaction, ~~generated~~Assertio Therapeutics held approximately $~~26.~~8.2 million ofin cash, insurance and retained a single-digit royalty based on net ~~product~~income ~~sales~~derived from INDOCIN. In addition, ~~despite~~Assertio ~~facing~~Therapeutics ~~generic~~retained ~~competition~~certain ~~throughout~~legal ~~2024.~~liabilities, ~~Sympazan~~including ~~generated~~those ~~$10~~related to opioid litigation.5 ~~million~~As a result of ~~net~~the ~~product~~Therapeutics ~~sales~~Transaction, ~~during~~we ~~2024~~are not defendants in any opioid-related litigation.

~~Our~~In ~~net~~the ~~loss~~third ~~from~~quarter ~~operations~~of in2025, ~~2024~~we ~~was~~advanced ~~$24.5~~key ~~million~~integration efforts to consolidate operations and align our ~~comprehensive~~products, ~~loss~~including ~~was~~ROLVEDON, ~~$21~~under a single subsidiary, Assertio Specialty.6 ~~million~~Sales of ROLVEDON in 2025 reflected normal demand through the first nine months of 2025, ~~compared~~as ~~with~~well ~~net~~as ~~loss~~large ~~from~~purchases ~~operations~~by several national distributors to help ensure consistent supply of ~~$254~~ROLVEDON during the fourth quarter of 2025 and the first quarter of 2026 as we complete the integration of ROLVEDON into Assertio Specialty.1 ~~million~~We did not record material net product sales of ROLVEDON during the fourth quarter of 2025 and ~~comprehensive~~do ~~loss~~not anticipate material net product sales in the first quarter of ~~$331~~2026.9 ~~million~~Sales of the newly labeled ROLVEDON are expected to commence at a normal volume in ~~2023~~the second quarter of 2026.

WeOn ~~generated~~October ~~$26.4~~7, ~~million~~2025, ~~and~~we ~~$49.6~~entered ~~million~~into ofan ~~operating~~amendment ~~cash flow during 2024~~ and ~~2023,~~restatement ~~respectively,~~of ~~and~~the ~~our~~Manufacturing ~~cash, cash equivalents~~ and ~~short-term~~Supply ~~investments~~Agreement ~~exceeded~~(the ~~$100~~“Hanmi ~~million~~Agreement,” as ~~of December 31~~amended, ~~2024.~~the ~~This~~“Amendment”) ~~cash~~with ~~flow~~Hanmi ~~and~~Pharmaceutical ~~significant~~Co. ~~cash,~~Ltd. ~~cash~~(“Hanmi”). ~~equivalents~~The ~~and~~Amendment ~~short-term~~fixes ~~investment~~the ~~balances~~price ~~are~~that ~~expected~~we topay ~~enable~~for usthe toremaining ~~continue~~term toof ~~finance~~ our ~~operations~~license ~~and~~agreement towith ~~engage~~Hanmi inand ~~business~~amends ~~development~~the ~~efforts~~payment timing for ~~additional~~certain ~~products~~product toroyalties ~~add~~due to ~~our portfolio~~Hanmi.

On December 26, 2025, we effected a 1-for-15 reverse stock split of our issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, our stockholders received one share of the Company’s common stock for every 15 shares held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all our issued and outstanding shares of common stock equally. Any fractional shares remaining as a result of the Reverse Stock Split were paid to the shareholder in cash. The par value and number of authorized shares of our common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected our outstanding stock-based awards and convertible senior notes due 2027 and resulted in the shares underlying such instruments being reduced and the

exercise price or conversion price being increased proportionately.

Results Overview

In 2025, we generated $117.1 million of net product sales, compared with $120.8 million in 2024, with ROLVEDON contributing $68.2 million of net product sales in 2025. INDOCIN and Sympazan generated $18.9 million and $11.3 million of net product sales in 2025, respectively. Our net product sales reflect our continued focus on ROLVEDON as our lead product.

Our net loss from operations was $21.5 million and our comprehensive loss was $30.4 million in 2025, compared with net loss from operations of $24.5 million and comprehensive loss of $21.6 million in 2024. Our net loss from operations and comprehensive loss were impacted by the items noted in the “2025 Transactions” section above.

We used $28.2 million of operating cash flow during 2025, compared with $26.4 million of operating cash flow generated during 2024, primarily as a result of the large purchases by several national distributors in the third quarter of 2025 noted above. Our cash, cash equivalents and short-term investments totaled $63.4 million as of December 31, 2025.

Our Business Strategy

~~Our~~We ~~success~~believe ~~depends~~we onare ~~our~~uniquely ~~people,~~positioned ~~our~~to ~~commercial~~create ~~capabilities,~~value ~~our~~for ~~financial~~patients, ~~position~~providers, and ~~the~~shareholders ~~opportunities~~in ~~that~~an ~~exist~~evolving inpharmaceutical ~~the marketplace~~landscape. Our ~~path~~strategy is to ~~commercial~~focus ~~success~~on finding products that leverage our existing capabilities to build an oncology portfolio. Our strategy is ~~built~~talent-driven ~~upon~~and ~~the~~underpinned ~~following~~by ~~foundations:~~proven commercial capabilities and a strong financial foundation.

•Our people ~~— Our people~~ are at the heart of our organization. ~~Their~~We ~~experience,~~believe ~~passion, and dedication drive~~ our ~~innovation and growth. We seek to cultivate a~~ culture of excellence ~~that~~ attracts and retains top talent, ~~which~~with ~~supports~~a ~~our~~shared ~~efforts~~passion tofor ~~stand~~driving atresults. ~~the~~Their ~~forefront~~dedication ofand ~~pharmaceutical~~expertise ~~advancements~~enable us to bring products to market and achieve commercial success.

•Our commercial ~~capabilities~~organization —maximizes Weproduct ~~have~~impact ~~developed~~and areach. ~~commercial~~Our ~~team with capabilities in~~ marketing, sales, and distribution tocapabilities ~~allow~~enable usbroad toproduct ~~bring our innovative products to market, with the aim of maximizing their impact and~~ reach. ~~Our~~We ~~commercial~~maintain ~~organization~~relationships iswith ~~comprised~~key ofpharmaceutical ~~multiple~~stakeholders ~~capabilities~~to ~~including~~ensure ~~marketing~~we ~~through~~remain ~~both~~competitive ain ~~sales~~the ~~force and an omni-channel promotion model,~~ market ~~access program through payor contracting, and trade and distribution~~.

•Our strong financial position —enables Welong-term ~~believe~~growth. ~~our~~Our financial ~~position~~foundation ~~supports~~provides ~~our~~flexibility ~~ability~~ to ~~fuel~~fund long-term growth initiatives, ~~invest in research~~ and pursue strategic acquisitions that ~~complement~~reinforce and expand our ~~strengths~~portfolio.

We ~~believe~~seek weto ~~are~~expand ~~uniquely~~our ~~positioned~~portfolio tothrough ~~leverage~~targeted ~~these~~acquisitions, ~~strengths~~including inindividual aproduct ~~rapidly~~acquisitions, ~~evolving~~commercialization ~~pharmaceutical~~agreements, ~~landscape~~licensing or technology agreements and/or business combinations. We primarily seek: (i) assets that provide commercial synergies with our current products, (ii) marketed products with significant remaining patent life or exclusivity, and (iii) products that are accretive to ~~create~~our ~~sustainable~~operating ~~value~~margins ~~for~~and ~~patients~~cash flows in the near or medium term. We evaluate potential products, ~~healthcare~~both ~~providers~~on-market and in development, that meet these criteria using a disciplined approach that utilizes both internal and ~~shareholders~~external ~~alike~~resources.

~~Our~~We ~~sales~~have ~~force~~recently ~~directly~~incurred ~~markets~~a ~~ROLVEDON.~~significant ~~This~~amount ~~experienced~~of ~~commercial~~expense ~~team~~on ~~seeks~~legal matters related to ~~drive~~various ~~value~~legal ~~with~~proceedings ~~oncology-specific~~as ~~growth~~further ~~opportunities~~described byin ~~building~~“Item ~~strong~~8. ~~relationships~~Financial ~~with~~Statements ~~key~~and ~~oncology~~Supplemental ~~stakeholders~~Data – Note 8. Commitments and aContingencies.” ~~focus~~We onplan ~~all~~to ~~commercial~~continue ~~aspects~~our ~~including~~strategy ~~sales,~~of ~~marketing,~~vigorously ~~national~~defending ~~accounts,~~ourselves ~~contracting,~~in ~~market~~these ~~access~~legal matters and ~~field~~seeking ~~reimbursement.~~to manage them in an efficient and cost-effective manner, while working towards a timely resolution.

Sympazan is marketed through both a sales force and an omni-channel sales platform, while our other products are marketed exclusively through our omni-channel sales platform.

We are also actively looking to expand our product portfolio by acquiring additional products, whether through individual product acquisitions, commercialization agreements, licensing or technology agreements and/or business combinations. In evaluating potential products for acquisition or licensing, we primarily seek assets that provide (i) commercial synergies with our current products, with a particular focus on oncology and neurology, (ii) on-market products that have significant remaining patent life or exclusivity, and/or (iii) products that are, or will be, accretive to our operating margins and cash flows. We evaluate potential products, both in development and on-market, that meet these criteria using a disciplined approach and utilize both internal and external resources to assist us in those evaluations. We also remain open to acquiring or licensing medical devices, informatics, or technology.

We have incurred a significant amount of expense on legal matters related to various legal proceedings as further described in “Item 8. Financial Statements and Supplemental Data – Note 8, Commitments and Contingencies.” We intend to vigorously defend ourselves in these legal matters, and seek to manage them in an efficient and cost-effective manner, while working towards a timely resolution.

Customers

To date, substantially all of our revenues are related to product sales in the U.S. Three large, national wholesale distributors represent the majority of our revenues from net product sales. The following table reflects the percentage of consolidated revenue ~~by customer~~ and ~~the percentage of~~ accounts receivable by customer related to product ~~shipments~~sales for the years ended December 31, ~~2024~~2025 and ~~2023~~2024.

	Consolidated Revenue				Accounts Receivable related to product shipments
	Consolidated revenue				Accounts receivable related to product sales
	For the years ended December 31,				As of December 31,
	Year ended December 31,				As of December 31,
	2024		2023		2024		2023
	2025		2024		2025		2024
Cencora (formerly AmerisourceBergen Corporation)	40	%	35	%	33	%	57	%
Cencora	45	%	40	%	44	%	33	%
McKesson Corporation	3031	%	2130	%	4239	%	1242	%
Cardinal Health	810	%	188	%	610	%	146	%
Other significant customer	7	%	10	%	13	%	10	%
All others	14	%	22	%	7	%	19	%
All others	15	%	16	%	6	%	7	%
Total	100	%	100	%	100	%	100	%

The changes in the percentage of consolidated revenue by customer and the percentage of accounts receivable related to product ~~shipments~~sales by customer for the years ended December 31, ~~2024~~2025 and December 31, ~~2023~~2024 were primarily driven by the ~~impact~~higher sales of ~~change~~ROLVEDON induring ~~product mix~~2025, including the ~~addition of ROLVEDON as a result of the acquisition of Spectrum on July 31, 2023, which resulted in a full year of ROLVEDON net product~~ sales ~~being~~made ~~included~~ in the ~~year~~third ~~ended~~quarter ~~December 31, 2024, compared to five months~~ of ~~net~~2025 ~~product~~noted ~~sales included in the year ended December 31~~above, ~~2023,~~ and the ~~decrease~~continued shift in ~~INDOCIN~~product ~~net~~mix ~~product~~towards ~~sales~~ROLVEDON ~~due~~from toour ~~generic~~other ~~launches~~products. ~~Each~~As wholesale ~~distributor~~distributors ~~purchases~~purchase a different ~~amount~~quantities of each product, ~~therefore~~changes ~~the change~~ in product mix ~~impacts~~impact the percentage of consolidated revenue and the percentage of accounts receivable related to product ~~shipments~~sales by customer.

We sell our products to our customers noted in the table above, who are primarily wholesalers. These wholesalers, in turn, sell our products to their customers, which include, but are not limited to, hospitals, outpatient clinics, and pharmacies. While we generally do not sell directly to the wholesaler’s customers, we build, maintain, and manage relationships with these entities and health care professionals through our sales force ~~and/or omni-channel product promotion model~~ in order to generate demand for our products.

Manufacturing

We neither own nor operate, and currently have no plans to own or operate, any manufacturing facilities. As such, we are dependent on our contract manufacturing partners for timely supply of our products, and our success depends on our ability to maintain good working relationships with our manufacturers.

We are responsible for the supply and distribution of our marketed products. Our approved products are manufactured at contract manufacturing facilities in the U.S., Canada, Italy, and South Korea. We have manufacturing, packaging, and supply agreements with sole commercial suppliers for each of our marketed products and we seek to mitigate potential supply risks for all of our marketed products through inventory management and through ~~exploring~~identifying potential additional manufacturers to provide our marketed products. However, in 2024 and 2025, the manufacturers of certain of our marketed products produced batches of our products that did not meet our quality standards, leading to the loss of salable product, which unfavorably impacted our cost of sales in ~~2024~~both years due to inventory write-downs. While the impacts in 2024 and 2025 related to these quality issues were not material to our financial statements, and we have taken steps to mitigate these quality issues, they may continue to impact cost of sales in ~~2025~~2026.

Drug Substances

The active pharmaceutical ingredient (“API”) used in ROLVEDON is eflapegrastim-xnst, which is sourced by our supplier, Hanmi, in South Korea. Both INDOCIN oral suspension and suppositories use indomethacin as the API. We currently procure the API used in the INDOCIN oral suspension formulation from one of our suppliers in Italy, while the API used in the INDOCIN suppository formulation is procured from Cosette Pharmaceuticals, Inc. Sympazan uses clobazam as the API, which is procured on a purchase order basis by our supplier from a manufacturer based in Italy. ~~OTREXUP uses methotrexate as the API, which is sourced by our supplier from a manufacturer based in Germany.~~ The API used in SPRIX is ketorolac tromethamine, which we acquire from European-based manufacturers. CAMBIA uses diclofenac potassium as the API, which we source from suppliers in Italy.

Manufacturing Requirements

We, our suppliers, contract manufacturers, and other entities involved in the manufacturing and distribution of approved drugs and biological products are required to comply with certain post-approval requirements and are subject to periodic unannounced inspections by the United States Food and Drug Administration (the “FDA”) and state agencies to assess compliance with current Good Manufacturing Practice (“cGMP”) requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Failure to achieve or maintain cGMP standards for our products would adversely impact their marketability.

We use third-party manufacturers to produce our products in clinical and commercial quantities, and we cannot be certain that future FDA inspections will not identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. Additionally, new government requirements regarding manufacturing may be established that could delay or prevent regulatory approval of our products under development.

Intellectual Property

We regard the protection of patents, designs, trademarks, and other proprietary rights that we own as critical to our success and competitive position.

Our Patents and Proprietary Rights

We are either a licensee or owner of U.S. and foreign patents and applications covering ROLVEDON, including patents and applications drawn to its composition of matter, method of manufacture, method of treatment, dosing, and formulation. If not otherwise invalidated (and not accounting for any patent term adjustment, patent term extension, or pediatric extensions that may be available), our issued U.S. patents for ROLVEDON expire in 2039. In addition, ~~including~~we ~~any~~have pending ~~patents~~U.S. patent applications which, ~~expire~~if ~~between~~issued, ~~2031~~would ~~and~~expire in 2042. We continue to prosecute and pursue patent protection to obtain additional patent coverage on ROLVEDON and its uses. Additionally, we have a biologic exclusivity, referred to as reference product exclusivity, in the U.S. covering ROLVEDON that will expire in 2034.

We are either a licensee or owner of U.S. and foreign patents for certain of our other products, including U.S. patents covering Sympazan through 2040, U.S. patents covering Otrexup through 2030, and U.S. patents covering CAMBIA through 2026. Certain parties who have entered into settlement agreements with us ~~are~~began ~~able~~ to market ~~and have begun marketing~~ generic versions of CAMBIA ~~starting~~in January 2023. We also have U.S. patents directed to the processes of manufacture related to SPRIX through 2029, which excludes any potential patent term adjustments.

Our success depends in part on our ability to obtain and maintain patent protection for our products and technologies. Our policy is to seek to protect our proprietary rights, by among other methods, filing patent applications in the U.S. and foreign jurisdictions to cover certain aspects of our technology. We also rely on trade secrets and proprietary know how, which are difficult to protect. We seek to protect such information, in part, through entering into confidentiality agreements with employees, consultants, collaborative partners and others before such persons or entities have access to our proprietary trade secrets and know how.

Collaboration and License Agreements

Searchlight: We have a license agreement with Tribute Pharmaceuticals Canada Ltd. (later known as Aralez Pharmaceuticals, Miravo Healthcare, and ~~now~~ Searchlight Pharma, or “Searchlight,” ~~now~~ owned by Apotex Inc.) granting them the rights to commercially market CAMBIA in Canada. Searchlight independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. We receive royalties on net sales on a quarterly basis ~~as well as certain one-time~~ .

10Under the license agreement, our royalties on net sales are reduced upon the launch of a generic version of CAMBIA in Canada. The patents underlying the license agreement that we have with Searchlight expire in June 2026, and we anticipate that there will be increased generic competition in Canada after the patents expire, or the earlier negotiated launch of generics in Canada in connection with the settlement of patent litigation.

contingent milestone payments upon the occurrence of certain events. We may receive additional one-time contingent milestone payments upon the achievement of scaling twelve-month cumulative sales targets and certain development milestones in the future.

Under the license agreement, our royalties on net sales are reduced upon the launch of a generic version of CAMBIA in Canada. On February 22, 2024, Searchlight commenced a patent infringement action in Canadian federal court against a generic company seeking approval of a generic version of CAMBIA in Canada. On June 9, 2024, Searchlight commenced a second patent infringement action in Canadian federal court against a second generic company seeking approval of a generic version of CAMBIA in Canada. Our royalties from Searchlight’s net sales of CAMBIA in Canada will be reduced if Searchlight’s patent infringement litigations fail to keep the generic companies from launching before the relevant patents expire.

Competition

We face competition from several sources, including pharmaceutical and biotechnology companies, generic drug companies, compounding pharmacies, and medical devices and drug delivery companies. Our sales have been, and will continue ~~to be, impacted by the loss of demand for our products, the lowering of our prices to retain market share for our products, and changes in customer mix (wholesalers, clinics, hospitals).~~

ROLVEDON is a novel long-acting G-CSF that employs a proprietary technology that is designed to prolong the duration of biologics, reducing the frequency of administration. Currently, one other novel long-acting G-CSF and six biosimilar G-CSFs marketed in the U.S. compete with ROLVEDON. In addition, there is one new molecular entity that has been approved by the FDA but is not currently marketed that may compete with ROLVEDON. 10

~~INDOCIN~~to ~~products compete with currently marketed oral opioids, transdermal opioids, local anesthetic patches, stimulants and implantable and external infusion pumps that can~~ be ~~used for infusion of opioids and local anesthetics~~, ~~non-narcotic~~impacted ~~analgesics,~~by ~~local and topical analgesics and anti-arthritics. There are no patents covering~~ the ~~INDOCIN~~loss ~~products~~of ~~and~~demand ~~we are facing generic competition~~ for ~~both~~ our ~~INDOCIN suppositories and INDOCIN oral suspension~~products, ~~including~~the alowering ~~new generic competitor for INDOCIN suppositories that launched in January 2025. In addition, we are aware~~ of ~~other~~our ~~drug~~prices ~~companies that have had interactions with regulatory agencies including the FDA relating~~ to ~~indomethacin,~~retain ~~which~~market ~~could~~share ~~indicate~~for ~~the~~our ~~development of one or more additional INDOCIN product generics or other formulations of indomethacin. In addition~~products, ~~we also face competition for compounded INDOCIN suppositories from hospitals~~ and ~~other~~changes ~~institutions,~~in ~~including~~customer amix ~~503B outsourcing facility~~ (~~commonly~~wholesalers, ~~referred to as a 503B compounder)~~clinics, which began compounding 100 mg indomethacin suppositories in 2022 in what we believe to be violation of state and federal requirements for new drugs and labeling requirements related to adequate directions for usehospitals).

11ROLVEDON is a novel long-acting G-CSF that employs a proprietary technology that is designed to prolong the duration of biologics, reducing the frequency of administration. Currently, two other novel long-acting G-CSF and six biosimilar G-CSFs marketed in the U.S. compete with ROLVEDON. In addition, there is one molecular entity that has been approved by the FDA but is not currently marketed that may compete with ROLVEDON.

INDOCIN products compete with currently marketed oral opioids, transdermal opioids, local anesthetic patches, stimulants and implantable and external infusion pumps that can be used for infusion of opioids and local anesthetics, non-narcotic analgesics, local and topical analgesics and anti-arthritics. There are no patents covering the INDOCIN products, and we are facing generic competition for both our INDOCIN suppositories and INDOCIN oral suspension. In addition, we are aware of other drug companies that have had interactions with regulatory agencies, including the FDA, relating to indomethacin, which could indicate the development of one or more additional INDOCIN product generics or other formulations of indomethacin. In addition, we also face competition for compounded INDOCIN suppositories from hospitals and other institutions, including a 503B outsourcing facility (commonly referred to as a 503B compounder), which began compounding 100 mg indomethacin suppositories in 2022 in what we believe to be violation of state and federal requirements for new drugs and labeling requirements related to adequate directions for use.

Sympazan competes with other generic and branded products in the treatment of LGS, including clobazam tablets and oral solution options. Competition in the LGS marketplace includes branded and generic anti-seizure medications, surgery, neuromodulations, and changes in diet.

~~Otrexup~~CAMBIA competes with ~~other~~a ~~branded~~number ~~methotrexate~~of ~~products,~~triptans ~~including~~that ~~other~~are ~~injection~~used to treat migraines and ~~auto-injector~~certain ~~products~~other headaches. ~~Competition~~Currently, eight triptans are available generically and sold in the ~~methotrexate~~U.S. ~~market~~(almotriptan, ~~also~~eletriptan, ~~includes~~frovatriptan, ~~tablets~~naratriptan, ~~and~~rizatriptan, ~~parenteral~~sumatriptan, ~~dosage~~sumatriptan-naproxen ~~forms~~and zolmitriptan). InThere ~~addition,~~are other ~~commonly~~products ~~used~~prescribed ~~pharmaceutical~~for ~~treatments~~or under development for ~~rheumatoid~~the ~~arthritis~~treatment ~~include~~or ~~analgesics,~~prevention ~~NSAIDs~~of migraines that are now or may become competitive with CAMBIA, ~~corticosteroids~~including ~~and~~CGRP ~~biologic~~inhibitor ~~response~~products. ~~modifiers~~Certain parties who have entered into settlement agreements with us began to market generic versions of CAMBIA starting in January 2023.

CAMBIA competes with a number of triptans that are used to treat migraines and certain other headaches. Currently, eight triptans are available generically and sold in the U.S. (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan-naproxen and zolmitriptan). There are other products prescribed for or under development for the treatment or prevention of migraines that are now or may become competitive with CAMBIA, including CGRP inhibitor products. Certain parties who have entered into settlement agreements with us began to market generic versions of CAMBIA in January 2023.

Government Regulation

FDA Approval Process

In the U.S., pharmaceutical and biological products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (the “FDCA”) and, for biological products, the Public Health Service Act, as well as other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA delay or refusal to approve pending New Drug Applications (“NDAs”) or, for biological products, biologics license applications (“BLAs”), or other marketing applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. The FDA approval process can be time consuming and cost intensive and companies may, and often do, re-evaluate the path of a particular product or product candidate at different points in the approval and post-approval process, even deciding, in some cases, to discontinue development of a product candidate or take a product off the market.

Preclinical and Clinical Studies

Governmental approval is required of all potential prescription pharmaceutical and biological products prior to the commercial use of those products. The regulatory process takes several years and requires substantial funds. Pharmaceutical product development in the U.S. for a new product or changes to an approved product typically involves preclinical laboratory and animal tests, the submission to the FDA of an investigational new drug application (“IND”), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements ~~typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.~~

typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.

Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with current good clinical practices, which includes the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol intended to study an investigational new drug formulation must be submitted to the FDA as part of the IND. Additionally, an independent institutional review board at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences.

Marketing Approval and Post-Approval Requirements

FDA approval of an NDA or BLA is required before a product may be marketed in the U.S. Currently, all of our products are approved to be marketed in the U.S. Even for products that have been approved, the FDA may still limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-marketing safety Phase 4 clinical studies be conducted, require surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, which can materially affect the potential market and profitability of the product. The results of post-marketing Phase 4 clinical studies may cause the FDA to prevent or limit further marketing of a product. After approval, certain changes to the approved product, such as manufacturing changes, new labeling claims, and new indications, are subject to additional requirements and FDA review and approval.

approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-marketing safety Phase 4 clinical studies be conducted, require surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy (“REMS”), which can materially affect the potential market and profitability of the product. The results of post-marketing Phase 4 clinical studies may cause the FDA to prevent or limit further marketing of a product. After approval, certain changes to the approved product, such as manufacturing changes, new labeling claims, and new indications, are subject to additional requirements and FDA review and approval.

Foreign regulatory approval of a product must also be obtained prior to marketing a product in an international market. The clinical testing requirements and the time required to obtain foreign regulatory approvals may differ from that required for FDA approval and the time required for approval may delay or prevent marketing in certain countries. We do not currently have any products that have been approved for marketing outside of the U.S.

Ongoing adverse event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug or biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs and NDA or BLA specifications after approval. Drug and biological product manufacturers and certain of their subcontractors are required to register their establishments with the FDA and obtain licenses from certain state agencies. Registration with the FDA subjects manufacturing facilities to periodic unannounced inspections by the FDA, during which the agency assesses compliance with cGMPs or other applicable laws, such as adverse event recordkeeping and reporting. Accordingly, manufacturers must continue to expend time, money, and training and compliance effort in the areas of production and quality control to maintain compliance with cGMPs or other applicable laws, such as adverse event recordkeeping and reporting requirements. Regulatory authorities may require remediation, withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems or new concerns are subsequently discovered. In addition, other regulatory or enforcement action, including, among other things, warning letters, the seizure of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, civil penalties, and criminal prosecution may be pursued.

Prescription Drug Marketing Act

The Prescription Drug Marketing Act of 1987 and the Prescription Drug Amendments of 1992 govern the storage, handling, and distribution of prescription drug samples. The law prohibits the sale, purchase, or trade (including an offer to sell, purchase or trade) of prescription drug samples. It also imposes various requirements upon manufacturers, including but not limited to, proper storage of samples, documentation of request and receipt of samples, validation of a requesting practitioner’s professional licensure, periodic inventory and reconciliation of samples, notification to the FDA of loss or theft of samples, and procedures for auditing sampling activity. Some similar state laws apply. In addition, section 6004 of the Patient Protection and Affordable Care Act also requires manufacturers to annually report the identity and quantity of drug samples that were requested and distributed to licensed health care providers (“HCPs”) in a given year.

Hatch-Waxman Act

The Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”) establishes two abbreviated approval pathways for pharmaceutical products that are in some way follow-on or bioequivalent versions of drugs ~~approved through the NDA process, including (i) the filing of an ANDA, and (ii) obtaining FDA approval under Section 505(b)(2).~~

In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant’s product, active ingredient, or method of use. Upon approval of a drug, each of the listed patents covering the approved drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book”. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient(s) in the same strengths and dosage form, with essentially the same labeling as the listed drug, and that has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are generally not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. In certain situations, an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability Petition. The FDA will approve the generic product as suitable for an ANDA if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. Drugs approved under 12

13approved through the NDA process, including (i) the filing of an ANDA, and (ii) obtaining FDA approval under Section 505(b)(2).

In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant’s product, active ingredient, or method of use. Upon approval of a drug, each of the listed patents covering the approved drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book.” Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient(s) in the same strengths and dosage form, with essentially the same labeling as the listed drug, and that has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are generally not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. In certain situations, an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability Petition. The FDA will approve the generic product as suitable for an ANDA if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. Drugs approved under an ANDA are commonly referred to as “generic equivalents” to the listed drug and often can or are required to be substituted by pharmacists fulfilling prescriptions written for the original listed drug.

The ANDA applicant is required to certify or make certain representations to the FDA concerning any patents currently listed for the approved product in the FDA’s Orange Book. Specifically, the applicant must certify that: (i) no relevant patent information has been filed, (ii) a listed patent has expired, (iii) a listed patent has not expired but will expire on a particular date and approval is sought after patent expiration, or (iv) a listed patent is invalid, unenforceable or will not be infringed by the marketing of the new product. The ANDA applicant may also submit a statement certifying that its proposed ANDA labeling does not contain (or carves out) any language regarding a patented method‑of‑use. If the ANDA applicant does not challenge the applicability of the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced NDA product have expired. The ANDA application also will not be approved until any applicable non‑patent exclusivity listed in the Orange Book for the referenced product has expired.

Section 505(b)(2) of the FDCA provides an alternate regulatory pathway to obtain FDA approval for product candidates that represent modifications to formulations or uses of previously approved drug products. Specifically, Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely to some extent upon the FDA’s findings of safety and effectiveness for an approved product that acts as the reference listed drug (“RLD”) and submit its own product-specific data—which may include data from preclinical studies or clinical trials conducted by or on behalf of the applicant—to address differences between the product candidate and the RLD. Unlike an ANDA, this approval pathway does not excuse the sponsor from demonstrating the proposed product candidate’s safety and effectiveness. Rather, the sponsor is permitted to rely to some degree on the FDA’s finding that the RLD is safe and effective, and must submit its own product candidate-specific data of safety and effectiveness to an extent necessary because of the differences between the products. An NDA approved under Section 505(b)(2) may in turn serve as an RLD for subsequent applications from other sponsors.

The Hatch-Waxman Act provides periods of regulatory exclusivity for products that would serve as ~~reference-listed drugs (“~~RLDs”) for products that are subject of an ANDA or 505(b)(2) application. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity (“NCE”)—a drug that contains no active moiety that has been approved by the FDA in any other NDA. An “active moiety” is defined as the molecule or ion responsible for the drug substance’s physiological or pharmacologic action. During this five-year exclusivity period, the FDA may not accept for filing any ANDA seeking approval of a generic version of that drug or any 505(b)(2) application for a drug with the same active moiety. An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a paragraph IV certification.

A product that is not an NCE, including a product approved through a 505(b)(2) NDA, may qualify for a three-year period of exclusivity if the NDA contains new clinical data, derived from studies conducted by or for the sponsor (other than bioavailability or bioequivalence studies), that were essential for approval. In that instance, the exclusivity period does not preclude filing or review of the ANDA or 505(b)(2) application; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2) application until three years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that required submission of the clinical data. For example, if an NDA is submitted for a product candidate that is not an NCE, but that seeks approval for a new indication, and clinical data were required to demonstrate the safety or effectiveness of the product candidate for that new application, the FDA could not approve an ANDA or 505(b)(2) application for another product candidate with that active moiety for that use.

safety or effectiveness of the product candidate for that new application, the FDA could not approve an ANDA or 505(b)(2) application for another product candidate with that active moiety for that use.

The Biologics Price Competition and Innovation Act

The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010, (collectively, the “ACA”) includes a subtitle called the Biologics Price Competition and Innovation Act (“BPCIA”), which authorizes the FDA to license a biological product candidate that is biosimilar to or interchangeable with an FDA-licensed biologic through an abbreviated pathway. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being addressed by the FDA.

often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being addressed by the FDA.

The BPCIA establishes criteria for determining that a product candidate is biosimilar to an already-licensed biologic, or reference product, and establishes a process by which a BLA for a biosimilar product candidate is submitted, reviewed, and licensed. The BPCIA provides periods of exclusivity that protect a reference product from biosimilars competition. Under the BPCIA, the FDA may not accept a biosimilar application for review until four years after the date of first licensure of the reference product, and the biosimilar may not be licensed until at least 12 years after the reference product’s approval. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product.

Additionally, the BPCIA establishes procedures by which the biosimilar applicant provides information about its application and product candidate to the reference product sponsor, and by which information about potentially relevant patents may be shared and litigation over patents may proceed in advance of approval. The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the reference product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any product candidates that are biosimilar to the branded product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant's favor of a lawsuit challenging the biologics’ patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, as these substitution practices are governed by state pharmacy law.

The contours of the BPCIA continue to be defined as the statute is implemented over a period of years. This likely will be accomplished by a variety of means, including decisions related to the statute by the relevant federal courts. The FDA has to date issued various guidance documents and other materials indicating the agency’s thinking regarding a number of issues implicated by the BPCIA. Additionally, the FDA’s approval of a number of biosimilar applications in recent years has helped define the agency’s approach to certain issues. However, the ultimate impact, implementation, and meaning of the BPCIA remains subject to significant uncertainty.

Third‑Party Payor Coverage and Reimbursement

The commercial success of our products is dependent on the availability of coverage and adequate reimbursement from public (i.e., federal and state government) and private (i.e., commercial) payors. These third‑party payors may deny coverage or reimbursement for a product or therapy, either in whole or in part, if they determine that the product or therapy was not medically appropriate or necessary. Also, third‑party payors continue to control costs by limiting coverage through the use of formularies and other cost‑containment mechanisms, and the amount of reimbursement for particular procedures or drug treatments.

The cost of pharmaceutical products continues to generate substantial governmental and third‑party payor interest. We expect the pharmaceutical industry will continue to experience pricing pressures, given the trend toward managed healthcare, the increasing influence of managed care organizations, and additional regulatory and legislative proposals. Our results of operations and business could be adversely affected by current and future third‑party payor policies, as well as healthcare legislative reforms.

Some third‑party payors also require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement or adoption of such proposals could have an adverse effect on our ability to obtain adequate prices for any future product candidates and to operate profitably.

The pricing and reimbursement of our pharmaceutical products is partially dependent on government regulation. We offer discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, including: (i) ~~Centers for Medicare & Medicaid Services’ (“~~CMS”) Medicaid Drug Rebate Program, (ii) Medicare Part B Program and Medicare Part D Coverage Gap Discount Programs, (iii) the U.S. Department of Veterans Affairs’ Federal Supply Schedule Program, and (iv) the Health Resources and Services Administration’s 340B Drug Pricing Program. These rebates are subject to our active participation in the respective programs. We must also report specific prices to government agencies under healthcare programs, such as the Medicaid Drug Rebate Program and Medicare Part B Program. The calculations necessary to determine the prices reported are complex and the failure to report prices accurately may in the future expose us to penalties.

In the U.S., federal and state government healthcare programs and private third-party payors routinely seek to manage utilization and control the costs of our products. In the U.S., there is an emphasis on managed healthcare, which has put additional pressure on pharmaceutical drug pricing, and reimbursement and usage, and has adversely affected our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, including formulary coverage and positioning, laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies, and pricing in general. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing, resulting in proposals to address the perceived high cost of pharmaceuticals, and drug pricing continues to be an agenda item at both the federal and state level. For example, in May 2025, the current U.S. Administration renewed the idea of international reference pricing through an executive order entitled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which, among other things, directs the U.S. Department of Health and Human Services (the “HHS”) and other agencies to communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for U.S. patients in line with comparably developed nations and to facilitate direct-to-consumer purchasing programs. The HHS subsequently issued guidance indicating the most-favored-nation (“MFN”) target price will be the lowest price paid in an Organisation for Economic Co-operation and Development country with a gross domestic product (“GDP”) per capita of at least 60% of the U.S. GDP per capita. In addition, in December 2025, CMS proposed new drug payment models to lower drug prices for Medicare beneficiaries, which are proposed to go into effect as early as October 2026. Under the models, CMS would explore potential adjustments to Medicare drug inflation rebate calculations by comparison to international drug pricing information. It is currently unclear whether and to what extent these measures will be implemented; however, any such implementation would likely have a negative financial impact on ROLVEDON.

Moreover, the U.S. pharmaceutical industry has already been significantly affected by major legislative initiatives, including, for example, the ACA. The ACA, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription drug medicines. It also contains substantial provisions intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, and impose additional health policy reforms, and, from time to time, our business has been affected by the ACA and certain of these provisions. Since its enactment, there have been judicial and congressional challenges to numerous provisions of the ACA. We continue to face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify, or invalidate some or all of the provisions of the ACA.

In addition, the Inflation Reduction Act of 2022 (“IRA”) contains provisions intended to lower beneficiary drug spending. Beginning in 2023, the IRA enables Medicare to negotiate prescription drug prices with manufacturers of certain high-cost drugs for the first time. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. In January 2025, CMS announced a list of fifteen additional Medicare Part D drugs that will be subject to price negotiations. To date, none of our products have been selected to be subject to price negotiations. A separate provision requires drug manufacturers to pay rebates to Medicare if their drug prices increase at a higher rate than the rate of inflation (the so-called inflation rebate provision). Additionally, in 2024, the IRA eliminated the 5% coinsurance for catastrophic coverage under Medicare Part D. In 2025, the IRA will cap the beneficiary annual out-of-pocket expenditure. These efforts to reduce aggregate beneficiary spending are expected to shift some costs to drug manufacturers.

Supply Schedule Program, and (iv) the Health Resources and Services Administration’s 340B Drug Pricing Program. These rebates are subject to our active participation in the respective programs. We must also report specific prices to government agencies under healthcare programs, such as the Medicaid Drug Rebate Program and Medicare Part B Program. The calculations necessary to determine the prices reported are complex and the failure to report prices accurately may in the future expose us to penalties.

The U.S. pharmaceutical industry has already been significantly affected by major legislative initiatives, including, for example, the ACA. The ACA, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription drug medicines. It also contains substantial provisions intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, and impose additional health policy reforms, and, from time to time, our business has been affected by the ACA and certain of these provisions. Since its enactment, there have been judicial and congressional challenges to numerous provisions of the ACA. We continue to face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify, or invalidate some or all of the provisions of the ACA.

In addition, the Inflation Reduction Act of 2022 (“IRA”) contains provisions intended to lower beneficiary drug spending. Beginning in 2023, the IRA enables Medicare to negotiate prescription drug prices with manufacturers of certain high-cost drugs for the first time. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations occurred in 2024. In January 2025, CMS announced a list of fifteen additional Medicare Part D drugs that will be subject to price negotiations. To date, none of our products have been selected to be subject to price negotiations. A separate provision requires drug manufacturers to pay rebates to Medicare if their drug prices increase at a higher rate than the rate of inflation (the so-called inflation rebate provision). Additionally, effective since 2024, the IRA eliminated the 5% coinsurance for catastrophic coverage under Medicare Part D; in 2025, the IRA will cap the beneficiary annual out-of-pocket expenditure. These efforts to reduce aggregate beneficiary spending are expected to shift some costs to drug manufacturers.

Fraud and Abuse

The Foreign Corrupt Practices Act (“FCPA”), prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for influencing any act or decision of the foreign entity to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

Pharmaceutical companies that participate in federal healthcare programs are subject to various U.S. federal and state laws pertaining to healthcare “fraud and abuse,” including anti‑kickback and false claims laws. Violations of U.S. federal and state fraud and abuse laws may be punishable by criminal or civil sanctions, including fines, civil monetary penalties and exclusion from federal healthcare programs (including Medicare and Medicaid).

The federal Anti‑Kickback Statute prohibits any person or entity, including a prescription drug manufacturer, or a party acting on its behalf, from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce another to (i) refer an individual for the furnishing of a pharmaceutical product for which payment may be made under a federal healthcare program, such as Medicare or Medicaid (“covered product”); (ii) purchase or order any covered product; (iii) arrange for the purchase or order of a covered product; or (iv) recommend a covered product. This statute has been interpreted broadly to apply to a wide range of arrangements between pharmaceutical manufacturers and others, including, but not limited to, any exchange of remuneration between a manufacturer and prescribers (such as physicians), purchasers, pharmacies, pharmacy benefit managers, formulary managers, group purchasing organizations, hospitals, clinics and other health care providers, and patients. Although there are several statutory exceptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce referrals, prescribing, purchasing, or recommending covered products may be subject to scrutiny if they do not qualify for an exception or safe harbor.

certain business arrangements from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce referrals, prescribing, purchasing, or recommending covered products may be subject to scrutiny if they do not qualify for an exception or safe harbor.

Additionally, many states have adopted laws like the federal Anti‑Kickback Statute, and some of these state prohibitions apply, in at least some cases, to the referral of patients for healthcare items or services reimbursed by any third‑party payor, not only the Medicare and Medicaid programs, and do not contain safe harbors. Violations of fraud and abuse laws such as the Anti-Kickback Statute may be punishable by criminal or civil sanctions and/or exclusion from federal healthcare programs (including Medicare and Medicaid).

The federal False Claims Act (“FCA”) imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The “qui tam” provisions of the FCA allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has violated the FCA, and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the FCA. Many of these state laws apply where a claim is submitted to any third‑party payor, not merely a federal healthcare program.

There are many potential bases for liability under the FCA. Liability primarily arises when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The FCA has been used to assert liability based on alleged kickbacks and other improper referrals, improperly reported government pricing metrics, such as Best Price or Average Manufacturer Price, improper use of Medicare numbers when detailing the provider of services, improper promotion of off‑label uses not expressly approved by FDA in a drug’s label, and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state, and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws.

Federal and state authorities have increased enforcement of fraud and abuse laws within the pharmaceutical industry, and private individuals have been active in alleging violations of the law and bringing suits on behalf of the government under the FCA and under state and local laws. These laws are broad in scope and there may not be regulations, guidance or court decisions that definitively interpret these laws and apply them to particular industry practices. In addition, these laws and their interpretations are subject to change.

Additionally, the federal Open Payments program, created under Section 6002 of the Affordable Care Act and its implementing regulations, requires that manufacturers of prescription drugs for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) report annually to HHS information related to “payments or other transfers of value” provided to U.S. “physicians” (defined to include doctors, dentists, optometrists, podiatrists and chiropractors); certain other “healthcare providers” (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives); and “teaching hospitals.” The Open Payments program also requires that manufacturers and applicable group purchasing organizations report annually to HHS ownership and investment interests held in them by physicians (as defined above) and their immediate family members. Manufacturers’ reports are filed annually with the CMS by March 31, covering the previous calendar year. CMS posts disclosed information on a publicly available website annually by June 30.

Medicaid or the Children’s Health Insurance Program (with certain exceptions) report annually to HHS information related to “payments or other transfers of value” provided to U.S. “physicians” (defined to include doctors, dentists, optometrists, podiatrists and chiropractors); certain other “healthcare providers” (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives); and “teaching hospitals.” The Open Payments program also requires that manufacturers and applicable group purchasing organizations report annually to HHS ownership and investment interests held in them by physicians (as defined above) and their immediate family members. Manufacturers’ reports are filed annually with the CMS by March 31, covering the previous calendar year. CMS posts disclosed information on a publicly available website annually by June 30.

There are also an increasing number of state laws that regulate or restrict pharmaceutical manufacturers’ interactions with healthcare providers licensed in the respective states. Beyond prohibiting the provision of certain payments or items of value, these laws require pharmaceutical manufacturers to, among other things, establish comprehensive compliance programs, adopt marketing codes of conduct, file periodic reports with state authorities regarding sales, marketing, pricing, and other activities, and register/license their sales representatives. Laws require manufacturers to file reports regarding payments and items of value provided to health care providers (similar to the federal Open Payments program). Many of these laws contain ambiguities as to what is required to comply with the laws. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. Given the lack of clarity with respect to these laws and their implementation, despite our best efforts to act in full compliance, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.

The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) created several federal crimes, including healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third‑party payors. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement about the delivery of or payment for healthcare benefits, items or services.

Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, from time to time some of our business activities are subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be in the future subject to penalties— including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre‑marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into supply contracts including government contracts and the curtailment or restructuring of our operations— any of which could adversely affect our ability to operate our business and our results of operations. With respect to any of our products sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable privacy laws and post‑marketing requirements, including safety surveillance, anti‑fraud and abuse laws, and implementation of corporate compliance programs, and reporting of payments or transfers of value to healthcare professionals.

Controlled Substances

Sympazan, a clobazam lingual film product, is regulated as a Schedule IV controlled substance by the Drug Enforcement Administration (“DEA”). The DEA is the federal agency responsible for domestic enforcement of the Controlled Substances Act of 1970 (“CSA”). The DEA regulates controlled substances as Schedule I, II, III, IV and V substances. Schedule I substances, by definition, have high potential for abuse, no currently accepted medical use in the U.S., and lack accepted safety for use under medical supervision, and may not be marketed or sold in the U.S. except for research and industrial purposes. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.

Healthcare Data Privacy and Security Requirements

Our marketing and other data processing activities may be limited by data privacy and security regulation by both the federal government and the states in which we conduct our business. For example, HIPAA and its implementing regulations established standards for “covered entities,” which are certain healthcare providers, health plans and healthcare clearinghouses, regarding the security and privacy of protected health information. While we are not a covered entity under HIPAA, many of our customers are, and this limits the information they can share with us. The Health Information Technology for Economic and Clinical Health Act (“HITECH”) expanded the applicability of HIPAA’s privacy, security, and breach notification standards. Among other things, HITECH makes HIPAA’s security and breach standards (and certain privacy standards) directly applicable to “business associates,” which are entities that perform certain services on behalf of covered entities involving the exchange of protected health information. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates, and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. While we do not currently perform any services that would render us a business associate under HIPAA/HITECH, it is possible that we may provide such services in the future and would be subject to the applicable provisions of HIPAA/HITECH. Finally, we are subject and are likely to be subject in the future to additional state privacy and security laws, regulations and other authorities, specifically including the California Consumer Privacy Act, which may limit our ability to use and disclose identifiable information for various purposes, and may impose requirements related to safeguarding such information, as well as reporting on breaches. While some of the data we process may be exempt from certain of these laws, other data may be covered, requiring compliance.

entities, business associates, and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. While we do not currently perform any services that would render us a business associate under HIPAA/HITECH, it is possible that we may provide such services in the future and would be subject to the applicable provisions of HIPAA/HITECH. Finally, we are subject and are likely to be subject in the future to additional state privacy and security laws, regulations and other authorities, specifically including the California Consumer Privacy Act, which may limit our ability to use and disclose identifiable information for various purposes, and may impose requirements related to safeguarding such information, as well as reporting on breaches. While some of the data we process may be exempt from certain of these laws, other data may be covered, requiring compliance.

Human Capital

As of March 79, ~~2025~~2026, we had 5853 full‑time employees, ~~all employed~~ in the U.S. Our workforce primarily consists of professionals engaged in commercial operations, medical affairs, market access, regulatory, and corporate support functions. None of our employees are represented by a collective bargaining agreement, ~~nor~~and we have wenot experienced any work ~~stoppage~~stoppages. We believe that our employee relations ~~with our employees~~ are good.

Our core values are passion, integrity, professionalism, collaboration, and tenacity, which ~~supports~~support our vision of improving lives through better medicine. WeOur ~~believe~~human ~~that~~capital ~~our~~strategy ~~vision~~is ~~and~~focused ~~values,~~on ~~in combination with our offering a desirable set of benefits~~attracting, ~~flexible working environment~~developing, and ~~career-enhancing~~retaining ~~development~~professionals ~~experiences~~needed ~~and initiatives help us~~ to ~~compete~~support ~~for highly-skilled talent. We recognize that~~ our ~~industry~~operations ~~is specialized~~ and ~~dynamic, and a significant aspect of our success is our continued ability to execute our human capital strategy of attracting, engaging, developing, and retaining highly~~long-~~skilled~~term ~~talent that our efficient operating model needs~~strategy. We ~~also~~aim ~~believe~~to weprovide ~~offer competitive compensation for our employees and strongly embrace~~ a ~~pay~~workplace ~~for~~that ~~performance~~promotes ~~culture~~professional ~~underpinned~~growth, bycollaboration, ~~our commitment to ethics~~ and ~~compliance~~engagement.

18Key elements of our talent strategy include competitive compensation and benefits, comprehensive benefits and wellness programs, professional development opportunities, and flexible working arrangements to support productivity and work-life balance. Our compensation philosophy is designed to align employee incentives with company performance and shareholder value creation to motivate performance and support retention.

Our ~~Employee~~leadership ~~Handbook~~team, ~~and~~including ~~Code~~executive ofmanagement ~~Business Conduct~~ and ~~Ethics~~human ~~outline~~resources, ~~our~~oversees ~~commitment~~human tocapital ~~inclusion,~~management ~~where~~programs ~~all~~that ~~employees~~ are ~~welcomed in an environment~~ designed to ~~make~~support ~~them~~employee ~~feel comfortable~~development, ~~respected,~~maintain ~~and accepted. We have~~ a ~~set~~safe ~~of policies explicitly setting forth our expectations for nondiscrimination~~ and arespectful ~~harassment-free~~workplace ~~work~~ environment., ~~We are also a proud equal opportunity employer~~ and ~~cultivate~~maintain acompliance ~~highly~~with ~~collaborative,~~employment ~~fast paced, and entrepreneurial culture~~laws.

We strive to maintain a culture built on accountability, integrity, collaboration, and innovation. We periodically review employee engagement and organizational effectiveness through internal feedback and surveys. Our Employee Handbook and Code of Business Conduct and Ethics outline our commitment to inclusion, where all employees are welcomed in an environment designed to make them feel comfortable, respected, and accepted. We have a set of policies explicitly setting forth our expectations for nondiscrimination and a harassment-free work environment. We are also an equal opportunity employer, and we seek to cultivate a highly collaborative, fast paced, and entrepreneurial culture.

Corporate Information

The address of our website is http://www.assertiotx.com. We make available, free of charge through our website, our Annual Reports on Form 10‑K, Quarterly Reports on Form 10‑Q, Current Reports on Form 8‑K, and other periodic Securities and Exchange Commission (“SEC”) reports, along with amendments to ~~all of~~ those reports, as soon as reasonably practicable after we file the reports with the SEC. Website references are provided throughout this document for convenience. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Annual Report on Form 10-K.

1918

RISK FACTOR SUMMARY

The following is a summary of the risks more fully described in “Item 1A. Risk Factors” in this Annual Report on Form 10-K that we believe are material to our investors and a reader should carefully consider them. Those risks are not all of the risks we face and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur.

Risks Related to Commercial Matters

•We may not be able to maintain attractive reimbursement of ROLVEDON through government programs such as Medicare and Medicaid.

•We may not be successful in driving the growth in sales and profitability of ROLVEDON.

•Failure to successfully commercialize our products could adversely impact our business, financial condition and results of operations.

•We depend on one qualified supplier for the active pharmaceutical ingredient in each of our products and single source suppliers to manufacture our products.

•Competition from generics has adversely affected and could continue to have further adverse effects on our business.

•Failure to successfully commercialize our other products.

•Commercial disputes may adversely affect the commercial success of our products.

•We may be unable to compete successfully in the pharmaceutical and biological product industry.

•We may be unable to negotiate acceptable pricing or obtain adequate reimbursement for our products.

•We may be impacted by our customer concentration.

Risks Related to Our Regulatory Environment

•We incur significant costs and devote significant management focus on governmental investigations and inquiries, regulatory actions and lawsuits regarding Assertio Therapeutics’ historical commercialization of opioids.

•We are impacted by changes in laws and regulations applicable to, and increased scrutiny and investigations of, the pharmaceutical and biological product industry.

•We may fail to comply with applicable statutes or regulations.

•We may incur significant liability if it is determined that we are promoting or have promoted “off-label” use of our products.

•Healthcare reform may reduce our revenues, increase our expenses and impact our products.

•We are not always able to protect our intellectual property and are subject to risks from liability for infringing the intellectual property of others.

•Macroeconomic conditions can adversely impact our business and operations.

Risks Related to Our Business Development Activities

•We may not succeed in executing business development strategies, strategic partnerships, acquisitions of businesses, products or technologies, and investment opportunities, which will limit our business growth and prospects.

•Strategic transactions that fail to achieve the anticipated levels of revenue, synergies and profit growth will cause our business to suffer.

•Failure to integrate any business, product or technology we acquire.

Risks Related to Our Financial Position

•Our existing capital resources may not be sufficient to fund our future operations or execute attractive product acquisitions and strategic transactions.

•We may be unable to ~~generate sufficient cash flow from our business to~~ make interest payments on and repay our 2027 Convertible Notes.

•We have incurred operating losses in the past and may incur operating losses in the future.

•We have significant amounts of long-lived assets which depend upon future positive cash flows to support the values recorded in our balance sheet.

•We have significant amounts of inventory, ~~which~~and ~~are~~we ~~stated at the lower of cost or net realizable value. We~~ have recognized inventory write -off charges in the past and may recognize write-off charges in the future.

•Our financial results are impacted by management’s assumptions and use of estimates.

•We may not be able to adequately insure ourselves from product liability losses and other litigation liability.

•Our ability to use our net operating loss (“NOL”) carryforwards may be limited.

Risks Related to Future Product Development

•Future product candidates may not be approved for marketing or, if approved, may not achieve market acceptance.

•We customarily depend on third-party contract research organizations, clinical investigators and clinical sites to conduct clinical trials with regard to product candidates, and we may not obtain necessary regulatory approvals.

•We are subject to risks associated with New Drug Applications we submit under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act.

2019

Risks Related to Share Ownership

•Our common stock may be delisted from The Nasdaq Capital Market if we are unable to ~~regain and~~ maintain compliance with its continued listing standards.

•The market price of our common stock historically has been volatile.

•We are subject to risks from ~~future~~ proxy ~~fights~~contests or the actions of activist shareholders.

•We are subject to risks related to unsolicited takeover attempts in the future.

•Conversions of the 2027 Convertible Notes or future sales of our common stock could adversely impact the prices of the 2027 Convertible Notes and common stock.

Risks Related to our Corporate Organization and General Business Risks

•Our success is dependent in large part upon continued services of our executive management team.

•Our corporate structure may not prevent veil piercing or other similar claims.

•We may be unable to satisfy regulatory requirements relating to internal controls.

•Business interruptions can adversely impact our ability to operate our business.

•Data breaches and cyber-attacks can adversely impact our ability to operate our business.

•Macroeconomic conditions can impact our business and operations.

•The use of new and evolving technologies may pose security and other risks to our sensitive data, and we may be exposed to reputational harm, other adverse consequences, and liability.

ITEM 1A. RISK FACTORS

In addition to other information in this Annual Report on Form 10-K, please consider the following discussion of factors that make an investment in our securities risky. The risks or uncertainties described in this Annual Report on Form 10‑K can materially and adversely affect our business, reputation, stock price, results of operations, cash flows or financial condition. ~~The~~While the risks and uncertainties described below have been grouped under general risk categories, one or more of ~~which~~the categories may be applicable to the risk factors described. The risks and uncertainties described in this Annual Report on Form 10‑K are not the only ones facing us. Additional risks and uncertainties of which we are unaware or that we currently deem immaterial may also become important factors that can harm our business, reputation, stock price, results of operations, cash flows, or financial condition. Some of the factors, events, and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events or contingencies have occurred in the past, and instead reflect our beliefs and opinions as to the factors, events or contingencies that could materially and adversely affect us in the future.

Risks Related to Commercial Matters

Sales of ROLVEDON depend on coverage and reimbursement from third-party payors, including under the Medicare Part B Average Sales Price (“ASP”) payment methodology, and a failure to obtain or a reduction in the coverage and/or reimbursement for our products, including as a result of disputes with government agencies regarding our submitted ASP data for ROLVEDON, which is subject to assumptions that may be challenged, could have a material adverse ~~effect~~impact on our product sales, business and results of operations.

Sales of ROLVEDON are dependent on the availability and extent of coverage and reimbursement, or level of reimbursement, from third-party payors, including government programs and private insurance plans. Governments and private payors may regulate prices, reimbursement levels and/or access to our products to contain costs or to affect levels of use. We rely in large part on the reimbursement of ROLVEDON through government programs such as Medicare and Medicaid in the U.S., and a failure to obtain or a reduction in the coverage and/or reimbursement for our products could have a material adverse effect on our product sales, business and results of operations. Failure to obtain, or a reduction in, coverage and/or reimbursement for our products may also lead to patients having to pay more or pay entirely out-of-pocket for ROLVEDON. If patients are unwilling to pay more or entirely out-of-pocket for ROLVEDON as a result of a reduction in, or lack of, coverage or reimbursement, it could have a material adverse effect on our product sales, results of operations, and cash flows. Further, a substantial portion of our ROLVEDON business relies on reimbursement to customers by the U.S. federal government at ROLVEDON’s Medicare Part B Average Sales Price (“ASP”), which declines based on discounts and other pricing concessions made by manufacturers. These discounts and other pricing concessions are necessary to remain competitive in the long-acting G-CSF market.

AFurther, a substantial portion of our ROLVEDON business relies on reimbursement ~~from~~to customers by the U.S. federal government ~~under~~utilizing ROLVEDON’s Medicare Part B ~~coverage~~ASP payment methodology, which declines based on discounts and other pricing concessions made by manufacturers. These discounts and other pricing concessions are necessary to remain competitive in the long-acting G-CSF market. Most of our products furnished to Medicare beneficiaries in both a physician office setting and hospital outpatient setting will be reimbursed under ASP payment methodology. ASP-based reimbursement of ROLVEDON under Medicare may be below, or could fall below, the cost that some medical providers pay for such products, which could materially and adversely affect sales of ROLVEDON. We also face risks relating to the reporting of pricing data that affect the U.S. reimbursement of and discounts for our products. ASP data are calculated by the manufacturer based on a ~~formula defined~~

2120

formula defined by statute and regulation and are then submitted to the Centers for Medicare and Medicaid Services (“CMS”), the agency responsible for administering the Medicare program, on a quarterly basis.

CMS uses those ASP data to determine the applicable reimbursement rates for ROLVEDON under Medicare Part B. However, government price reporting and payment regulations are complex, and we are continually assessing the ~~statute~~methods by which we calculate and report pricing in accordance with these requirements. The applicable statutes, regulations and ~~CMS~~ guidance do not define specific methodologies for all aspects of ~~the~~ reporting ofapplicable ~~ASP~~ data. As a result, we are required to apply our reasonable judgment to certain aspects of calculating ASP data and other government price reporting metrics. While we believe our methodologies for calculations are reasonable, such calculations are inherently subject to assumptions, including assumptions related to our efforts to consolidate operations and align ROLVEDON under a single subsidiary, Assertio Specialty. These calculations may be subject to review and challenge by various government agencies, which may disagree with our calculations. If our submitted ASP or other government price reporting data are incorrect, we may need to restate previously reported data and could become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse impact on our product sales, business and results of operations.

If we are not successful in driving the growth in sales and profitability of ROLVEDON, our business, financial condition and results of operations will be materially and adversely affected.

InOur ~~2024,~~future ~~ROLVEDON~~success ~~became~~is ~~our~~highly ~~lead~~dependent ~~product.~~on Asthe acommercial ~~result~~success of ROLVEDON, and there is greater ~~focus~~reliance on ROLVEDON sales and profitability for the Company ~~going forward~~. Any failure to successfully grow or maintain sales and profitability of ROLVEDON ~~could~~would likely have a material and adverse impact on our business. In addition, if any of the national distributors who previously participated in the large purchases of ROLVEDON in the third quarter of 2025 to ensure consistent supply of ROLVEDON (as noted in Item 1. Business above) do not purchase, or purchase less than, their historical volumes of ROLVEDON once sales of our newly labeled ROLVEDON commence, it would have a material adverse impact on our business. If the markets or patient subsets that we are targeting are not as significant as we estimate, or if we are unable to maintain and grow our market share or are unable to maintain or expand our pricing, we may not generate significant growth in revenues from sales of ROLVEDON. The commercial success of ROLVEDON ~~will~~depends ~~depend~~ on a number of factors, including the following:

•our ability to successfully ~~develop and~~ execute a commercial strategy focusing on clinics and hospitals;

•patient demand for ROLVEDON;

•the extent to which the results from the ROLVEDON same-day dosing trial is recognized in the National Comprehensive Cancer Network guidelines, which may support or enhance our commercialization efforts;

•coverage and reimbursement from third-party payors;

•our partners’ ability to consistently manufacture ROLVEDON on a timely basis and supply product to us on commercially acceptable terms;

•achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to ROLVEDON;

•the prevalence, duration and severity of potential side effects or other safety issues that patients may experience with ROLVEDON;

•the differentiation of ROLVEDON from other available approved or investigational drugs and treatments for patients with chemotherapy-induced neutropenia, and the willingness of physicians, operators of hospitals and clinics and patients to adopt and utilize ROLVEDON;

•our ability to establish and enforce intellectual property rights in and to ROLVEDON; and

•our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.

WeIf ~~depend on one qualified supplier for the API in each of our products, and~~ we ~~depend on third parties that~~ are ~~single~~not ~~source~~successful ~~suppliers~~in tocommercializing ~~manufacture~~ our products~~. Insufficient availability of our products~~, ~~the API or other raw materials necessary to manufacture~~ our ~~products~~business, orfinancial ~~the~~condition ~~inability of our suppliers to manufacture~~ and ~~supply~~results ~~our~~of ~~products~~operations ~~on commercially reasonable terms,~~ will ~~adversely~~be ~~impact~~materially ~~our sales~~ and~~/or~~ ~~margins~~adversely ~~upon depletion of our API and product inventories~~affected.

WeIf ~~have~~we ~~one~~are ~~qualified~~unable ~~supplier~~to ~~for~~successfully ~~the~~market ~~API in each of~~ our products ~~and have single source suppliers for the manufacture of our products. We do not have~~, ~~and~~ we dowill not ~~intend~~be able to ~~establish~~maintain inor ~~the~~increase ~~foreseeable~~our ~~future,~~revenues ~~internal~~and ~~commercial-scale~~our ~~manufacturing capabilities. Rather~~business, wefinancial ~~intend~~condition toand ~~use~~results ~~the facilities~~ of ~~third~~operations ~~parties~~will tobe ~~manufacture~~materially ~~products for commercialization~~ and ~~clinical~~adversely ~~trials~~affected. ~~Our~~In ~~dependence~~addition onto ~~third parties for~~ the ~~manufacture~~risks ofdiscussed ~~our~~elsewhere ~~products~~in ~~and~~this ~~any~~section, ~~future product candidates may adversely affect~~ our ability to ~~obtain~~successfully ~~such~~commercialize ~~products~~and ongenerate arevenues ~~timely~~from ~~or competitive basis, if at all. Any stock out, quality concern or failure to obtain sufficient supplies of~~ our products, ordepends ~~the~~on ~~necessary APIs, excipients or components, from our suppliers, including as~~ a ~~result~~number of ~~disruptions to supplier operations resulting from~~ factors ~~such as supply chain delays~~, ~~public health emergencies~~including, ~~climate~~but ~~events~~not orlimited ~~political unrest, or failures by us~~ to ~~satisfy minimum order requirements due to declines in product demand or otherwise~~, ~~would adversely affect~~ our ~~business,~~ability ~~results of operations and financial condition.~~to:

~~We,~~•develop ~~our third-party manufacturers~~ and execute our ~~suppliers are subject to numerous regulations~~sales, ~~including~~marketing ~~current FDA regulations governing manufacturing processes, stability testing, record keeping, product serialization~~ and ~~quality~~promotional ~~standards.~~strategies ~~Similar regulations are in effect in other countries. The manufacturing process~~ for ~~pharmaceutical~~our products ~~is highly regulated, and regulators may from time to time shut down manufacturing facilities that they believe do not comply with their regulations.~~ ;

2221

Our third-party manufacturers and suppliers are independent entities who are subject to their own operational and financial risks which are out of our control. If we or any third-party manufacturer or supplier fails to perform as required or fails to comply with the regulations of the FDA and other applicable governmental authorities, our ability to deliver adequate supplies of our products to our customers on a timely basis and on commercially reasonable terms, or to conduct clinical trials, could be adversely affected. For example, in October 2023, Spectrum’s drug product manufacturer for ROLVEDON demanded a significant price increase despite fixed pricing provisions in Spectrum’s supply agreement through the latter half of 2025. We have renegotiated supply to meet our demands into 2027 and had to accept higher prices than were previously contracted for, but have no assurance our supplier will not make further demands that may impact future supply or have a material adverse impact on our business. We are in pricing negotiations with the drug product manufacturer under the supply agreement to set pricing after the fixed pricing provision ends. Additionally, although we have fixed pricing with our contract manufacturer for INDOCIN suppositories through July 2028, we understand the API provider to our INDOCIN contract manufacturer has demanded a significant price increase to continue supplying API to our contract manufacturer on a purchase order basis.

We are assessing the legal and business implications of these circumstances and cannot predict how they may ultimately be resolved. The manufacturing processes of our third-party manufacturers and suppliers may also be found to violate the proprietary rights of others. To the extent these risks materialize and adversely affect such third-party manufacturers’ and/or suppliers’ performance obligations to us, and we are unable to contract for a sufficient supply of required products on acceptable terms, or if we encounter delays and difficulties in our relationships with manufacturers or suppliers, our business, results of operations and financial condition could be adversely affected.

A number of our products, including the INDOCIN products and Cambia, are facing competition from generics, which adversely affects our business. Approval of additional generic versions of our products would have a further adverse effect on our business.

Under the FDCA, the U.S. Food and Drug Administration (“FDA”) can approve an abbreviated new drug application (“ANDA”) for a generic version of a branded drug without the ANDA applicant undertaking the clinical testing necessary to obtain approval to market a new drug. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s) and is bioequivalent to the branded product, in addition to any data necessary to establish that any difference in strength, dosage, form, inactive ingredients or delivery mechanism does not result in different safety or efficacy profiles, as compared to the reference drug.

There are no patents covering our INDOCIN products (which accounted for 21% and 57% of our revenue in 2024 and 2023, respectively), which allows a generic drug company to introduce a generic alternative for these drugs at any time. Generic versions of our INDOCIN products have been approved and launched, including one in January 2025, and as a result, we are currently facing competition from these generics. In addition, we are aware of other drug companies that have had interactions with regulatory agencies including the FDA relating to indomethacin, which could indicate the development of one or more additional INDOCIN product generics or other formulations of indomethacin and, as a result, we could face competition from additional generics. As a result of the generic competition, we have lost significant market share and have had to provide pricing concessions to certain customers of INDOCIN products.

In addition, we also face competition for INDOCIN products from hospitals and other institutions, including a 503B outsourcing facility (commonly referred to as a 503B compounder), which began compounding 100 mg indomethacin suppositories in 2022 in what we believe to be violation of state and federal requirements for new drugs and labeling requirements related to adequate directions for use. For a 503B compounder to qualify for exemptions from these state and federal requirements, the 503B compounder must meet certain conditions set forth in Section 503B of the FDCA. We believe that the 503B compounder compounding 100 mg indomethacin suppositories does not meet these conditions. While indomethacin it is included on the FDA’s Category 1 list of bulk substances it is evaluating, it is not on the FDA’s list of bulk substances for which there is a clinical need and INDOCIN suppositories are not on the FDA’s drug shortage list either. We also believe that the 100 mg indomethacin suppositories being compounded are essentially a copy of our FDA-approved INDOCIN suppositories. We cannot guarantee that we will be successful in causing the 503B compounder to discontinue sales of its unapproved indomethacin suppository product. We filed an unfair competition lawsuit in the U.S. District Court (Southern District of Texas) against this 503B compounder, which was dismissed on September 27, 2023. We have appealed to the Fifth Circuit Court of Appeals. The appeal is fully briefed and argued, and we are awaiting a ruling from the court.

With respect to CAMBIA, which accounted for 4% and 5% of our revenue in 2024 and 2023, respectively, generic versions of this product have been approved and launched in the U.S. and as a result, we currently face competition from generic versions of CAMBIA. On February 22, 2024, our partner Searchlight, which commercializes a specific formulation of CAMBIA in Canada, commenced a patent infringement action in Canadian federal court against a generic company seeking approval of a generic version of CAMBIA in Canada. On June 9, 2024, Searchlight commenced a second patent infringement

action in Canadian federal court against a second generic company seeking approval of a generic version of CAMBIA in Canada. Under our license agreement with Searchlight, we are obligated to reimburse Searchlight for a portion of its litigation expenses, which has and is expected to continue to reduce our quarterly royalties during the litigation. Our royalties from Searchlight’s net sales of CAMBIA in Canada will be further adversely impacted if Searchlight’s patent infringement litigations fail to keep the generic companies from launching before the relevant patents expire.

The introduction of known and potential additional generic versions of our products, as well as sales of indomethacin suppositories by compounders, or disclosure of ANDA filings and/or similar applications in respect to any of our products, have and in the future could adversely impact our business, financial condition, results of operations and stock price. Moreover, if the patents covering ROLVEDON (which expire in 2042), Sympazan (which expire in 2040) and/or Otrexup (which expire in 2031) are not upheld in litigation or if a generic competitor is found not to infringe these patents, the resulting generic competition for ROLVEDON, Sympazan and/or Otrexup would have a further adverse effect on our business, financial condition and results of operations.

If we are not successful in commercializing our other products, our business, financial condition and results of operations will be materially and adversely affected.

We currently utilize an omni-channel product promotion model for all of our products except for ROLVEDON. We utilize both a sales force and an omni-channel product promotion model for Sympazan. Our reliance on our omni-channel model to promote our products may be less successful than in-person promotion. If we are unable to successfully achieve or perform these functions, including our capabilities to market products through both a sales force and an omni-channel promotion model, we will not be able to maintain or increase our revenues and our business, financial condition and results of operations will be materially and adversely affected.

In addition to the risks discussed elsewhere in this section, our ability to successfully commercialize and generate revenues from our products depends on a number of factors, including, but not limited to, our ability to:

•develop and execute our sales, marketing and promotion strategies for our products using our capability to market products through both a sales force and an omni-channel promotion model;

•achieve, maintain and grow market acceptance of, and demand for, our products;

•obtain and maintain adequate coverage, reimbursement and pricing from managed care, government and other third-party payors;

•adapt our commercial strategies while minimizing disruption of relationships with prescribers and other decision-makers;

•maintain, manage or scale the necessary sales, marketing, manufacturing, managed markets and other capabilities and infrastructure that are required to successfully integrate and commercialize our products;

•obtain adequate supply of our products;

•maintain and extend intellectual property protection for our products; and

•comply with applicable legal and regulatory requirements.

We depend on one qualified supplier for the API in each of our products, and we depend on third parties that are single source suppliers to manufacture our products. Insufficient availability of our products, the API or other raw materials necessary to manufacture our products, or the inability of our suppliers to manufacture and supply our products on commercially reasonable terms, will adversely impact our sales and/or margins upon depletion of our API and product inventories.

We have one qualified supplier for the API in each of our products and have single source suppliers for the manufacture of our products. We do not have, and we do not intend to establish in the foreseeable future, internal commercial-scale manufacturing capabilities. Rather, we intend to use the facilities of third parties to manufacture products for commercialization and clinical trials. Our dependence on third parties for the manufacture of our products and any future product candidates may adversely affect our ability to obtain such products on a timely or competitive basis, if at all. Any stock out, quality concern or failure to obtain sufficient supplies of our products, or the necessary APIs, excipients or components, from our suppliers, including as a result of disruptions to supplier operations resulting from factors such as supply chain delays, public health emergencies, climate events or political unrest, or failures by us to satisfy minimum order requirements due to declines in product demand or otherwise, would adversely affect our business, results of operations and financial condition.

We, our third-party manufacturers and our suppliers are subject to numerous regulations, including current FDA regulations governing manufacturing processes, stability testing, record keeping, product serialization and quality standards. Similar regulations are in effect in other countries. The manufacturing process for pharmaceutical products is highly regulated, and regulators may from time to time shut down manufacturing facilities that they believe do not comply with their regulations. Our third-party manufacturers and suppliers are independent entities who are subject to their own operational and financial risks which are out of our control. If we or any third-party manufacturer or supplier fails to perform as required or fails to comply with the regulations of the FDA and other applicable governmental authorities, or if our manufacturers and/or their suppliers demand higher prices, our ability to deliver adequate supplies of our products to our customers on a timely basis and on commercially reasonable terms, or to conduct clinical trials, could be adversely affected. For example, in October 2023, the drug product manufacturer for ROLVEDON demanded a significant price increase despite fixed pricing provisions in our supply agreement through the latter half of 2025. We renegotiated supply to meet our demands into 2027 and had to accept higher prices than were previously contracted for. Subsequently, on October 7, 2025, we entered into an amendment of the supply agreement that fixes the price that we pay for the remaining term of the agreement. Additionally, although we have fixed pricing with our contract manufacturer for INDOCIN suppositories through July 2028, we understand the API provider to our INDOCIN contract manufacturer has demanded a significant price increase to continue supplying API to our contract manufacturer on a purchase order basis. We may be subject to similar demands for higher prices from our suppliers in the future, which could adversely affect our business, results of operations and financial condition.

A number of our products, including the INDOCIN products and Cambia, are facing competition from generics, which adversely affects our business. Approval of additional generic or biosimilar versions of our products would have a further adverse effect on our business.

At the present time, the FDA will not accept an application for a biosimilar or interchangeable product based on ROLVEDON as the reference biological product until four years after the date of first licensure of the reference product (i.e., September 2026), and the FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until 12 years after the date of first licensure of the reference product (i.e., September 2034). However, during this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, provided that their application does not rely on the reference product or our data and is not submitted as a biosimilar application. If the patents covering ROLVEDON (which, not accounting for any patent term adjustment, patent term extension, or pediatric extensions that may be available, expire in 2039) are not upheld in litigation or if a biosimilar or other competing biologic is found not to infringe these patents, the resulting competition for ROLVEDON would have an adverse effect on our business, financial condition and results of operations.

Under the FDCA, the FDA can approve an abbreviated new drug application (“ANDA”) for a generic version of a branded drug without the ANDA applicant undertaking the clinical testing necessary to obtain approval to market a new drug. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s) and is bioequivalent to the branded product, in addition to any data necessary to establish that any difference in strength, dosage, form, inactive ingredients or delivery mechanism does not result in different safety or efficacy profiles, as compared to the reference drug.

There are no patents covering our INDOCIN products (which accounted for 16% and 21% of our Total revenues in 2025 and 2024, respectively), which allows a generic drug company to introduce a generic alternative for these drugs at any time. Over the past several years, generic versions of our INDOCIN products have been approved and launched, and as a result, we are currently facing competition from these generics. In addition, we are aware of other drug companies that have had interactions with regulatory agencies including the FDA relating to indomethacin, which could indicate the development of additional INDOCIN product generics or other formulations of indomethacin and, as a result, we could face competition from additional generics. As a result of the generic competition, net product sales of INDOCIN have declined as we have lost significant market share and have had to provide pricing concessions to certain customers.

In addition, we also face competition for INDOCIN products from hospitals and other institutions, including a 503B outsourcing facility (commonly referred to as a 503B compounder), which began compounding 100 mg indomethacin suppositories in 2022 in what we believe to be violation of state and federal requirements for new drugs and labeling requirements related to adequate directions for use. For a 503B compounder to qualify for exemptions from these state and federal requirements, the 503B compounder must meet certain conditions set forth in Section 503B of the FDCA. We believe that the 503B compounder compounding 100 mg indomethacin suppositories does not meet these conditions. While indomethacin is included on the FDA’s Category 1 list of bulk substances it is evaluating, it is not on the FDA’s list of bulk substances for which there is a clinical need and INDOCIN suppositories are not on the FDA’s drug shortage list either. We also believe that the 100 mg indomethacin suppositories being compounded are essentially a copy of our FDA-approved INDOCIN suppositories. We cannot guarantee that we will be successful in causing the 503B compounder to discontinue sales of its unapproved indomethacin suppository product. We filed an unfair competition lawsuit in the U.S. District Court (Southern District of Texas) against this 503B compounder, which was dismissed on September 27, 2023. We appealed this decision, and on April 10, 2025, the Fifth Circuit Court of Appeals reversed the dismissal in our favor. Thereafter, following the 503B compounder’s petition for certiorari, on January 12, 2026 the U.S. Supreme Court invited the U.S. Solicitor General to file a brief expressing the views of the U.S., which is still pending.

With respect to CAMBIA, which is included in Other net product sales, generic versions of this product have been approved and launched in the U.S. and as a result, we currently face competition from generic versions of CAMBIA. In addition, our partner Searchlight, commercializes a specific formulation of CAMBIA in Canada. The patents underlying the license agreement that we have with Searchlight expire in June 2026, and we anticipate that there will be generic competition in Canada after the patents expire, or the earlier negotiated launch of generics in Canada in connection with the settlement of patent litigation. As a result, we anticipate the amount of royalty revenue earned under the license agreement could be reduced to zero beginning in the third quarter of 2026.

patents covering Sympazan (which expire in 2040) are not upheld in litigation or if a generic competitor is found not to infringe these patents, the resulting generic competition for Sympazan would have a further adverse effect on our business, financial condition and results of operations.

Our commercialization, collaborative and/or licensing arrangements may give rise to disputes over commercial terms, contract interpretation and ownership or protection of our intellectual property and may adversely affect the commercial success of our products.

We currently have, or have had in the past, collaboration or license arrangements with a number of companies, including commercialization or collaborative arrangements, some of which have been based on less definitive agreements, such as memoranda of understanding, material transfer agreements, options or feasibility agreements.

Commercialization, collaborative and licensing arrangements are generally complex and can give rise to disputes regarding the relative rights, obligations and revenues of the parties, including the ownership of intellectual property and associated rights and obligations. Such disputes have arisen in the past from time to time and, if they arise again could delay collaborative research, development or commercialization of potential products, and can lead to lengthy, expensive litigation or arbitration. The terms of such arrangements may also limit or preclude us from commercializing products or technologies developed pursuant to such collaborations. Additionally, the commercialization, collaborative or licensing partners under these arrangements might breach the terms of their respective agreements or fail to maintain, protect or prevent infringement of the licensed patents or our other intellectual property rights by third parties. Moreover, negotiating commercialization, collaborative and/or licensing arrangements may cause us to enter into less favorable agreement terms that delay or defer recovery of our development costs and reduce the funding available to support key programs. Any failure by our commercialization, collaborative, or licensing partners to abide by the terms of their respective agreements with us (including their failure to accurately calculate, report or pay any royalties payable to either us or a third party or their failure to repay, in full or in part, either any outstanding receivables or any other amounts for which we are entitled to reimbursement) may adversely affect our results of operations.

development costs and reduce the funding available to support key programs. Any failure by our commercialization, collaborative, or licensing partners to abide by the terms of their respective agreements with us (including their failure to accurately calculate, report or pay any royalties payable to either us or a third party or their failure to repay, in full or in part, either any outstanding receivables or any other amounts for which we are entitled to reimbursement) may adversely affect our results of operations.

We are not always able to enter into commercialization, collaborative or licensing arrangements on acceptable terms, which can harm our ability to develop and commercialize our current and potential future products and technologies. Other factors relating to collaborations that may adversely affect the commercial success of our products include:

•any parallel development by a commercialization or collaborative partner of competitive technologies or products;

•arrangements with commercialization or collaborative partners that limit or preclude us from developing products or technologies;

•failure by a commercialization or collaborative partner to devote sufficient resources to the development and commercial sales of products using our current and potential future products and technologies; or

•premature termination of a commercialization or collaboration agreement or the inability to renegotiate existing agreements on favorable terms.

Our commercialization, collaborative or licensing arrangements do not necessarily restrict our commercialization, collaborative or licensing partners from competing with us or restrict their ability to market or sell competitive products. Our current and any future commercialization, collaborative or licensing partners may pursue existing or other development-stage products or alternative technologies in preference to those being commercialized or developed in collaboration with us.

In addition, contract disputes with customers or other third parties may arise from time to time. Our commercialization, collaborative, or licensing partners, or customers or other third parties, may also terminate their relationships with us or otherwise decide not to proceed with the development, commercialization or purchase of our products.

We and our commercial partners may be unable to compete successfully in the pharmaceutical and biological product industry.

Competition in the pharmaceutical and biological product industry is intense and we expect competition to increase. Competing products currently under development or developed in the future may prove superior to our products. These products under development, along with currently approved and marketed products, may achieve greater commercial acceptance than our products. Most of our principal competitors have substantially greater financial, sales, marketing, personnel and research and development resources than we and our commercial partners do.

ROLVEDON is a novel long-acting G-CSF that employs a proprietary technology that is designed to prolong the duration of biologics, reducing the frequency of administration. Currently, two other novel long-acting G-CSF and six biosimilar G-CSFs marketed in the U.S. compete with ROLVEDON. In addition, there is one molecular entity that has been approved by the FDA but is not currently marketed that may compete with ROLVEDON.

SPRIX competes with currently marketed oral opioids, transdermal opioids, local anesthetic patches, stimulants and implantable and external infusion pumps that can be used for infusion of opioids and local anesthetics, non-narcotic analgesics, local and topical analgesics and anti-arthritics. We face and will continue to face competition from other companies in the pharmaceutical, medical devices and drug delivery industries with respect to SPRIX and INDOCIN products.

25CAMBIA competes with a number of triptans that are used to treat migraines and certain other headaches. Currently, eight triptans are available generically and sold in the U.S. (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan-naproxen and zolmitriptan). There are other products prescribed for or under development for the treatment or prevention of migraines that are now or may become competitive with CAMBIA, including CGRP inhibitor products. Certain parties who have entered into settlement agreements with us began to market generic versions of CAMBIA starting in January 2023.

Otrexup competes with other branded methotrexate products, including other injection and auto-injector products. Competition in the methotrexate market also includes tablets and parenteral dosage forms. In addition, other commonly used pharmaceutical treatments for rheumatoid arthritis include analgesics, NSAIDs, corticosteroids and biologic response modifiers.

If we are unable to negotiate acceptable pricing or obtain adequate reimbursement for our products from third-party payors, our business will suffer.

Sales of our products depend significantly on the availability of acceptable pricing and adequate reimbursement from third-party payors such as:

•government health administration authorities;

•private health insurers;

•health maintenance organizations;

•managed care organizations;

•pharmacy benefit management companies; and

•other healthcare-related organizations.

If reimbursement is not available for our products or any future product candidates, demand for our products may be limited. Further, any delay in receiving approval for reimbursement from third‑party payors could have an adverse effect on our future revenues.

Third-party payors frequently require pharmaceutical companies to negotiate agreements that provide discounts or rebates from list prices and that protect the payors from price increases above a specified annual limit. We have agreed to provide such discounts and rebates to certain third-party payors, and expect increasing pressure to offer larger discounts and rebates or discounts and rebates to a greater number of third-party payors to maintain acceptable reimbursement levels for and access to our products for patients at co-pay levels that are reasonable and customary. Consolidation among large third-party payors may increase their leverage in negotiations with pharmaceutical companies. If we are forced to provide additional discounts and rebates to third-party payors to maintain acceptable access to our products for patients, our results of operations and financial condition could be adversely affected. If third-party payors or wholesalers do not accurately and timely report the eligibility and utilization of our products under discounted programs, our reserves for rebates or other amounts payable to third-party payors may be lower than the amount we are invoiced and we may be required to dispute the amount payable, which would adversely affect our business, financial condition and results of operations. For example, we have had, and continue to have, disputes with managed care providers over rebates related to our products. Even when rebate claims made by such managed care providers are without merit, we may be forced to pay such disputed amounts to the extent our failure to do so could otherwise adversely impact our business, such as our ability to maintain a favorable position on such provider’s formulary. In addition, if competitors reduce the prices of their products, or otherwise demonstrate that they are better or more cost effective than our products, this may result in a greater level of reimbursement for their products relative to our products, which would reduce sales of our products and harm our results of operations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that such third-party payor will pay for the product once coverage is approved. Third-party payors have in the past and may in the future limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, including one or more of our products. Any third-party payor decision not to approve pricing for, or provide adequate coverage and reimbursement of, our products, including by reducing, limiting or denying reimbursement for new products or excluding products that were previously eligible for reimbursement, would limit the market acceptance and commercial prospects of our products and harm our business, financial condition and results of operations. In addition, any third-party payor decision to impose restrictions, limitations or conditions on prescribing or reimbursement of our products, including on the dosing or duration of prescriptions for our products, would harm our business, financial condition and results of operations.

2625

which would reduce sales of our products and harm our results of operations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that such third-party payor will pay for the product once coverage is approved. Third-party payors have in the past and may in the future limit coverage to specific products on an approved list, or formulary, which might not include all the approved products for a particular indication, including one or more of our products. Any third-party payor decision not to approve pricing for, or provide adequate coverage and reimbursement of, our products, including by reducing, limiting or denying reimbursement for new products or excluding products that were previously eligible for reimbursement, would limit the market acceptance and commercial prospects of our products and harm our business, financial condition and results of operations. In addition, any third-party payor decision to impose restrictions, limitations or conditions on prescribing or reimbursement of our products, including on the dosing or duration of prescriptions for our products, would harm our business, financial condition and results of operations.

Our customer concentration can materially adversely affect our financial condition and results of operations.

We sell a significant amount of our products to a limited number of independent wholesale drug distributors. If we were to lose the business of one or more of these distributors, if any of these distributors failed to fulfill their obligations, if any of these distributors experienced difficulty in paying us on a timely basis, or if any of these distributors negotiated lower pricing or extended payment terms, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows.

Risks Related to Our Regulatory Environment

~~Governmental~~We ~~investigations~~are ~~and~~subject ~~inquiries,~~to ~~regulatory~~risks ~~actions~~from ~~and~~changes ~~lawsuits~~in ~~brought~~laws ~~against~~and usregulations byapplicable ~~government~~to, ~~agencies~~ and ~~private~~increased ~~parties~~scrutiny ~~with~~and ~~respect~~investigations toof, ~~Assertio~~the ~~Therapeutics’~~pharmaceutical ~~historical~~industry, ~~commercialization~~which ~~of opioids~~ can adversely affect our business, financial condition and results of operations.

AsThe amanufacture, ~~result~~marketing, ofsale, ~~the~~promotion, ~~greater~~and ~~public~~distribution ~~awareness~~ of ~~the~~our ~~public~~products ~~health~~are ~~issue~~subject ofto ~~opioid~~comprehensive ~~abuse~~government regulation. In addition, ~~there~~the recent change in U.S. federal administration has ~~been~~led ~~increased~~and ~~scrutiny~~is expected to continue to lead to changes in the leadership of, various U.S. federal regulatory agencies and ~~investigation~~changes ~~into~~or proposed or threatened changes to U.S. federal government policy that have led to, in some cases, legal challenges as well as uncertainty around the ~~commercial~~funding, ~~practices~~functioning and policy priorities of ~~opioid~~U.S. ~~manufacturers~~federal ~~generally~~regulatory byagencies and the status of current and future regulations. U.S. federal government policy changes have included seeking to temporarily broadly halt federal funding, ~~state~~seeking to aggressively downsize the U.S. federal government’s workforce and ~~local~~instructing federal agencies to re-prioritize or to cease operating or enforcing certain laws or regulations. We are unable to predict the extent to which the current U.S. federal administration may impose or seek to impose leadership or policy changes at the U.S. federal regulatory agencies responsible for regulating our business or changes to rules and ~~governmental~~policies ~~agencies~~impacting our operations. Any such changes could impose additional costs, asrequire ~~well~~the asattention ~~increased~~of ~~legal~~senior ~~action~~management ~~brought~~or byresult ~~state~~in other changes to or limitations on our business. Government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA, CMS and ~~local~~other ~~governmental~~related ~~entities~~government agencies. These budgetary pressures may reduce the FDA’s and ~~private~~CMS’s ~~parties~~ability to perform their responsibilities. For example, ~~Assertio~~the ~~Therapeutics~~U.S. isgovernment ~~currently~~shut ~~named~~down asin aOctober ~~defendant~~2025. During that shutdown, ~~along~~the ~~with~~FDA ~~numerous~~was ~~other~~not ~~manufacturers~~able ~~and~~to ~~distributors~~accept ofapplications ~~opioid~~for new drugs, ingenerics, ~~multiple~~biologics, ~~lawsuits~~biosimilars ~~alleging~~or ~~common-law~~medical ~~and~~devices ~~statutory~~that ~~causes~~require payment of ~~action~~a ~~for~~user ~~alleged~~fee. ~~misleading~~Any delay in the acceptance, review or ~~otherwise~~approval ~~improper~~of our investigational new drug applications (“INDs”), clinical trial applications, marketing applications (including NDAs/BLAs and ~~promotion~~supplements), or facility inspections could delay or increase the cost of ~~opioid~~our ~~drugs.~~clinical ~~Such~~trials, ~~litigation~~manufacturing ~~and~~scale-up, ~~related~~product ~~matters~~launches ~~are~~or ~~described~~post-approval inchanges. ~~“Item~~Prolonged 8U.S. ~~Financial~~federal ~~Statements~~government shutdowns could materially delay our regulatory timelines, clinical development, reimbursement decisions and ~~Supplementary~~access ~~Data~~to capital. Impacts of the government shutdown on CMS, including a pause on most certification, survey activities, delayed rule-making, ~~Note~~and 8.a ~~Commitments~~temporary hold on some Medicare claims payments, may also impact our ability to obtain acceptable pricing or adequate reimbursement for our products from such government health programs and ~~Contingencies~~our business could be adversely affected.”

In March 2017, Assertio Therapeutics received a letter from Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information regarding Assertio Therapeutics’ historical commercialization of opioid products. Assertio Therapeutics voluntarily furnished information responsive to Sen. McCaskill’s request. Assertio Therapeutics has also received subpoenas or civil investigative demands focused on historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding our historical sales and marketing of opioid products. In addition, the California Department of Insurance (“CDI”) has issued a subpoena to Assertio Therapeutics seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also sought information on Gralise, a non-opioid product which Assertio Therapeutics divested to Alvogen in 2020. Assertio Therapeutics has also received subpoenas from the DOJ and the New York Department of Financial Services seeking documents and information regarding its historical sales and marketing of opioid products. We have also received a subpoena from the New York Attorney General in May 2023, pursuant to which the New York Attorney General is seeking information concerning the historical sales and marketing of former opioid products (Lazanda, NUCYNTA, NUCYNTA ER, and OXAYDO) by Assertio Therapeutics and Zyla. The Company from time to time receives and complies with subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.

These and other governmental investigations or inquiries, as well as lawsuits, in which we are and may become involved may result in additional claims and lawsuits being brought against us by governmental agencies or private parties. It is not possible at this time to predict either the outcome or the potential financial impact of the opioid-related lawsuits mentioned above, any governmental investigations or inquiries of us or any lawsuits or regulatory responses that may result from such investigations or inquiries, settlements of any of the matters discussed above, or otherwise. It is also not possible at this time to predict the additional expenses related to such ongoing opioid-related litigation and investigations, which may be significant. The initiation of any additional investigation, inquiry or lawsuit relating to us, the costs and expenses associated therewith, or any assertion, claim or finding of wrongdoing by us, could:

•adversely affect our business, financial condition and results of operations;

•result in reputational harm and reduced market acceptance and demand for our products;

•harm our ability and our commercial partners’ ability to market our products;

•cause us to incur significant liabilities, costs and expenses; and

•cause our senior management to be distracted from execution of our business strategy.

Furthermore, these pending investigations, inquiries and lawsuits could negatively affect our ability to raise capital and impair our ability to engage in strategic transactions.

We are subject to risks from changes in laws and regulations applicable to, and increased scrutiny and investigations of, the pharmaceutical industry, including the opioid market, which can adversely affect our business, financial condition and results of operations.

The manufacture, marketing, sale, promotion, and distribution of our products are subject to comprehensive government regulation. Changes in laws and regulations applicable to, and increased scrutiny and investigations of, the pharmaceutical industry, including the opioid market, could adversely affect our business and our ability to commercialize our products, thereby adversely affecting our financial condition and results of operations. For example, various federal and state governmental entities, including the U.S. Department of Justice (“DOJ”) and a number of state attorneys general, have launched investigations into the marketing and sales practices of pharmaceutical companies that market or have marketed opioid and non-opioid pain medications, including us. For instance, we have received subpoenas or civil investigative demands from the DOJ, several state attorneys general, the New York Department of Financial Services and other state regulators seeking documentation and information in connection with Assertio Therapeutics’ historical sales and marketing of opioid products. Any negative regulatory request or action taken by a regulatory agency, including the FDA, with respect to our products could adversely affect our ability to commercialize such products or otherwise adversely affect our business, results of operations, and financial condition and may result in increased administrative costs in responding to government inquiries. In addition, the recent change in U.S. federal administration has led and is expected to continue to lead to changes in the leadership of various U.S. federal regulatory agencies and changes or proposed or threatened changes to U.S. federal government policy that have led to, in some cases, legal challenges as well as uncertainty around the funding, functioning and policy priorities of U.S. federal regulatory agencies and the status of current and future regulations. U.S. federal government policy changes have included seeking to temporarily broadly halt federal funding, seeking to aggressively downsize the U.S. federal government’s workforce and instructing federal agencies to re-prioritize or to cease operating or enforcing certain laws or regulations. We are unable to predict the extent to which the current U.S. federal administration may impose or seek to impose leadership or policy changes at the U.S. federal regulatory agencies responsible for regulating our business or changes to rules and policies impacting our operations. Any such changes could impose additional costs, require the attention of senior management or result in other changes to or limitations on our business. For example, the Department of Government Efficiency, an executive administrative agency established by executive order of President Trump, reportedly has been provided access to key payment and contracting systems at CMS to look for opportunities for more effective and efficient use of resources. If the U.S. federal administration imposes or seeks to impose policy changes to the administration of government health programs at CMS, including Medicare and Medicaid, it may impact our ability to obtain acceptable pricing or adequate reimbursement for our products from such government health programs and our business could be adversely affected.

The regulatory actions described above, as well as the related litigation and investigations, not only create financial and operational pressure on us, but could also put pressure on other companies in our industry and with which we have contractual arrangements. Such pressures could negatively impact our contractual counterparties and may give rise to contract cancellations, breaches or rejections in bankruptcy. Furthermore, in the event that a contract counterparty seeks to reject a contract, we may have an unsecured claim for damages, which may not be paid in full (if at all), and we may be forced to return payments made within 90 days of the date of filing for bankruptcy protection. If any of these events should occur, it may have a material adverse effect on our business, financial condition and results of operations.

Our products, including the marketing of our products, is subject to substantial regulation in the U.S. and any failure by us or our commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business.

Our current marketing activities associated with our products, as well as marketing activities related to any other products that we may acquire, or for which we or our collaborative partners obtain regulatory approval, are and will be subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical and biological products. The FDA regulates post-approval promotional labeling and advertising to ensure that they conform to statutory and regulatory requirements. In addition to FDA restrictions, the marketing of prescription drugs is subject to laws and regulations prohibiting fraud and abuse under government healthcare programs. For example, the federal healthcare program anti-kickback statute (“Anti-Kickback Statute”) prohibits giving things of value to induce the prescribing or purchase of products that are reimbursed by federal healthcare programs, such as Medicare and Medicaid. Our arrangements and practices may not, in every case, meet all criteria for applicable exceptions and/or safe harbors for the Anti‑Kickback Statute, and thus would not be immune from prosecution under the statute. Additionally, the Anti‑Kickback Statute and similar state laws are subject to differing interpretations and may contain ambiguous requirements or require administrative guidance for implementation. Finally, some of the safe harbor rules are currently under review for potential revision and may be revised in the future. Given this, our activities could be subject to the penalties under the Anti-Kickback Statute and similar authorities. In addition, federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government. Under these laws, in recent years, the federal government has brought claims against drug manufacturers alleging that certain marketing activities caused false claims for prescription drugs to be submitted to federal programs. Many states have similar statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, and, in some states, such statutes or regulations apply regardless of the payor.

that certain marketing activities caused false claims for prescription drugs to be submitted to federal programs. Many states have similar statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, and, in some states, such statutes or regulations apply regardless of the payor.

Governmental authorities may also seek to hold us responsible for any failure of our commercialization or collaborative partners to comply with applicable statutes or regulations. If we, or our commercial or collaborative partners, fail to comply with applicable FDA regulations or other laws or regulations relating to the marketing of our products, we could be subject to criminal prosecution, civil penalties, seizure of products, injunctions and exclusion of our products from reimbursement under government programs, as well as other regulatory or investigatory actions against our future product candidates, our commercial or collaborative partners or us.

We are subject to numerous ongoing regulatory requirements and continual review with respect to products that have obtained regulatory approval. In addition, the discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer or manufacturing facility, including withdrawal of the product from the market. Manufacturers of approved products are also subject to ongoing regulation and inspection, including compliance with FDA regulations governing cGMP. The FDCA, the Public Health Services Authority, the Controlled Substance Act of 1970 and other federal and foreign statutes and regulations govern and influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of our products. In addition, we and our partners are also subject to ongoing DEA regulatory obligations, including annual registration renewal, security, record keeping, theft and loss reporting, periodic inspection and annual quota allotments for the raw material for commercial production of our products. The failure to comply with these regulations could result in, among other things, warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, non-renewal of marketing applications or authorizations or criminal prosecution, which could adversely affect our business, results of operations and financial condition.

We are also required to report adverse events associated with our products to the FDA and other regulatory authorities. Unexpected or serious health or safety concerns could result in labeling changes, recalls, market withdrawals or other regulatory actions. Recalls may be issued at our discretion or at the discretion of the FDA or other empowered regulatory agencies.

We may incur significant liability if it is determined that we are promoting or have in the past promoted the “off-label” use of our products.

Companies may not promote drugs for “off-label” use—that is, uses that are not described in the product’s labeling and that are not consistent with those approved by the FDA. Physicians may prescribe drug products for off-label uses, and such off-label uses are common across some medical specialties. Although the FDA and other regulatory agencies do not regulate a physician’s choice of treatments, the FDCA and FDA regulations restrict communications on the subject of off-label uses of drug products by pharmaceutical companies. The Office of Inspector General of the U.S. Department of Health and Human Services, the FDA, and the DOJ all actively enforce laws and regulations prohibiting promotion of off-label use and the promotion of products for which marketing clearance has not been obtained. If any ofregulatory ~~the~~agencies open investigations ofor ~~the~~bring ~~DOJ, the attorneys general identified above, and the State of California Department of Insurance (“CDI”), as well as the~~ actions ~~filed by states and municipalities~~ against us, that result in a finding that we engaged in wrongdoing, including sales and marketing practices for our former, current and/or future products that violate applicable laws and regulations, we would be subject to significant liabilities. Such liabilities would damage our reputation, divert management’s attention from our business operations, and harm our business, financial condition and results of operations. For additional information regarding potential liability, see also “ – Governmental investigations and inquiries, regulatory actions and lawsuits brought against us by government agencies and private parties with respect to Assertio Therapeutics’ historical commercialization of opioids can adversely affect our business, financial condition and results of operations.”

Such liabilities would damage our reputation, divert management’s attention from our business operations, and harm our business, financial condition and results of operations.

Healthcare reform can reduce our revenues, increase our expenses and adversely affect the commercial success of our products.

There have been, and there will continue to be, legislative, regulatory and third-party payor proposals to change the healthcare system in ways that could impact our ability to commercialize our products profitably. We anticipate that the federal and state legislatures and the private sector will continue to consider and may adopt and implement healthcare policies, such as the IRA and ACA, intended to curb rising healthcare costs. These cost-containment measures may include, among other measures: requirements for pharmaceutical companies to negotiate prescription drug prices with government healthcare programs; controls on government-funded reimbursement for drugs; new or increased requirements to pay prescription drug rebates to government healthcare programs, including if drug prices increase at a higher rate than inflation; controls on healthcare providers; challenges to or limits on the pricing of drugs, including pricing controls or limits or prohibitions on reimbursement for specific products through other means; requirements to try less expensive products or generics before a more expensive branded product; and public funding for cost effectiveness research, which may be used by government and private third-party payors to make coverage and payment decisions.

29For example, the ACA includes numerous provisions that affect pharmaceutical companies, including provisions intended to expand healthcare coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The ACA also imposes substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit and an annual fee imposed on all manufacturers of brand prescription drugs in the U.S. The ACA also requires increased disclosure obligations and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics and contains cost-containment measures that could reduce reimbursement levels for pharmaceutical products. The ACA also includes provisions known as the Physician Payments Sunshine Act, which require manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid to record any transfers of value to certain U.S. healthcare providers (including, but not limited to, physicians, physician assistants, nurse practitioners, dentists, optometrists, podiatrists, chiropractors and other healthcare providers) and teaching hospitals and to report this data to the CMS annually for subsequent public disclosure. Similar reporting requirements have also been enacted on the state level domestically, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with healthcare professionals. Failure to report appropriate data may result in civil or criminal fines and/or penalties.

~~reimbursement~~In addition, the IRA contains provisions intended to lower beneficiary drug spending. The IRA enables Medicare to negotiate prescription drug prices with manufacturers of certain high-cost drugs for ~~specific~~the ~~products~~first ~~through~~time. ~~other~~A ~~means;~~separate ~~requirements~~provision requires drug manufacturers to ~~try~~pay ~~less~~rebates ~~expensive~~to ~~products~~Medicare orif ~~generics~~their ~~before~~drug prices increase at a ~~more~~higher ~~expensive~~rate ~~branded~~than ~~product;~~the ~~and~~rate ~~public~~of ~~funding~~inflation ~~for~~(the ~~cost~~so-called ~~effectiveness~~inflation ~~research~~rebate provision). Additionally, ~~which~~beginning ~~may~~in be2024, ~~used~~the byIRA ~~government~~eliminates the 5% coinsurance for catastrophic coverage under Medicare Part D; and ~~private~~in ~~third~~2025, the IRA capped the beneficiary annual out-~~party~~of-pocket ~~payors~~expenditure and required new mandatory manufacturer discounts. Since its enactment, CMS has taken steps to ~~make~~implement ~~coverage~~various provisions of the IRA, including negotiating and ~~payment~~publishing ~~decisions~~maximum fair prices for drugs selected under the IRA’s negotiation framework. The ultimate impact of the IRA’s drug pricing provisions on the pharmaceutical industry, including on pricing, reimbursement, and market dynamics, remains uncertain.

~~For~~Legislative ~~example,~~and ~~the~~regulatory ~~ACA~~efforts ~~includes~~to ~~numerous~~implement ~~provisions~~drug ~~that~~pricing reforms, including MFN models, can adversely affect ~~pharmaceutical~~our ~~companies~~business, if implemented. For example, ~~the~~in ~~ACA~~May ~~seeks~~2025, tothe ~~expand~~President ~~healthcare~~of ~~coverage to~~ the ~~uninsured~~United ~~through~~States ~~private~~issued ~~health~~an ~~insurance~~executive ~~reforms~~order ~~and~~instructing anthe ~~expansion~~executive ofbranch ~~Medicaid.~~to ~~The~~communicate ~~ACA~~MFN ~~also~~price ~~imposes~~targets ~~substantial~~to ~~costs on~~ pharmaceutical manufacturers, ~~such~~aiming asto analign ~~increase~~prices with those in ~~liability~~comparably ~~for~~developed ~~rebates~~nations. ~~paid~~In toDecember ~~Medicaid~~2025, CMS subsequently proposed new ~~drug~~mandatory ~~discounts~~demonstration ~~that~~payment ~~must~~models, beincluding ~~offered~~the toGlobal ~~certain~~Benchmark ~~enrollees~~for inEfficient ~~the~~Drug ~~Medicare~~Pricing ~~prescription~~(“GLOBE”) ~~drug~~for ~~benefit~~Medicare Part B and anGuarding ~~annual~~U.S. ~~fee~~Medicare ~~imposed~~Against onRising ~~all~~Drug ~~manufacturers~~Costs of(“GUARD”) ~~brand~~for ~~prescription~~Medicare ~~drugs~~Part inD ~~the~~under ~~U.S.~~its ~~The~~Center ~~ACA~~for ~~also~~Medicare ~~requires~~and ~~increased~~Medicaid ~~disclosure~~Innovation ~~obligations~~(“CMMI”) authority. If finalized, the GLOBE and anGUARD ~~expansion~~models ofwould animpose ~~existing~~additional ~~program~~mandatory ~~requiring~~rebates ~~pharmaceutical~~on ~~discounts~~manufacturers toof certain ~~types~~Medicare ofPart ~~hospitals~~B and ~~federally~~Medicare ~~subsidized~~Part ~~clinics~~D ~~and~~drugs, ~~contains~~for ~~cost-containment~~select ~~measures~~Medicare ~~that~~populations ~~could~~intended ~~reduce~~to ~~reimbursement~~represent ~~levels~~25% ~~for~~of ~~pharmaceutical~~Medicare ~~products.~~patients, ~~The~~if ~~ACA~~the ~~also~~Medicare ~~includes~~prices ~~provisions~~for ~~known~~such asproducts ~~the~~exceed ~~Physician~~those ~~Payments~~paid ~~Sunshine~~in ~~Act,~~economically ~~which~~comparable ~~require~~countries. ~~manufacturers~~Both ofthe ~~drugs,~~GLOBE ~~biologics,~~and ~~devices~~GUARD ~~and~~models ~~medical~~would ~~supplies~~be ~~covered~~tested ~~under~~over ~~Medicare~~a ~~and~~5-year ~~Medicaid~~performance toperiod ~~record~~and ~~any~~would ~~transfers~~run ofthrough ~~value~~2031, towith ~~physicians~~rebate invoicing and ~~teaching~~reconciliation ~~hospitals~~continuing ~~and~~into to2033. ~~report~~If ~~this~~these ~~data~~models toare ~~the~~finalized ~~CMS~~as ~~for~~proposed ~~subsequent~~under ~~public~~CMMI ~~disclosure.~~authority, ~~Similar~~we ~~reporting~~could ~~requirements~~be ~~have~~required ~~also~~to ~~been~~pay ~~enacted~~additional rebates on ~~the~~products ~~state~~reimbursed ~~level~~by ~~domestically,~~Medicare ~~and~~for anROLVEDON ~~increasing~~for ~~number~~the ofcovered ~~countries~~populations ~~worldwide~~during ~~either~~the ~~have~~applicable ~~adopted~~model orperiods. ~~are~~These ~~considering~~proposed ~~similar~~reforms ~~laws~~create ~~requiring~~uncertainty ~~transparency~~for ofour ~~interactions~~business, ~~with~~and ~~healthcare~~they ~~professionals.~~remain ~~Failure~~subject to ~~report~~change ~~appropriate~~through ~~data~~potential ~~may~~legal ~~result~~challenges ~~in civil~~ or ~~criminal~~subsequent ~~fines~~rulemaking ~~and/~~or ~~penalties~~sub-regulatory guidance. While we are unable to predict

In addition, the IRA contains provisions intended to lower beneficiary drug spending. The IRA enables Medicare to negotiate prescription drug prices with manufacturers of certain high-cost drugs for the first time. A separate provision requires drug manufacturers to pay rebates to Medicare if their drug prices increase at a higher rate than the rate of inflation (the so-called inflation rebate provision). Additionally, beginning in 2024, the IRA eliminates the 5% coinsurance for catastrophic coverage under Medicare Part D; in 2025, the IRA will cap the beneficiary annual out-of-pocket expenditure. These efforts to reduce aggregate beneficiary spending are expected to shift some costs to drug manufacturers. However, actions by the new administration in the U.S. may spark uncertainty for the IRA. Although a full repeal of the IRA may be unlikely due to its budgetary impact, the new U.S. administration could change some of the IRA provisions, including Medicare drug price negotiations.28

Inwhether ~~addition,~~any ~~while~~pending weor ~~are~~future ~~not~~reforms ~~currently~~may ~~engaged~~be ~~in a significant number of clinical trials at this time~~adopted, if ~~that~~such ~~changes~~reforms ~~and we~~ are ~~unable~~adopted tothey ~~adapt~~could tolower ~~changes in existing requirements or the adoption of new requirements or policies governing clinical trials,~~ our ~~development plans may be impacted. For example~~pricing, inwhich ~~December~~would ~~2022,~~have ~~with the passage of Food and Drug Omnibus Reform Act (“FDORA”), Congress required sponsors to develop and submit~~ a ~~Diversity~~material ~~Action~~negative ~~Plan~~impact ~~(“DAP”)~~on ~~for~~our ~~each~~competitive ~~Phase~~position ~~3 clinical trial or any other “pivotal study” of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations~~ in ~~late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA,~~ the ~~FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA~~market, ~~the~~our ~~DAP~~sales ~~guidance~~levels ~~when finalized will have the force of law because FDORA specifically dictates that the form~~ and ~~manner~~our ~~for submission of DAPs are specified in FDA guidance~~profitability. On January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025, on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website. This action raises questions about the applicability of statutory obligations to submit DAPs and the agency’s current thinking on best practices for clinical development.

In addition, while we are not currently engaged in a significant number of clinical trials at this time, if that changes and we are unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of Food and Drug Omnibus Reform Act (“FDORA”), Congress required sponsors to develop and submit a Diversity Action Plan (“DAP”) for each Phase 3 clinical trial or any other “pivotal study” of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. In January 2025, in response to an Executive Order issued by the President of the United States on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website. This action raises questions about the applicability of statutory obligations to submit DAPs and the agency’s current thinking on best practices for clinical development.

Any new laws or regulations that have the effect of imposing additional costs or regulatory burden on pharmaceutical manufacturers, or otherwise negatively affect the industry, could adversely affect our ability to successfully commercialize our products and any future product candidates. The implementation of any price controls, caps on prescription drugs or price transparency requirements, whether at the federal level or state level, could adversely affect our business, operating results and financial condition.

We are not always able to protect our intellectual property and are subject to risks from liability for infringing the intellectual property of others.

Our success depends in part on our ability to obtain and maintain patent protection for our products and technologies, and to preserve our trade secrets. Our policy is to seek to protect our proprietary rights by, among other methods, filing patent applications in the U.S. and foreign jurisdictions to cover certain aspects of our technology. We hold patents in the U.S. and in foreign countries. In addition, we may pursue patent applications relating to our technologies in the U.S. and abroad. Any such patent applications may lack priority over other applications or may not result in the issuance of patents. Even if issued, our patents may not be sufficiently broad to provide protection against competitors with similar technologies and may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or may not provide us with competitive advantages against competing products. We also rely on trade secrets and proprietary know-how, which are difficult to protect. We seek to protect such information, in part, by entering into confidentiality agreements with employees, consultants, collaborative partners and others before such persons or entities have access to our proprietary trade secrets and know-how. These confidentiality agreements may not be effective in certain cases, due to, among other things, the lack of an adequate remedy for breach of an agreement or a finding that an agreement is unenforceable. In addition, our trade secrets may otherwise become known or be independently developed by competitors.

agreements with employees, consultants, collaborative partners and others before such persons or entities have access to our proprietary trade secrets and know-how. These confidentiality agreements may not be effective in certain cases, due to, among other things, the lack of an adequate remedy for breach of an agreement or a finding that an agreement is unenforceable. In addition, our trade secrets may otherwise become known or be independently developed by competitors.

Our ability to develop our technologies and to make commercial sales of products using our technologies also depends on not infringing other patents or intellectual property rights. We are not aware of any such intellectual property claims directly against us. However, the pharmaceutical industry has experienced extensive litigation regarding patents and other intellectual property rights. Patents issued to third parties in the future could be asserted against us, although we believe that we do not infringe any valid claim of any patents. If claims concerning any of our products were to arise and it was determined that these products infringe a third party’s proprietary rights, we or our commercial partners could be subject to substantial damages for past infringement or could be forced to stop or delay activities with respect to any infringing product, unless we or our commercial partner, as applicable, can obtain a license, or our product may need to be redesigned so that it does not infringe upon such third party’s patent rights, which may not be possible or could require substantial funds or time. Such a license may not be available on acceptable terms, or at all. Even if we, our collaborators or our licensors were able to obtain a license, the rights may be nonexclusive, which could give our competitors access to the same intellectual property. In addition, any public announcements related to litigation or interference proceedings initiated or threatened against us, even if such claims are without merit, could cause our stock price to decline.

Macroeconomic conditions can materially impact our business and operations.

Adverse economic conditions, including inflationary pressures, economic slowdown or recession, relatively high interest rates, government shutdowns, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotechnology areas), potential U.S. federal government shutdowns, geopolitical conflicts, financial institution instability and similar events beyond our control can affect our business and financial results. For instance, recent

supply chain constraints have led to higher inflation, which if sustained could have a negative impact on the acquisition of our APIs or the cost to manufacture and purchase our products, as well as our business and results of operations. If inflation or other factors were to significantly increase our business costs or the costs of the manufacturers we use to manufacture our products, our ability to purchase our APIs or our products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of our business and our ability to raise capital on favorable terms, or at all, in order to fund our operations, business development efforts and other business plans. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers to supply our APIs and our manufacturers to manufacture our products cost effectively. For example, in September 2025, the U.S. announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity (the “Pharma Tariffs”). Certain major drug producers and manufacturers have negotiated or are in negotiations with the U.S. federal administration to receive relief from such tariffs. While implementation of the Pharma Tariffs is subject to uncertainty, there is a possibility that the Pharma Tariffs could impact the cost at which we purchase the APIs or other components for our products. Current and threatened tariffs are subject to implementation or change with little notice. For example, the U.S. Supreme Court ruled in February 2026 that certain tariffs imposed by the U.S. federal government under the International Emergency Economic Powers Act exceeded presidential authority and therefore are invalid. However, tariffs imposed under different statutes (including the Pharma Tariffs, if implemented) were not directly impacted by the decision and therefore remain in place. The scope and durability of existing and future tariffs remain uncertain, and any potential impact on our business is unclear at this time. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. New tariffs (including potential tariffs on imported pharmaceuticals into the U.S.) and greater restrictions on trade generally may be imposed. Concerns also remain around the social, political and economic impacts of the changing political landscape in Europe and elsewhere. Broader geopolitical tensions remain high among the U.S. Russia, China and across the Middle East. Given the international scope of our supply chain, any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, can have a material adverse effect on our business, financial condition, cash flows and results of operations and can cause the market value of our common shares and/or debt securities to decline.

Risks Related to Our Business Development Activities

Our success is dependent on our ability to successfully execute business development strategies, strategic partnerships, acquisitions of businesses, product candidates, products, or technologies, and investment opportunities to build and grow for the future. ~~Failure~~Our failure or inability to do so will limit our business growth and prospects.

Over the past several years, we have actively pursued and executed several opportunistic business development and strategic transactions designed to grow our revenues and profits and improve our balance sheet, with varying levels of success. Successfully identifying and executing on such business development and strategic transactions is not easily achievable and depends on several factors, including, but not limited to, the availability and willingness of other parties to transact on terms we find attractive and our ability to fund such transactions from our existing cash flows or raise funds from third parties. If we are unable to find attractive opportunities, finance them and successfully execute and integrate such acquisitions, our business growth and prospects will be adversely impacted.

AnOur ~~important~~ability ~~element~~to offund our business ~~strategy~~development isstrategies tomay ~~actively~~be ~~seek~~limited toby ~~acquire~~the ~~products,~~financial ~~technologies~~resources orwe ~~companies~~are ~~and~~able to ~~in-license~~obtain, orwhich ~~seek~~may ~~co-promotion~~restrict ~~rights~~our ability to ~~additional products. In the past~~pursue, wefund ~~have~~and ~~acquired~~complete ~~ROLVEDON,~~acquisitions ~~Otrexup,~~or ~~Sympazan,~~other ~~CAMBIA,~~strategic ~~the~~transactions. ~~INDOCIN~~We ~~products,~~may ~~SPRIX,~~be ~~NUCYNTA~~unable ~~and~~to ~~NUCYNTA~~finance ERpotential ~~(both~~transactions ~~NUCYNTA~~from ~~products~~existing ~~were~~cash ~~subsequently~~flows, ~~divested~~and tothere ~~Collegium~~can ~~in February 2020). We cannot~~ be ~~certain~~no assurance that we will be able to ~~successfully~~raise ~~identify,~~necessary ~~pursue,~~third-party ~~finance~~financing ~~and~~on ~~complete~~acceptable ~~any~~terms ~~future acquisitions~~ or ~~whether~~at weall. ~~would~~As bea ~~able~~result, towe ~~successfully~~may ~~integrate~~forgo or ~~develop~~be ~~any~~unable ~~acquired~~to ~~business,~~complete ~~product~~attractive orbusiness ~~technology~~development opportunities, ~~successfully~~or ~~commercialize~~we ~~and~~may ~~realize~~be ~~the~~required ~~anticipated~~to ~~benefits~~accept ~~from~~less ~~acquired~~favorable ~~products~~terms, orthereby ~~retain~~limiting ~~any~~our ~~key~~ability ~~employees.~~to Ifenhance weor ~~are~~expand ~~unable~~our toproduct ~~enhance~~portfolio. ~~and~~This ~~broaden~~would ~~our~~further ~~product~~adversely ~~offerings,~~impact our business growth and prospects ~~will be limited~~.

InAn ~~addition,~~important ifelement of our ~~executive~~business ~~management~~strategy ~~team~~ is ~~not~~to ~~able~~actively seek to acquire product candidates, products, technologies or companies and to in-license aor ~~timely~~seek ~~manner,~~co-promotion rights to ~~develop~~additional products. In the past, ~~implement~~we ~~and~~have ~~execute~~acquired ~~successful~~ROLVEDON, ~~business~~Otrexup, ~~development~~Sympazan, ~~strategies~~CAMBIA, the INDOCIN products, SPRIX, NUCYNTA and ~~plans~~NUCYNTA ER (both NUCYNTA products were subsequently divested to ~~maintain~~Collegium in February 2020 and ~~increase~~we ~~our~~ceased ~~product~~commercializing ~~revenues,~~Otrexup ~~our~~in ~~business,~~July ~~financial~~2025). ~~condition~~We ~~and~~cannot ~~results~~be ofcertain ~~operations~~that we will be ~~materially~~able ~~and~~to ~~adversely~~successfully ~~affected~~identify, pursue, finance and ~~the~~complete ~~existing~~any ~~business~~future ~~may~~acquisitions beor ~~required~~whether towe ~~take~~would ~~further~~be ~~steps~~able to ~~reduce~~successfully ~~its~~obtain ~~costs~~regulatory atapprovals ~~some~~and ~~point~~launch, inif ~~time.~~applicable, Itintegrate ~~may~~or ~~take~~develop ~~time~~any ~~for~~acquired ~~our~~business, ~~executive~~product ~~management~~candidate, ~~team~~product or technology, ~~despite~~successfully ~~their~~commercialize ~~significant~~and ~~industry-related~~realize ~~experience,~~the toanticipated ~~develop,~~benefits ~~implement~~from acquired products or retain any key employees. If we are unable to enhance and ~~execute~~broaden our ~~business~~product ~~strategies~~offerings, our business and ~~plans.~~prospects will be limited.

In addition, if our executive management team is not able to develop, implement and execute successful business development strategies and plans to maintain and increase our product revenues in a timely manner, our business, financial condition and results of operations will be materially and adversely affected, and the existing business may be required to take further steps to reduce its costs at some point in time. It may take time for our executive management team, despite their significant industry-related experience, to develop, implement and execute our business strategies and plans.

Further, our future business strategies and plans may differ materially, or may continue to evolve, from those we previously pursued. If our business strategies and plans, or our efforts to realize future operational efficiencies, cause disruption in our business or operations or do not achieve the level of success or results we anticipate, our business, financial condition and results of operations will be materially and adversely affected.

Strategic transactions that fail to achieve the anticipated levels of revenue, synergies and profit growth will cause our business to suffer.

We seek to engage in strategic transactions with third parties, such as product acquisitions, strategic partnerships, joint ventures, business combinations or divestitures. We face significant competition in seeking potential strategic partners and transactions, and the negotiation process for acquiring any product or engaging in strategic transactions can be time-consuming and complex. Engaging in strategic transactions, such as acquisitions of product rights, businesses combinations and divestitures, and commercialization arrangements, have in the past and may in the future require us to incur non-recurring and other charges, increase our near- and long-term expenditures, pose integration challenges and fail to achieve the anticipated results or synergies or distract our management and business, which may harm our business.

31As part of an effort to acquire a product candidate, product or company or to enter into other strategic transactions, we conduct due diligence with the goal of identifying, evaluating and assessing material risks involved in the transaction. However, it is not possible to ascertain, evaluate and accurately assess all potential risks, which may impact our ability to realize the intended advantages of the transaction. We also assume liabilities and legal risks in connection with a transaction, including those relating to activities of the seller prior to the consummation of the transaction and contracts that we assume. Failure to realize the expected benefits from acquisitions or strategic transactions that we may consummate, or that we have completed, such as those described above, whether as a result of identified or unidentified risks, integration difficulties, regulatory setbacks, governmental investigations, independent actions of or financial position of our collaborative partners, litigation or other events, could adversely affect our business, results of operations and financial condition.

divestitures, and commercialization arrangements, have in the past and may in the future require us to incur non-recurring and other charges, increase our near- and long-term expenditures, pose integration challenges and fail to achieve the anticipated results or synergies or distract our management and business, which may harm our business.

As part of an effort to acquire a product or company or to enter into other strategic transactions, we conduct due diligence with the goal of identifying, evaluating and assessing material risks involved in the transaction. However, it is not possible to ascertain, evaluate and accurately assess all potential risks, which may impact our ability to realize the intended advantages of the transaction. We also assume liabilities and legal risks in connection with a transaction, including those relating to activities of the seller prior to the consummation of the transaction and contracts that we assume. Failure to realize the expected benefits from acquisitions or strategic transactions that we may consummate, or that we have completed, such as those described above, whether as a result of identified or unidentified risks, integration difficulties, regulatory setbacks, governmental investigations, independent actions of or financial position of our collaborative partners, litigation or other events, could adversely affect our business, results of operations and financial condition.

These factors, many of which are beyond our control, could delay or prevent the achievement of our business objectives and cause our business, financial condition and results of operations to be materially and adversely affected.

Failure to integrate any business, product or technology we acquire, will cause our business, financial condition and operating results to suffer.

Integrating any business, product or technology we acquire is expensive and time-consuming and can disrupt and adversely affect our ongoing business, including product sales, and distract our management. Our ability to successfully integrate any business, product or technology we acquire depends on a number of factors, including, but not limited to, our ability to:

•maintain existing agreements with customers, suppliers, distributors and vendors, avoid delays in entering into new agreements with prospective customers, suppliers, distributors and vendors, and leverage relationships with such third parties;

•obtain and maintain adequate coverage, reimbursement and pricing from managed care, government and other third-party payors with respect to any acquired product;

•maintain and increase sales of our existing products;

•establish or manage the transition of the manufacture and supply of any acquired product, including the necessary active pharmaceutical ingredients, excipients and components;

•integrate and unify the offerings and services available to customers;

•integrate the owned and licensed technologies from third parties;

•integrate personnel from the acquired business;

•combine our and the acquired business’ operations and corporate functions, if any;

•address possible differences in business backgrounds, corporate cultures and management philosophies, if any;

•meet the capital requirements of the acquired business in a manner that permits us to achieve any cost savings or other synergies anticipated to result from the acquisition;

•identify and add the necessary sales, marketing, manufacturing, regulatory and other related personnel, capabilities and infrastructure that are required to successfully integrate any acquired business, product or technology;

•minimize the disruption and distraction of our management and other employees in connection with the integration of any acquired business, product or technology;

•harmonize our and the acquired business’ operating practices, compensation programs, internal controls and other policies, processes and procedures;

•manage the transition and migration of all commercial, financial, legal, clinical, regulatory and other pertinent information relating to any acquired business, product or technology;

•identify and eliminate redundant and underperforming functions and assets;

•comply with legal, regulatory and contractual requirements applicable to any acquired business, product or technology; and

•maintain and extend intellectual property protection for any acquired product or technology.

If we are unable to perform the above functions or otherwise effectively integrate any acquired businesses, products or technologies, our business, financial condition and operating results will suffer.

Risks Related to Our Financial Position

Our existing capital resources may not be sufficient to fund our future operations or product acquisitions and strategic transactions that we may pursue.

We fund our operations primarily through ~~revenues~~our ~~from~~existing ~~product~~capital ~~sales~~resources and operating cash flows and do not have any committed sources of capital. To the extent that our existing capital resources and ~~revenues~~operating ~~from~~cash ~~ongoing~~flows ~~operations~~ are insufficient to fund our future operations, including our litigation-related costs, product acquisitions and strategic transactions that we may pursue, we will have to seek to raise additional funds through the sale of our equity securities, through additional debt financing, from development and licensing arrangements and/or from the sale of assets. We may be unable to raise such additional capital on a timely basis and on favorable terms, or at all. If we raise additional capital by selling our equity or convertible debt securities, the issuance of such securities could result in dilution of our shareholders’ equity positions.

Our failure to generate sufficient cash flow from our business to make payments on our debt would adversely affect our business, financial condition and results of operations. Our indebtedness could limit our ability to incur additional debt to fund our operations.

We have ~~significant~~$40 ~~indebtedness~~million aggregate principal amount outstanding under our 6.5% Convertible Senior Notes, which mature on September 1, 2027, with interest payable semi-annually in arrears on March 1 and September 1 of each year (the “2027 Convertible Notes”). Holders of the 2027 Convertible Notes will have the right to require us to repurchase their 2027 Convertible Notes for cash upon the occurrence of a “fundamental change,” as defined in the indenture for the 2027 Convertible Notes, and we may elect to settle all or a portion of the conversion obligation of the 2027 Convertible Notes in cash. Our ability to make scheduled payments of the principal of, to pay interest on, to offer to repurchase the 2027 Convertible Notes upon a fundamental change as defined in the indenture for the 2027 Convertible Notes, or to refinance the 2027 Convertible Notes and any additional debt obligations we may incur depends on our future performance, which is subject to economic, financial, competitive and other factors that may be beyond our control. If we are unable to generate the necessary cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Any failure to generate sufficient cash flow to satisfy our obligations under the 2027 Convertible Notes or any future indebtedness could lead to a default under the 2027 Convertible Notes or such indebtedness.

The indenture for the 2027 Convertible Notes contains covenants limiting our ability in the future to secure our or our subsidiaries’ assets or have our subsidiaries issue guarantees without equally and ratably securing or guaranteeing the 2027 Convertible Notes. These covenants may make it more difficult for us to incur indebtedness to fund our operations on attractive terms or at all.

We may seek to refinance all or a portion of our outstanding indebtedness in the future. Any such refinancing would depend on the capital markets and business and financial conditions at the time, which could affect our ability to obtain attractive terms if or when desired or at all.

In addition, our significant indebtedness, combined with our other financial obligations and contractual commitments, could have other important consequences to our business. For example, it could:

•limit our ability to borrow additional amounts for working capital and other general corporate purposes, including funding possible acquisitions of, or investments in, new and complementary businesses, products and technologies, which is a key element of our corporate strategy;

•make it more difficult for us to meet our payment and other obligations under our indebtedness;

•require the dedication of a substantial portion of our cash flow from operations to service our indebtedness, thereby reducing the amount of our cash flow available for other purposes, including working capital, business development activities, any future clinical trials and/or research and development, capital expenditures and other general corporate purposes;

•result in other events of default under our indebtedness, which events of default could result in all of our debt becoming immediately due and payable;

•make us more vulnerable to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;

•limit our flexibility in planning for, or reacting to, changes in our business and our industry; and

•put us at a disadvantage compared to our competitors who have less debt.

Any of these factors can adversely affect our business, financial condition and results of operations. In addition, if we incur additional indebtedness, the risks related to our business and our ability to service or repay our indebtedness would increase.

We have incurred operating losses in the past and may incur operating losses in the future.

We have incurred net losses in many of the years of our existence, including in the past ~~two~~three years. We may incur operating losses in future years. Any such losses may have an adverse impact on our total assets, shareholders’ equity and working capital.

We have significant amounts of long-lived assets which depend upon future positive cash flows to support the value recorded in our balance sheet. We have recognized impairment charges in the past and may recognize impairment charges in the future should actual financial results differ materially from our projections.

Our consolidated balance sheet contains significant amounts of long-lived assets, including intangible assets representing the product rights which we have acquired., Wewhich ~~review~~have ~~the~~a total net carrying value of $48.9 million as of December 31, 2025. The net carrying amount of our ~~long-lived~~product rights intangible assets ~~when~~related ~~indicators~~to ofROLVEDON ~~impairment~~and Sympazan are ~~present~~$34.7 million and $10.7 million, respectively, as ~~was~~of ~~the~~December ~~case~~31, in2025. ~~the~~We ~~third~~review ~~quarter~~the ~~and~~carrying ~~fourth~~value ~~quarter~~ of ~~2023~~our ~~and~~long-lived inassets ~~each~~when ~~quarter~~indicators of ~~2024~~impairment are present. Conditions that could indicate impairment of long-lived assets include, but are not limited to, our market capitalization declining below the book value of our equity, a significant adverse change in market conditions, significant competing product launches by our competitors, a significant adverse change in the manner in which the long-lived asset is being used, and adverse legal or regulatory outcomes.

During each quarter of ~~the~~2025 ~~three~~and ~~months ended December 31,~~ 2024, ~~September~~our ~~30,~~market ~~2024,~~capitalization ~~June~~was ~~30,~~below ~~2024 and March 31, 2024, we determined that~~ the book value of our equity ~~exceeded our market capitalization~~, which management determined represented an indicator of impairment with respect to our long-lived assets. ~~Applying~~For the ~~relevant~~three ~~accounting~~months ~~guidance,~~ended ~~management~~September ~~first~~30, ~~assessed~~2025, ~~the~~we ~~recoverability~~also ofrecognized ~~our~~an ~~long-lived~~additional ~~assets~~indicator atof ~~the~~impairment ~~product~~in ~~level~~our atSPRIX ~~each~~asset ~~date.~~group ~~After~~related ~~grouping~~to ~~the~~a ~~long-lived~~change ~~assets~~in at the ~~lowest~~expected ~~level~~timing ~~for~~of ~~which there are identifiable~~ cash flows ~~that~~from ~~are~~SPRIX ~~largely~~net ~~independent~~product ofsales. Applying the ~~cash~~relevant ~~flows~~accounting ~~of other assets and liabilities~~guidance, we ~~estimated~~first ~~the~~assessed ~~future net undiscounted cash flows expected to be generated from~~ the ~~use~~recoverability of ~~the~~our long-lived ~~asset~~assets ~~groups and their eventual disposition~~ at ~~each impairment testing date. We then compared~~ the ~~estimated~~product ~~undiscounted~~level ~~cash flows to the carrying amounts of the long-lived asset groups~~ at each date.

For the assessment performed for the three months ended ~~December~~September 3130, ~~2024~~2025, we determined that the ~~estimated~~ undiscounted cash flows and the fair value of the ~~Otrexup~~SPRIX asset group were less than its carrying value and recognized an impairment ~~loss~~ for this asset group of ~~approximately~~ $51.27 million, ~~reducing~~during ~~its~~the ~~carrying~~third ~~value~~quarter ~~to zero. For all~~ of ~~our other asset groups~~2025, ~~the~~reducing ~~estimated~~its ~~undiscounted cash flows exceeded their~~ carrying ~~amounts,~~value ~~and we concluded that the other asset groups were fully recoverable and no adjustment~~ to ~~the~~$4.6 ~~carrying values was required~~million.

For the ~~assessments~~assessment performed for ~~each of~~ the three months ended ~~September~~December ~~30, 2024, June 30, 2024 and March~~ 31, 2024, we determined that the estimated undiscounted cash flows ~~were~~and infair ~~excess~~value of the ~~carrying~~Otrexup ~~amounts~~asset ~~for~~group ~~all~~were ofless ~~the~~than ~~long-lived~~its ~~asset~~carrying ~~groups~~value atand ~~each~~recognized an impairment ~~testing~~for ~~date.~~this ~~Accordingly,~~asset wegroup ~~concluded~~of ~~that~~$5.2 ~~the~~million ~~long-lived~~during ~~asset~~the ~~groups~~fourth ~~were~~quarter ~~fully~~of ~~recoverable~~2024, ~~and~~reducing noits ~~adjustment to their~~ carrying ~~values~~value ~~was~~to ~~required~~zero.

During each of the three months ended December 31, 2023 and September 30, 2023, we performed an assessment of the recoverability and impairment of our long-lived assets as a result of the book value of our equity exceeding our market capitalization, which management determined represented an indicator of impairment. Similar to each of the assessments performed in each quarter of 2024, for the three months ended December 31, 2023 management assessed the recoverability of our long-lived assets at the product level at that date. For the three months ended September 30, 2023, management assessed the recoverability of our long-lived assets at the entity level. In each case, management determined that the fair value of the identified asset group was not fully recoverable and was less than each of their carrying values and recognized an impairment loss for the asset group. For the three months ended December 31, 2023, we recognized an impairment loss for the INDOCIN and Otrexup product asset groups of approximately $36.0 million and $4.8 million, respectively. For the three months ended September 30, 2023, management concluded that the fair value of the entity level asset group was less than its carrying value and recognized an impairment loss of approximately $238.8 million, which was allocated to the intangible assets of the group. 33

InFor ~~performing~~all the assessments for our ~~impairment~~other ~~tests,~~asset ~~which~~groups ~~assess~~performed ~~the~~during ~~recoverability~~each ofquarter ~~our~~in ~~assets~~2025 and 2024, we ~~utilize~~determined ~~our~~that ~~future~~the ~~projections~~estimated ofundiscounted cash flows. ~~Projections~~were in excess of ~~future~~the ~~cash~~carrying ~~flows~~amounts ~~are~~for ~~inherently~~all ~~subjective~~our ~~and~~long-lived ~~reflect~~asset ~~assumptions~~groups ~~that~~at ~~may~~each orimpairment ~~may~~testing ~~not~~date. ~~ultimately~~Accordingly, bewe ~~realized.~~concluded ~~Significant~~that ~~assumptions~~the ~~utilized~~long-lived inasset ~~our~~groups ~~projections~~were ~~include,~~fully ~~but~~recoverable ~~are~~and ~~not~~no ~~limited~~adjustment to, ~~our~~their ~~evaluation~~carrying ofvalues ~~the~~was ~~market~~ required.

34In performing our impairment tests, which assess the recoverability of our assets, we utilize our future projections of cash flows. Projections of future cash flows are inherently subjective and reflect assumptions that may or may not ultimately be realized. Significant assumptions utilized in our projections include, but are not limited to, our evaluation of the market opportunity for our products, the current and future competitive landscape and resulting impacts to product pricing, future regulatory actions, planned strategic initiatives and the realization of benefits associated with our existing patents. Given the inherent subjectivity and uncertainty in projections, we could experience significant unfavorable variances in future periods or revise our projections downward. This would result in an increased risk that our long-lived assets may be impaired. Any future impairments could have a material adverse effect on our financial condition and results of operations.

~~opportunity~~We ~~for~~have ~~our~~significant ~~products,~~amounts ~~the~~of ~~current and future competitive landscape and resulting impacts to product pricing~~inventory, ~~future regulatory actions, planned strategic initiatives~~ and ~~the~~we ~~realization~~have ofrecognized ~~benefits~~inventory ~~associated~~write-off ~~with~~charges ~~our~~in ~~existing patents. Given~~ the ~~inherent~~past ~~subjectivity~~ and ~~uncertainty~~may inrecognize ~~projections,~~write-off wecharges ~~could experience significant unfavorable variances~~ in ~~future~~the ~~periods or revise our projections downward. This would result in an increased risk that our long-lived assets may be impaired. Any~~ future ~~impairments could have a material adverse effect on our financial condition and results of operations~~.

WeInventories ~~have significant amounts of inventory which~~ are stated at the lower of cost or net realizable value, with cost determined by specific manufactured lot. Inventories consist of costs of the active pharmaceutical ingredient, contract manufacturing and packaging costs. We ~~have~~review ~~recognized~~for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand and projected demand, as well as inventory that may not be salable because it does not meet our quality standards. We write ~~off~~down ~~charges~~the invalue of potentially excess, dated or obsolete inventory, or inventory with quality issues impacting its salability, when evidence of these conditions exist. For the ~~past~~years ended December 31, 2025 and 2024, we recognized $4.5 million and $9.0 million of inventory write-downs, respectively. We may recognize inventory write-~~off~~downs ~~charges~~ in the future based on changes in projected demand, continuing quality issues and/or other factors that we are not yet aware, any of which could have an adverse effect on our financial condition, results of operations or cash flows.

Inventories are stated at the lower of cost or net realizable value, with cost determined by specific manufactured lot. Inventories consist of costs of the active pharmaceutical ingredient, contract manufacturing and packaging costs. We review for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand and projected demand, as well as inventory that may not be salable because it does not meet our quality standards. We write down the value of potentially excess, dated or obsolete inventory, or inventory with quality issues impacting its salability, when evidence of these conditions exist. For the years ended December 31, 2024 and 2023, we recognized $9.0 million and $3.3 million of inventory write-downs, respectively. We may recognize inventory write-downs in the future based on changes in projected demand, continuing quality issues and/or other factors that we are not yet aware, any of which could have an adverse effect on our financial condition, results of operations or cash flows.

Our financial results are impacted by management’s assumptions and use of estimates.

The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used ~~when accounting for amounts recorded~~ in ~~connection with acquisitions, including initial fair value determinations of assets and liabilities as well as subsequent fair value measurements. Additionally, estimates are used in~~ determining items such as product returns, rebates, evaluation of impairment of intangible assets, amounts recorded in connection with acquisitions and taxes on income. Although management believes these estimates are based upon reasonable assumptions within the bounds of its knowledge of our business and operations, actual results could differ materially from these estimates. For additional information, please refer to the Critical Accounting Policies and Significant Estimates section within “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

We face risks relating to product liability losses and other litigation liability for which we may be unable to maintain or obtain adequate insurance.

We are, or may be, involved in various legal proceedings, lawsuits and certain government inquiries and investigations, including with respect to, but not limited to, securities class action lawsuits, Medicare and Medicaid reimbursement claims, patent infringement, product liability, personal injury, antitrust matters, breach of contract, ~~opioid-related matters,~~ promotional practices and compliance with laws relating to the manufacture and sale of controlled substances. For example, ~~as discussed below,~~ we, along with other opioid manufacturers and, often, distributors, have been named in lawsuits related to the manufacturing, distribution, marketing and promotion of opioids, and received various subpoenas and requests for information on the same matters. Further, we are subject to ~~pending antitrust litigation and pending and potential future~~ shareholder litigation relating to the Spectrum Merger and/or the approval and launch of generic indomethacin suppositories in the second half of 2023, and Spectrum is named in several securities class action and shareholder derivative lawsuits filed by former Spectrum stockholders. ~~We also have a qui tam complaint filed against Depomed, Inc. (now known as Assertio Therapeutics) for which a settlement in principle was reached in the fourth quarter of 2024.~~ Such litigation and related matters are described in “Item 8. Financial Statements and Supplementary Data – Note 8. Commitments and Contingencies.”

The defense of these legal proceedings, inquiries, and investigations have resulted in, and are expected to continue to result in, us incurring significant expenses and may adversely impact our ability to execute product acquisitions and strategic transactions using our common stock, obtain financing or refinance existing debt, or could make us less attractive to potential acquirers. In addition, other than with respect to shareholder litigation, we do not presently anticipate receiving any insurance coverage for any of our pending litigation ~~(or for potential future claims relating to our historical commercialization of opioids)~~. With respect to shareholder litigation, we have provided notice to our insurance carriers with respect to such litigation, and we have received, and further anticipate receiving, some amount of insurance coverage with respect to such litigation;. ~~there~~There is, however, no guarantee that our shareholder litigation insurance coverage will adequately protect us from our pending or future shareholder litigation claims. If any of these legal proceedings, inquiries or ~~investigations were to result in an adverse outcome, the impact could have an adverse effect on our competitive position, business, financial condition, results of operations and cash flows.~~

3534

investigations were to result in an adverse outcome, the impact could have an adverse effect on our competitive position, business, financial condition, results of operations and cash flows.

We have obtained product liability insurance for sales of our products and any clinical trials currently underway, but:

•we may be unable to maintain product liability insurance on acceptable terms;

•we may be unable to obtain product liability insurance for future trials;

•we may be unable to obtain product liability insurance for future products; or

•our insurance may not provide adequate protection against potential liabilities or may provide no protection at all.

Our inability to obtain or maintain adequate insurance coverage at an acceptable cost could prevent or inhibit the commercialization of our products. Defending a lawsuit could be costly and significantly divert management’s attention from conducting our business. If third parties were to bring a successful product liability or other claims, or series of claims, against us for uninsured liabilities, or in excess of our insured liability limits, our business, results of operations and financial condition could be adversely affected.

Our ability to use NOLs to offset future taxable income may be limited.

We have recognized NOLs for losses we incurred during our history. As of December 31, 2025, we have U.S. federal NOLs of $256.1 million that expire between 2029 and 2037 and state NOL carryforwards of $554.6 million, which begin to expire in 2026. Additionally, we have U.S. federal NOLs generated in taxable years beginning after December 31, 2017 of $690.5 million that under current U.S. federal income tax law can be carried forward indefinitely, but the deductibility of such U.S. federal NOLs in taxable years beginning after December 31, 2020 is limited to 80% of our taxable income. State NOL carryforward periods, expirations and limitations may differ from federal tax laws.

Accordingly, our pre-2018 NOL carryforwards may expire prior to being used, our NOL carryforwards generated in 2018 and thereafter will be subject to a percentage limitation and our ability to use pre-2018 NOL carryforwards and other 2018 tax attributes (such as research tax credits) to offset income or cash taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state NOLs. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could increase state taxes owed. Utilization of our NOLs are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. We currently have a full valuation allowance established against our NOLs and tax credit carryforwards, primarily due to our recurring net operating losses. As a result, even if we regain profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect future cash flows.

Risks Related to Future Product Development

The development of drug and biological product candidates is inherently difficult and uncertain, and we cannot be certain that any of our future product candidates will be approved for marketing or, if approved, will achieve market acceptance. Failure to obtain regulatory approval for our products, our raw materials or future product candidates, will limit our ability to commercialize our products, and our business will suffer.

Other than our ongoing post-marketing pediatric Phase 4 clinical study of ROLVEDON, we are currently not engaged in any material clinical or preclinical trials, but may be in the future. Clinical development is a long, expensive and uncertain process and is subject to delays and failures. As a condition to regulatory approval, each future product candidate must undergo extensive and expensive preclinical studies and clinical trials to demonstrate to a statistically significant degree that any such product candidate is safe and effective. The results at any stage of the development process may lack the desired safety, efficacy or pharmacokinetic characteristics. Positive or encouraging results of prior clinical trials are not necessarily indicative of the results obtained in later clinical trials, and later clinical trials may fail to show the desired safety and efficacy despite having progressed in development. In addition, data obtained from pivotal clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.

Product candidates are subject to the risk that any or all of them may be found to be ineffective or unsafe, or otherwise may fail to receive necessary regulatory clearances. The FDA or other applicable regulatory agencies may determine that our data is not sufficiently compelling to warrant marketing approval and require us to engage in additional clinical trials or provide further analysis, which may be costly and time-consuming. A number of companies in the pharmaceutical and biological product industry have suffered significant setbacks in clinical trials, even in later clinical trials after showing positive results in preclinical studies or earlier clinical trials. If our future product candidates fail at any stage of development, they will not receive regulatory approval, we will not be able to commercialize them and we will not receive any return on our investment in any such product candidates. We may also have asset impairments, other asset write-offs, or additional liabilities as a result of the failure of any of our future product candidates, which would impact our results from operations and financial position.

product industry have suffered significant setbacks in clinical trials, even in later clinical trials after showing positive results in preclinical studies or earlier clinical trials. If our future product candidates fail at any stage of development, they will not receive regulatory approval, we will not be able to commercialize them and we will not receive any return on our investment in any such product candidates. We may also have asset impairments, other asset write-offs, or additional liabilities as a result of the failure of any of our future product candidates, which would impact our results from operations and financial position.

Other factors could delay or result in the termination of our future clinical trials and related development programs, including:

•negative or inconclusive results;

•patient enrollment requirements and rates;

•patient noncompliance with the clinical trial protocol;

•adverse medical events or side effects among patients during the clinical trials;

•any findings resulting from FDA inspections of clinical operations;

•failure to meet FDA preferred or recommended clinical trial design, end points or statistical power;

•failure to comply with current good clinical practices;

•our failure, and the failure of third-party clinical trial vendors to comply with applicable regulatory laws and regulations;

•inability of third-party clinical trial vendors to satisfactorily perform their contractual obligations, comply with applicable laws and regulations or meet deadlines;

•delays or failures in obtaining clinical materials or manufacturing sufficient quantities of the product candidate for use in clinical trials; and

•unexpected external medical threats such as epidemics, pandemics, or other disease outbreaks.

36We are unable to predict whether any future product candidates will receive regulatory clearances or be successfully manufactured or marketed. Further, due to the extended testing and regulatory review process required before marketing clearance can be obtained, the time frame for commercializing a product is long and uncertain. Additionally, disruptions at the FDA and other regulatory agencies, including as a result of reductions in budget, personnel, or operations, may cause delays in the review and/or approval of our product candidates. Even if product candidates receive regulatory clearance, these products may not achieve or maintain market acceptance. If it is discovered that our products or technologies have potential adverse effects or other characteristics that indicate they may be ineffective as therapeutics, our product development efforts and our business could be significantly harmed.

We are unable to predict whether any future product candidates will receive regulatory clearances or be successfully manufactured or marketed. Further, due to the extended testing and regulatory review process required before marketing clearance can be obtained, the time frame for commercializing a product is long and uncertain. Even if product candidates receive regulatory clearance, these products may not achieve or maintain market acceptance. If it is discovered that our products or technologies have potential adverse effects or other characteristics that indicate they may be ineffective as therapeutics, our product development efforts and our business could be significantly harmed.

Even assuming our products obtain regulatory approval, successful commercialization requires:

•market acceptance;

•a cost-effective commercial-scale production; and

•reimbursement under private or governmental health plans.

Any material delay or failure in the governmental approval process, the successful production of commercial product or the successful commercialization of any future approved product candidates could adversely impact our business, financial condition and results of operations.

The regulatory process is expensive and time consuming. Even after investing significant time and expenditures on clinical trials, we may not obtain regulatory approval of any future product candidates. Data obtained from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval, and the FDA may not agree with our methods of clinical data analysis or our conclusions regarding safety and/or efficacy. Significant clinical trial delays could impair our ability to commercialize any future products and could allow our competitors to bring products to market before we do. In addition, changes in regulatory policy for product approval during the period of product development and regulatory agency review of each submitted new application may cause delays or rejections. Even if we receive regulatory approval, this approval may entail limitations on the indicated uses for which we can market a product.

We and our collaborative partners customarily depend on third-party contract research organizations, clinical investigators and clinical sites to conduct clinical trials with regard to product candidates, and if they do not perform their regulatory, legal and contractual obligations, or successfully enroll patients in and manage our clinical trials, we and our collaborative partners may not be able to obtain regulatory approvals for future product candidates.

We and our collaborative partners customarily depend on third-party contract research organizations and other third parties to assist us in designing, managing, monitoring and otherwise conducting clinical trials. We and our collaborative partners do not directly control these third parties and, as a result, we and our collaborative partners may be unable to control the amount and timing of resources that they devote to our or our collaborative partners’ clinical trials.

Although we and our collaborative partners rely on third parties to conduct clinical trials, we and our collaborative partners are responsible for confirming that each clinical trial is conducted in accordance with its general investigational plan and protocol, as well as the FDA’s and other applicable regulatory agencies’ requirements, including good clinical practices, for conducting, recording and reporting the results of clinical trials to ensure that the data and results are credible and accurate and that the trial participants are adequately protected. If we, contract research organizations or other third parties assisting us or our collaborative partners with clinical trials fail to comply with applicable good clinical practices, the clinical data generated in such clinical trials may be deemed unreliable and the FDA, or other applicable regulatory agencies, may require us or our collaborative partners to perform additional clinical trials before approving any marketing applications with regard to future product candidates. We cannot be certain that, upon inspection, the FDA or other applicable regulatory agencies will determine that any of our clinical trials or those of our collaborative partners comply with good clinical practices. In addition, clinical trials must be conducted with product produced under the FDA’s cGMP regulations and similar regulations outside of the U.S. Our or our collaborative partners’ failure, or the failure of our product manufacturers, to comply with these regulations may require the repeat or redesign of clinical trials, which would delay the regulatory approval process.

We and our collaborative partners also customarily rely on clinical investigators and clinical sites to enroll patients and other third parties to manage clinical trials and to perform related data collection and analysis. If clinical investigators and clinical sites fail to enroll a sufficient number of patients in such clinical trials or fail to enroll them on the planned schedule, these trials may not be completed or completed as planned, which could delay or prevent us or our collaborative partners from obtaining regulatory approvals for future product candidates.

Agreements with clinical investigators and clinical sites for clinical testing and for trial management services place substantial responsibilities on these parties, which could result in delays in, or termination of, clinical trials if these parties fail to perform as expected. If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to clinical protocols or for other reasons, clinical trials may be extended, delayed or terminated, and we and our collaborative partners may be unable to obtain regulatory approval for, or successfully commercialize, product candidates. In addition, clinical trials sometimes need to be amended once the trial is in process in order to ensure enrollment and/or successful prosecution of a trial, and such amendments could introduce significant delays and/or additional costs to our or our collaborative partners’ clinical programs.

to perform as expected. If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to clinical protocols or for other reasons, clinical trials may be extended, delayed or terminated, and we and our collaborative partners may be unable to obtain regulatory approval for, or successfully commercialize, product candidates. In addition, clinical trials sometimes need to be amended once the trial is in process in order to ensure enrollment and/or successful prosecution of a trial, and such amendments could introduce significant delays and/or additional costs to our or our collaborative partners’ clinical programs.

We are subject to risks associated with NDAs we submit under Section 505(b)(2) of the FDCA.

The products we and our collaborative partners develop or acquire generally are or will be submitted for approval under Section 505(b)(2) of the FDCA, which was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. For ~~instance~~example, the NDA for CAMBIA relies on the FDA’s previous findings of safety and efficacy of Cataflam, the diclofenac initially approved by the FDA.

For NDAs submitted under Section 505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act, such NDAs may be required to include certifications, known as “Paragraph IV certifications,” that certify any patents listed in the Orange Book publication in respect to any product referenced in the 505(b)(2) application are invalid, unenforceable and/or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) application. Under the Hatch-Waxman Act, the holder of the NDA which the 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the Paragraph IV certification. Filing of a patent infringement lawsuit triggers a one-time automatic 30-month stay of the FDA’s ability to approve the 505(b)(2) application. Accordingly, we may invest a significant amount of time and expense in the development of one or more products only to be subject to significant delay and patent litigation before such products may be commercialized, if at all. A Section 505(b)(2) application may also not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired.

Section 505(b)(2) application may also not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired.

The FDA may also require us to perform one or more additional clinical studies or measurements to support the change from the approved product. The FDA may then approve the new formulation for all or only some of the indications sought by us. If the FDA disagrees with the use of the Section 505(b)(2) regulatory pathway for future product candidates, we would need to reconsider our plans and might not be able to obtain approval for any such product candidates in a timely or cost-efficient manner, or at all. The FDA may also reject our future Section 505(b)(2) submissions and may require us to file such submissions under Section 501(b)(1) of the FDCA, which could be considerably more expensive and time-consuming.

Risks Related to Share Ownership

Our common stock may be delisted from The Nasdaq Capital Market if we are unable to ~~regain and~~ maintain compliance with its continued listing standards.

Our common stock is listed on The Nasdaq Capital Market (“Nasdaq”). There are a number of continued listing requirements that we must satisfy in order to maintain our listing on Nasdaq, including the requirement to maintain a minimum bid price of at least $1.00 (the “Bid Price Rule”). If a deficiency with respect to this requirement continues for a period of 30 consecutive business days, Nasdaq may require us to satisfy a minimum bid price per share of our common stock of at least $1.00 for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that we have demonstrated an ability to maintain long-term compliance with the Bid Price Rule. OnWe ~~January~~have ~~22,~~been ~~2025,~~unable ~~we received notification from Nasdaq indicating that our common stock is subject~~ to ~~potential~~comply ~~delisting from Nasdaq because we are not in compliance~~ with the Bid Price Rule. ~~It did not result~~ in the ~~immediate~~past ~~delisting of our common stock. We have until July 21, 2025 to regain compliance~~ and, ~~if we do not, we may be eligible~~ for anperiods ~~additional 180-day calendar period~~ in ~~which~~2021 toand ~~regain~~2025 ~~compliance.~~our Ifcontinued welisting doon ~~not~~Nasdaq ~~regain~~required ~~compliance with~~ the ~~Bid~~granting ~~Price~~of ~~Rule~~a bygrace ~~the~~period ~~applicable~~from ~~deadline,~~ Nasdaq ~~will~~and ~~provide~~the ~~written~~implementation ~~notification~~of toreverse ~~us that our common~~ stock ~~will be subject to delisting~~splits. AtIf ~~that time,~~ we ~~may~~fail ~~appeal Nasdaq’s delisting determination~~ to acomply ~~Nasdaq~~with ~~Listing Qualifications Panel (~~the ~~“Panel”).~~Bid WePrice ~~expect~~Rule ~~that~~in ~~our common stock would remain listed pending~~ the ~~Panel’s decision. However~~future, there can be no assurance that, if we dowill ~~appeal~~be ~~the~~granted ~~delisting~~such ~~determination~~grace byperiods ~~Nasdaq~~or ~~to the Panel,~~ that ~~such~~we ~~appeal~~will ~~would~~ be ~~successful.~~able ~~We are actively monitoring the closing bid price of our common stock and may, if appropriate, consider available options~~ to ~~regain~~receive ~~compliance with~~ the ~~Bid Price Rule, which could include, if~~ necessary, ~~seeking~~shareholder approval to ~~effect~~implement aan additional reverse stock split. ~~However~~In particular, ~~there~~we ~~can~~may beencounter nodifficulties ~~assurance~~obtaining ~~that~~such weshareholder ~~will~~approval bedue ~~able~~ to ~~regain~~our ~~compliance~~heavily ~~with~~retail ~~the~~investor ~~Bid~~shareholder ~~Price~~base, ~~Rule.~~which Wemay ~~have~~ also ~~been~~affect ~~unable to comply with the Bid Price Rule in the past and for periods in 2021~~ our ~~continued~~ability ~~listing~~to onobtain ~~Nasdaq~~shareholder ~~required~~approval ~~the grant~~ of aother ~~grace~~significant ~~period~~corporate ~~from Nasdaq and the implementation of a one-for-four reverse~~ actions.

stock split. If we fail to comply with the Bid Price Rule in the future, there can be no assurance that we will be granted such grace periods or that we will be able to receive the necessary shareholder approval to implement an additional reverse stock split. In particular, we may encounter difficulties obtaining such shareholder approval due to our heavily retail investor shareholder base, which may also affect our ability to obtain shareholder approval of other significant corporate actions.

Any delisting of our common stock would likely adversely affect the market liquidity and market price of our common stock and our ability to obtain financing for the continuation of our operations and/or result in the loss of confidence by investors. If we were delisted from Nasdaq, it would constitute a “fundamental change” under the 2027 Convertible Notes, which would require us to offer to repurchase the 2027 Convertible Notes and would allow the holders of the 2027 Convertible Notes to convert their 2027 Convertible Notes into our common stock at an increased conversion rate, which would make conversion of the 2027 Convertible Notes more dilutive.

The market price of our common stock historically has been volatile. Our results of operations have and may continue to fluctuate and affect our stock price.

The trading price of our common stock has been, and is likely to continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. Factors affecting our operating results and that could adversely affect our stock price include the other risk factors noted in this Item 1A.

As a result of these and other such factors, our stock price may continue to be volatile and investors may be unable to sell their shares at a price equal to, or above, the price paid. Any significant drops in our stock price, including those we experienced in ~~2023~~2024 and ~~2024~~2025, have and could give rise to shareholder lawsuits, which are costly and time-consuming to defend against and which may adversely affect our ability to raise capital while the suits are pending, even if the suits are ultimately resolved in our favor.

In addition, if the market for pharmaceutical stocks or the stock market in general experiences uneven investor confidence, the market price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. For example, if one or more securities or industry analysts downgrades our stock or publishes an inaccurate research report about our company, the market price for our common stock would likely decline. The market price of our common stock might also decline in reaction to events that affect other companies within, or outside, our industry even if these events do not directly affect us.

Fluctuations in the market price of our common stock may also impact the trading price of the 2027 Convertible Notes, and investors may be unable to sell their notes at a price equal to or above the price paid thereof.

~~Our business could be impacted as a result of actions by activist shareholders, including as a result of a potential proxy contest for the election of directors at our annual meeting.~~38

~~The~~Our ~~Company~~business ~~was~~could ~~subjected~~be toimpacted ~~vote-no campaigns and a threatened proxy contest in the run-up to its 2024 Annual Meeting of Stockholders~~ as a result of ~~activist investors, one of whom attempted to launch a proxy contest for the Company’s 2025 Annual Meeting of Stockholders. The continuing~~ actions ofby activist ~~investors have resulted in significant legal and other fees being incurred by the Company. In particular~~shareholders, ~~one activist investor has engaged in ongoing activity harmful to the Company~~ including ~~but~~as not limited to (i) making false and unwarranted claims concerning the safety of the Company’s products, (ii) releasing and threatening to release the Company’s confidential and proprietary information obtained by a ~~former~~result Company employee, and (iii) threatening litigation against the Company in connection with his false claims concerning the Company’s products. These activities have compelled the Company to file a lawsuit against the investor and have required significant time and attention by management and the Board of ~~Directors. We have also been named in~~ a ~~lawsuit~~potential byproxy ancontest ~~activist investor who purported to nominate candidates~~ for the ~~Company’s~~election ~~Board~~ of ~~Directors~~directors ~~for consideration~~ at ~~the~~future ~~Company’s~~annual ~~2025 Annual Meeting of Stockholders~~meetings. The Nominating and Corporate Governance Committee of the Company’s Board of Directors determined that the activist investor’s purported nominations were invalid under the Company’s bylaws, and the activist investor has filed suit objecting to that determination and asserting other claims against the Company and its current and former directors and officers.

In the past, activist investors have subjected us to vote-no campaigns and threatened proxy contests in connection with its annual stockholder meeting. These actions by activist investors have resulted in significant legal and other fees being incurred by us, including as a result of litigation arising out of activist shareholders’ activities. The potential offor additional proxy contests, vote-no campaigns or other continuing actions by ~~these or other~~ activist investors could result in further costly and time-consuming litigation, interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future direction, adversely affect our relationships with customers, suppliers, investors, prospective and current team members and others, result in the loss of potential business opportunities, or make it more difficult to attract and retain qualified personnel, any of which could materially and adversely affect our business and operating results.

We are subject to risks related to unsolicited takeover attempts in the future.

We have in the past and may in the future be subject to unsolicited attempts to gain control of our company. Responding to any such attempt would distract management attention away from our business and would require us to incur significant costs. Moreover, any unsolicited takeover attempt may disrupt our business by causing uncertainty among current and potential employees, producers, suppliers, customers and other constituencies important to our success, which could negatively impact our financial results and business initiatives. Other disruptions to our business include potential volatility in our stock price and potential adverse impacts on the timing of, and our ability to consummate, acquisitions of products and companies.

Conversions of the 2027 Convertible Notes or future sales of our common stock or equity-linked securities in the public market could lower the market price of our common stock and adversely impact the trading price of the 2027 Convertible Notes.

In 2022, we issued the 2027 Convertible Notes, and in the future, we may sell additional shares of our common stock or equity-linked securities to raise capital. A substantial number of shares of our common stock is reserved for issuance upon the exercise of restricted stock units and stock options, and upon conversion of the 2027 Convertible Notes. We cannot predict the effect, if any, that conversions of the 2027 Convertible Notes or of any future issuances of common stock or equity-linked securities, may have on the market price of our common stock. The issuance and sale or conversion of substantial amounts of common stock or equity-linked securities, or the perception that such issuances and sales may occur, could adversely affect the trading price of the 2027 Convertible Notes and the market price of our common stock and impair our ability to raise capital through the sale of additional equity or equity-linked securities.

Risks Related to our Corporate Organization and General Business Risks

Our success is dependent in large part upon the continued services of our executive management team.

Our success is dependent in large part upon the continued services of members of our executive management team, and on our ability to attract and retain key management and operating personnel. Management, scientific and operating personnel are in high demand in our industry and are often subject to competing offers. Changes in our management team may disrupt our business, strategic and employee relationships, which may delay or prevent the achievement of our business objectives, strategies and plans. During such transition periods, there may be uncertainty among investors, employees and others concerning our future direction and performance. For example, ~~Dan~~Brendan AP. ~~Peisert~~O’Grady separated from his service as our Chief Executive Officer (“CEO”) effective as of ~~January~~October 227, ~~2024~~2025 and ~~Heather~~resigned L.from ~~Mason,~~his anposition ~~existing~~on ~~member of~~ our Board of Directors, ~~was~~effective ~~appointed~~November to17, ~~serve as our interim CEO~~2025. Effective ~~May~~October 2927, ~~2024~~2025, ~~our~~Mark ~~Board~~Reisenauer, ofan ~~Directors~~existing ~~appointed~~member ~~Brendan~~of ~~P. O’Grady to serve as~~ our ~~CEO~~board ~~and~~of ~~Ms.~~directors, ~~Mason~~was ~~transitioned~~appointed ~~back~~ to ~~her~~serve ~~role~~ as anour ~~independent director~~CEO. ~~Further,~~Effective onNovember ~~December 12~~3, ~~2024~~2025, our ~~Board~~board of ~~Directors~~directors ~~announced~~appointed ~~the appointment of~~ Paul Schwichtenberg, asthe ~~our~~Company’s Chief ~~Transition~~Transformation Officer, ~~and~~to ~~Mary~~serve ~~Pietryga~~as our President and Chief ~~Commercial~~Operating Officer. As with any significant leadership change, these transitions involve inherent risks and any failure to execute a smooth transition could hinder employee retention and recruitment and our strategic planning, business execution, and future performance, which could have an adverse effect on our business, financial condition and results of operations. We cannot provide assurances that any current or future changes of management personnel will not cause disruption to operations or customer relationships, a decline in our operating results or a delay in the execution of our business strategies and plans. The loss of the services of one or more members of management or key employees or the inability to hire additional personnel as needed could result in delays in the research, development and commercialization of our products and potential product candidates, or otherwise adversely impact our business.

Despite our corporate structure, creditors of our operating subsidiaries could be successful in piercing the corporate veil and reaching the assets of one another, which could have an adverse effect on us and our operating results, results from continued operations, and financial condition.39

~~Our~~Despite ~~operating subsidiaries are separate legal entities within~~ our ~~holding company~~ corporate structure~~. There can be no assurance that our efforts to preclude corporate veil-piercing~~, ~~alter ego, control person, or other similar claims by~~ creditors of ~~any one particular entity within~~ our ~~corporate~~current ~~structure~~or ~~from~~former ~~reaching~~operating ~~the~~subsidiaries ~~assets~~could ~~of the other entities, including Assertio Holdings, within our corporate structure to satisfy claims will~~ be successful. Ifin apiercing ~~court were to allow a creditor to pierce~~ the corporate veil ~~and~~otherwise ~~reach~~reaching the assets of ~~such~~one ~~other entities within our corporate structure~~another, ~~despite~~which ~~such entities not being directly liable for the underlying claims, it~~ could have aan ~~material~~ adverse effect on us and our operating results, results from continued operations, and financial condition.

40Our operating subsidiaries are separate legal entities within our holding company corporate structure. There can be no assurance that our efforts to preclude corporate veil-piercing, alter ego, control person, or other similar claims by creditors of any one particular current or former entity within our corporate structure (including Assertio Therapeutics, which was sold in May 2025 to an independent company that is not affiliated with us) from reaching the assets of the other entities, including Assertio Holdings, within our corporate structure to satisfy claims will be successful. If a court were to allow a creditor to pierce the corporate veil and reach the assets of such other entities within our corporate structure, despite such entities not being directly liable for the underlying claims, it could have a material adverse effect on us and our operating results, results from continued operations, and financial condition.

If we are unable to satisfy regulatory requirements relating to internal controls, our stock price could suffer.

Section 404 of the Sarbanes-Oxley Act of 2002 requires companies to conduct a comprehensive evaluation of the effectiveness of their internal control over financial reporting. At the end of each fiscal year, we must perform an evaluation of our internal control over financial reporting, include in our annual report the results of the evaluation and have our external auditors also publicly attest to the effectiveness of our internal control over financial reporting.

Our ability to produce accurate financial statements and comply with applicable laws, rules and regulations is largely dependent on our maintenance of internal control and reporting systems, as well as on our ability to attract and retain qualified management and accounting personnel to further develop our accounting function and internal control policies. If we fail to effectively establish and maintain such reporting and accounting systems or fail to attract and retain personnel who are capable of designing and operating such systems, these failures will increase the likelihood that we may be required to restate our financial results to correct errors or that we will become subject to legal and regulatory infractions, which may entail civil litigation and investigations by regulatory agencies including the SEC. In addition, if material weaknesses are found in our internal controls in the future, if we fail to complete future evaluations on time or if our external auditors cannot attest to the effectiveness of our internal control over financial reporting, we could fail to meet our regulatory reporting requirements and be subject to regulatory scrutiny and a loss of public confidence in our internal controls, which could have an adverse effect on our stock price or expose us to litigation or regulatory proceedings, which may be costly or divert management attention.

Business interruptions due to natural disasters and other emergencies could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.

Our operations and infrastructure, and those of our partners, third-party suppliers, manufacturers and vendors are vulnerable to damage or interruption from natural disasters or other crises. Our business and operations can be seriously interrupted by natural disasters, fire, flood, the effects of climate change, actual or threatened public health crises, power loss, telecommunications failures, equipment failures, intentional acts of theft, vandalism, terrorism, epidemics, pandemics and other disease outbreak and other public health crises. Our back-up operations and our business interruption insurance as part of our formal disaster recovery plan may not be adequate to compensate us for losses that occur. A significant business interruption could result in losses or damages incurred by us and require us to cease or curtail our operations.

Data breaches and ~~cyberattacks~~cyber-attacks or other failures in our telecommunications or information technology systems, or those of our third-party vendors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations.

Securities breaches can adversely impact our operations and financial results. In the ordinary course of our business, we collect, maintain and transmit sensitive data on our computer networks and information technology systems, including our intellectual property and proprietary or confidential business information. The secure maintenance of such information is critical to our business. Furthermore, we have outsourced elements of our operations to third-party vendors, who each have access to our confidential information, which increases our risk of data breaches or cyber-attacks. Companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access, including ransomware attacks. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motives (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted to target our information systems or those of our third-party vendors. Cyber-attacks are becoming increasingly more prevalent and much harder to detect and defend against. Sophisticated cyber attackers are skilled at adapting to existing security technology and developing new methods of gaining access to organizations’ sensitive business data, which could result in the loss of proprietary information, including trade secrets. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently and may not be recognized until or after they are launched. Cybersecurity incidents, including phishing attacks and attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems are becoming increasingly frequent and more sophisticated. Cybersecurity incidents increasingly involve the use of artificial intelligence (“AI”) and ML to launch more automated, targeted and coordinated attacks on targets. The information and data processed and stored in our technology systems, and those of our strategic partners, contract research organizations, contract manufacturers, suppliers, distributors or other third parties for which we depend to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation.

41we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently and may not be recognized until or after they are launched. Cybersecurity incidents, including phishing attacks and attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems are becoming increasingly frequent and more sophisticated. Cybersecurity incidents increasingly involve the use of artificial intelligence (“AI”) and machine learning (“ML”) to launch more automated, targeted and coordinated attacks on targets. Additionally, businesses which we have acquired, or may in the future acquire, may have information technology system vulnerabilities which could increase our risk of cybersecurity attacks. The information and data processed and stored in our technology systems, and those of our strategic partners, contract research organizations, contract manufacturers, suppliers, distributors or other third parties for which we depend to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation.

Our network and storage applications and those of our third-party vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. We and certain of the third parties for which we depend on to operate our business may, and certain of such third parties have, experienced cybersecurity incidents, including third-party unauthorized access to and misappropriation of personal information, and may experience similar incidents in the future. These incidents could compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our data or data that is processed or maintained on our behalf, or other assets.

There can be no assurance that our cybersecurity risk management protocols will be sufficient to prevent or mitigate cyber-attacks. In addition, it is often difficult to anticipate or immediately detect such incidents and the damage that may be caused by such incidents, and it may take considerable time for us to investigate and evaluate the full impact of cyber-attacks, particularly for sophisticated attacks, which may inhibit our ability to provide prompt, full, and reliable information about cybersecurity incidents to our customers, regulators, and the public. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information, including our financial information or the information of our business partners. Cyber-attacks could cause us to incur significant remediation costs, disrupt key business operations, harm our reputation and divert attention of management and key information technology resources. We expect to incur significant costs in an effort to detect and prevent security incidents and otherwise implement our internal security and business continuity measures, and actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. We may face increased costs and find it necessary or appropriate to expend substantial resources in the event of an actual or perceived security breach. Our network security and data recovery measures and those of our third-party vendors may not be adequate to protect against such security breaches and disruptions. These incidents could also subject us to litigation and regulatory investigations, expose us to significant expense and cause significant harm to our business. Our insurance coverage may not be sufficient to prevent or recover from cyber-attacks, including coverage of applicable resulting losses arising from any such incident. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. Furthermore, if the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.

Macroeconomic conditions can materially impact our business and operations.

Adverse economic conditions, including inflationary pressures, economic slowdown or recession, relatively high interest rates, changes in monetary policy, potential U.S. federal government shutdowns, geopolitical conflicts, financial institution instability and similar events beyond our control can affect our business and financial results. For instance, recent supply chain constraints have led to higher inflation, which if sustained could have a negative impact on the acquisition of our APIs or the cost to manufacture and purchase our products, as well as our business and results of operations. If inflation or other factors were to significantly increase our business costs or the costs of the manufacturers we use to manufacture our products, our ability to purchase our APIs or our products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of our business and our ability to raise capital on favorable terms, or at all, in order to fund our operations. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers to supply our APIs and our manufacturers to manufacture our products cost effectively. As a result of changes to U.S. policy, especially in light of recent comments made by the new U.S. federal administration, there may be changes to existing trade agreements, the imposition of new tariffs (including potential tariffs on imported pharmaceuticals into the United States) and greater restrictions on trade generally. In addition, support for protectionism and rising anti-globalization sentiment in the United States and other countries may slow global growth. In particular, a protracted and wide-ranging trade conflict between the United States its trading partners, including China, Canada and Mexico, or the imposition of tariffs or other trade protection measures by either country in any other context, can adversely affect global economic growth. Concerns also remain around the social, political and economic impacts of the changing political landscape in Europe and elsewhere. Broader geopolitical tensions remain high among the United States, Russia, China and across the Middle East. Given the international scope of our operations, any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, can have a material adverse effect on our business, financial condition, cash flows and results of operations and can cause the market value of our common shares and/or debt securities to decline.

The use of new and evolving technologies, such as AI and ML, in our operations, and the operations of third parties upon which we rely, may result in spending additional resources and present new risks and challenges that can impact our business including by posing security and other risks to our sensitive data, and as a result we may be exposed to reputational harm, other adverse consequences, and liability.

The use of new and evolving technologies, such as AI/ML, in our operations, and the operations of third parties upon which we rely presents new risks and challenges that could negatively impact our business. The use of certain AI/ML technologies can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, several U.S. jurisdictions have proposed, enacted, or are considering, laws governing the development and use of AI/ML. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal data) and regulate automated decision making, which may be incompatible with our use of AI/ML. These obligations may make it harder for us to conduct our business using AI/ML, lead to regulatory fines or penalties, require us to change our business practices, retrain our AI/ML, or prevent or limit our use of AI/ML. For example, the Federal Trade Commission has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of AI/ML where they allege the company has violated privacy and consumer protection laws. If we cannot use AI/ML or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage. In addition, our vendors may in

4241

governing the development and use of AI/ML. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal data) and regulate automated decision making, which may be incompatible with our use of AI/ML. These obligations may make it harder for us to conduct our business using AI/ML, lead to regulatory fines or penalties, require us to change our business practices, retrain our AI/ML, or prevent or limit our use of AI/ML. For example, the Federal Trade Commission has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of AI/ML where they allege the company has violated privacy and consumer protection laws. If we cannot use AI/ML or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage. In addition, our vendors may in turn incorporate AI/ML tools into their own offerings, and the providers of these AI/ML tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI/ML, to engage in illegal activities involving the theft and misuse of sensitive data. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

Risk Management and Strategy

In the ordinary course of our business, we collect, use, store, and transmit digitally large amounts of confidential, sensitive, proprietary, personal, and health-related information. The secure maintenance of this information and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes designed to assess, identify, and manage risks arising from internal and external cybersecurity threats and vulnerabilities from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by a third-party information technology team, which reports to our ~~Senior~~ Vice President ~~of Human Resources~~ and ~~Administration~~Controller, and includes mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data while also maintaining a stable information technology environment. For example, we conduct penetration and vulnerability testing, data recovery testing, security audits, and ongoing risk assessments, including due diligence on and audits of our key technology vendors. We have an incident response plan designed to mitigate and remediate identified cybersecurity incidents at both Assertio and our customers and vendors and escalate certain incidents to senior management and, as appropriate, the Audit Committee. We also conduct periodic employee trainings on ~~cyber~~cybersecurity and information security, among other topics. As needed, we consult with outside advisors and experts to assist with assessing, identifying, and managing cybersecurity risks in order to anticipate future threats and trends, and their impact on the Company’s risk environment. Cybersecurity risks and threats are integrated into our enterprise risk management (“ERM”) program, which establishes a risk management framework that seeks to identify and assess risks that could materially impact our business and operations.

Governance

The Board of Directors (the “Board”), as a whole and at the committee level, has oversight ~~for~~over the most significant risks facing us and ~~for~~over our processes to identify, prioritize, assess, manage, and mitigate those risks. The Board oversees the ERM program and oversees an enterprise-wide approach to risk management, including risks related to cybersecurity.

The Audit Committee, which is comprised solely of independent directors, has been designated by our Board ~~of Directors~~ to oversee cybersecurity risks. The Audit Committee receives, at a minimum, quarterly updates on cybersecurity and information technology matters and related risk exposures from our ~~Senior~~ Vice President ~~of Human Resources~~ and ~~Administration~~Controller as well as other members of the senior leadership team, including, if necessary, the Chief Financial Officer. The Board also receives updates from management and the Audit Committee on cybersecurity risks on at least an annual basis.

Our ~~Senior~~ Vice President ~~of Human Resources~~ and ~~Administration~~Controller, who reports directly to our Chief ~~Executive~~Financial Officer, ~~and~~ has been ~~responsible~~involved ~~for~~in overseeing the assessment and management of cybersecurity risks at Assertio for approximately atwo ~~year~~years and ahas ~~half~~an additional four years of experience managing financial systems at another public company.

Since the beginning of the last fiscal year, there were no identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, “Risk Factors,” under the heading “Data breaches and cyber-attacks or other failures in our telecommunications or information technology systems, or those of our third-party vendors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations.

4342

discussed in Part I, Item 1A, “Risk Factors,” under the heading “Business interruptions, including data breaches and cyber-attacks can compromise our intellectual property or other sensitive information and cause significant damage to our business, can limit our ability to operate our business, and adversely impact the success of our commercialization partners.”

ITEM 2. PROPERTIES

Our corporate headquarters is located in Lake Forest, Illinois, where we lease approximately 20,000 square feet of office space ~~(the “Lake Forest Lease”)~~ through December 31, 2030. Our facility is used for office purposes only and no commercial manufacturing takes place at our facility. For additional information ~~regarding the Lake Forest Lease~~, see “Item 8. Financial Statements and Supplementary Data - Note 7,. Leases.”

Additionally, in connection with the Spectrum Merger, we assumed leases for two facilities (whose terms ended in the third quarter of 2025) and certain office equipment (which term ends in September 2026) for which Spectrum had previously been the lessee. For additional information regarding these leases, see “Item 8. Financial Statements and Supplementary Data - Note 16. Restructuring Charges.”

ITEM 3. LEGAL PROCEEDINGS

For a description of our material pending legal proceedings, see “Item 8. Financial Statements and Supplementary Data - Note 8. Commitments and Contingencies.”

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

4443

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information and Holders of Common Stock

Our common stock trades on The Nasdaq Capital Market under the symbol “ASRT.” As of December 31, ~~2024~~2025, there were ~~268~~145 shareholders of record for our common stock, one of which is Cede & Co., a nominee for The Depository Trust Company, or DTC. All of the shares of common stock held by brokerage firms, banks, and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede & Co. as one shareholder. Accordingly, the number of holders of record does not include beneficial owners whose shares are held by nominees in street name.

Dividends

We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not currently intend to pay cash dividends on our common stock for the foreseeable future. In addition, our ability to pay cash dividends on our common stock may be prohibited or limited by the terms of any future debt financing arrangement. Any return to shareholders will therefore be limited to the increase, if any, of our stock price.

Recent Sales of Unregistered Securities

None.

Stock Performance Graph

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and therefore are not required to provide the stock performance graph.

Issuer Purchases of Equity Securities

We did not repurchase any shares of the Company’s common stock during the period covered by this Annual Report on Form 10-K, except for shares surrendered to us, as reflected in the following table, to satisfy tax withholding obligations in connection with the vesting of equity awards.

(a) Total Number of Shares (or Units) Purchased (1)

(b) Average Price Paid per Share

(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs

(a) Total Number of Shares (or Units) Purchased (1)(2)

(b) Average Price Paid per Share(2)

(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs

October 1, 2024 - October 31, 2024

52,833

$1.15

N/A

October 1, 2025 - October 31, 2025

164

$13.72

N/A

November 1, 2024 - November 30, 2024

—

N/A

November 1, 2025 - November 30, 2025

—

N/A

December 1, 2024 - December 31, 2024

—

N/A

December 1, 2025 - December 31, 2025

—

N/A

Total

~~52,833~~164

$113.1572

(1) Consists of shares withheld to pay employees’ tax liability in connection with the vesting of restricted stock units granted under our stock-based compensation plans. These shares may be deemed to be “issuer purchases” of shares.

45(2) Adjusted to reflect the 1-for-15 reverse stock split effected on December 26, 2025.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our historical consolidated financial statements and the related notes thereto included in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in this discussion and analysis or set forth under Part I, Item 1, “Business” and elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward‑looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in ~~the~~Part I, Item 1A “Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward‑looking statements contained in the following discussion and analysis or elsewhere in this Annual Report on Form 10-K. For a discussion and analysis of our results of operations for the year ended December 31, ~~2023~~2024 compared to the year ended December 31, ~~2022~~2023, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, ~~2023~~2024.

Overview

WeUnless ~~are~~otherwise anoted ~~pharmaceutical~~or ~~company~~required ~~with~~by ~~comprehensive~~context, ~~commercial~~use ~~capabilities~~of ~~offering~~“Assertio,” ~~differentiated~~the ~~products~~“Company,” ~~designed~~“we,” “our” and “us” refer to ~~address~~Assertio ~~patients’~~Holdings ~~needs.~~and/or ~~Our~~its ~~focus~~applicable issubsidiary onor ~~supporting~~subsidiaries. ~~patients~~Reference byto ~~marketing~~“Assertio ~~products~~Specialty” inrefers ~~oncology~~to Assertio Specialty Pharmaceuticals, ~~neurology~~LLC, and ~~pain~~“Spectrum” ~~management~~refers to Spectrum Pharmaceuticals, Inc. ~~Our~~and/or ~~primary~~its ~~marketed~~applicable ~~products~~subsidiary or subsidiaries. Both Assertio Specialty and Spectrum are: wholly-owned subsidiaries of the Company. Additionally, the use of “Assertio Therapeutics” refers to Assertio Therapeutics, Inc., and/or its applicable subsidiary or subsidiaries. Assertio Therapeutics was divested on May 9, 2025.

ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use			A long-acting granulocyte colony-stimulating factor (“G-CSF”) with a novel formulation that is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Sympazan® (clobazam) oral film			A benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (“LGS”) in patients aged two years of age or older. Sympazan is the only product to offer clobazam in a convenient film with PharmFilm® technology. Sympazan is taken without water or liquid, adheres to the tongue, and dissolves to deliver clobazam.
INDOCIN® (indomethacin) Suppositories			A suppository and oral solution of indomethacin used both in hospitals and out-patient settings. Both products are nonsteroidal anti-inflammatory drugs (“NSAIDs”), indicated for:
			• Moderate to severe rheumatoid arthritis including acute flares of chronic disease
			• Moderate to severe ankylosing spondylitis
INDOCIN® (indomethacin) Oral Suspension			• Moderate to severe osteoarthritis
			• Acute painful shoulder (bursitis and/or tendinitis)
			• Acute gouty arthritis
Otrexup® (methotrexate)injection for subcutaneous use			A once weekly single-dose auto-injector containing methotrexate. Otrexup is a folate analog metabolic inhibitor indicated for the:
			• Management of patients with severe, active rheumatoid arthritis (“RA”) and polyarticular juvenile idiopathic arthritis (“pJIA”), who are intolerant of or had an inadequate response to first-line therapy.
			• Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.
SPRIX® (ketorolac tromethamine) Nasal Spray			A prescription NSAID indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at an opioid level. SPRIX is a non-narcotic nasal spray that provides patients with moderate to moderately severe short-term pain relief through a form of ketorolac that is absorbed rapidly but does not require an injection administered by a healthcare provider.
CAMBIA® (diclofenac potassium for oral solution)			A prescription NSAID indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. CAMBIA can help patients with migraine pain, nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). CAMBIA is not a pill; it is a powder, and combining CAMBIA with water activates the medicine in a unique way.

We are a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. Our primary marketed products are:

On July 31, 2023 (the “Effective Date”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 24, 2023, we completed the acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology products (the “Spectrum Merger”), through a merger of a wholly-owned subsidiary of ours with and into Spectrum, with Spectrum surviving the merger as a wholly-owned subsidiary of ours. We acquired ROLVEDON, through the Spectrum Merger. The results of operations of Spectrum are included in our consolidated financial statements as of the Effective Date.


ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use			A long-acting granulocyte colony-stimulating factor (“G-CSF”) with a novel formulation that is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Sympazan® (clobazam) oral film			A benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (“LGS”) in patients aged two years of age or older. Sympazan is the only product to offer clobazam in a convenient film with PharmFilm® technology. Sympazan is taken without water or liquid, adheres to the tongue, and dissolves to deliver clobazam.
INDOCIN® (indomethacin) Suppositories			A suppository and oral solution of indomethacin used both in hospitals and out-patient settings. Both products are nonsteroidal anti-inflammatory drugs (“NSAIDs”), indicated for:
			• Moderate to severe rheumatoid arthritis including acute flares of chronic disease
			• Moderate to severe ankylosing spondylitis
INDOCIN® (indomethacin) Oral Suspension			• Moderate to severe osteoarthritis
			• Acute painful shoulder (bursitis and/or tendinitis)
			• Acute gouty arthritis




SPRIX® (ketorolac tromethamine) Nasal Spray			A prescription NSAID indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at an opioid level. SPRIX is a non-narcotic nasal spray that provides patients with moderate to moderately severe short-term pain relief through a form of ketorolac that is absorbed rapidly but does not require an injection administered by a healthcare provider.
CAMBIA® (diclofenac potassium for oral solution)			A prescription NSAID indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. CAMBIA can help patients with migraine pain, nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). CAMBIA is not a pill; it is a powder, and combining CAMBIA with water activates the medicine in a unique way.

4745

2025 Transactions

On May 9, 2025, we transferred all the equity interests in Assertio Therapeutics to an established purchaser of legacy litigation matters, resulting in Assertio Therapeutics being owned by the purchaser’s related company, ATIH Industries, LLC (the “Therapeutics Transaction”). At the closing of the Therapeutics Transaction, Assertio Therapeutics held approximately $8.2 million in cash, insurance and retained a single-digit royalty based on net income derived from INDOCIN. In addition, Assertio Therapeutics retained certain legal liabilities, including those related to opioid litigation. As a result of the Therapeutics Transaction, we are not defendants in any opioid-related litigation.

As part of our ongoing commercial portfolio assessment, we ceased commercialization of Otrexup in July 2025.

In the third quarter of 2025, we advanced key integration efforts to consolidate operations and align our products, including ROLVEDON, under a single subsidiary, Assertio Specialty. Sales of ROLVEDON in 2025 reflected normal demand through the first nine months of 2025, as well as large purchases by several national distributors to help ensure consistent supply of ROLVEDON during the fourth quarter of 2025 and first quarter of 2026 as we complete the integration of ROLVEDON into Assertio Specialty. We did not record material net product sales of ROLVEDON during the fourth quarter of 2025 and do not anticipate material net product sales in the first quarter of 2026. Sales of the newly labeled ROLVEDON are expected to commence at a normal volume in the second quarter of 2026.

To facilitate the large purchases of ROLVEDON by several national distributors in the third quarter of 2025, we provided our customers with higher-than-historical levels of discounts and extended payment terms. These factors unfavorably impacted our net selling price and gross profit in the third quarter of 2025. The extended payment terms provided as part of these sales also led to reduced cash collections and a decline in our cash and short-term investments balance in the fourth quarter of 2025. We anticipate that the extended payment terms will lead to further reduced cash collections and a decline in our cash and short-term investments balances for the first quarter of 2026, but we expect that cash collections and our cash and short-term investments balances will increase in the second quarter of 2026. These factors will further lead to variability in our working capital balances during these periods.

On October 7, 2025, we entered into an amendment and restatement of the Manufacturing and Supply Agreement (the “Hanmi Agreement,” as amended, the “Amendment”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”). The Amendment fixes the price that we pay for the remaining term of our license agreement with Hanmi and amends the payment timing for certain product royalties due to Hanmi, which have been fully accrued and resulted in an immaterial reclassification between Other current liabilities and Other long-term liabilities in our Consolidated Balance Sheet during the third quarter of 2025.

RESULTS OF OPERATIONS

The following table reflects our results of operations for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	Year ended December 31,
	2024		2023
	2025		2024
Revenues:
Product sales, net	$	~~120~~117,~~849~~100	$	~~149~~120,~~451~~849
Royalties and milestones	2,012		2,433
Royalty revenue	1,613		2,012
Other revenue	~~2,100~~—		~~185~~2,100
Total revenues	~~124~~118,~~961~~713		~~152~~124,~~069~~961
Costs and expenses:
Cost of sales	3935,~~227~~383		2739,~~020~~227
Research and development expenses	31,~~822~~690		23,~~843~~822
Selling, general and administrative expenses	7569,~~051~~000		7875,~~638~~051
Change in fair value of contingent consideration	(~~244~~276)		(~~25,538~~244)
Amortization of intangible assets	2529,~~644~~863		2725,~~527~~644
Loss on impairment of intangible assets	5,217		279,639
Impairment of intangible assets	1,700		5,217
Restructuring charges	~~720~~2,889		~~5,476~~720
Total costs and expenses	~~149~~140,~~437~~249		~~395~~149,~~605~~437
Loss from operations	(2421,~~476~~536)		(~~243~~24,~~536~~476)
Other income (expense):
Other (expense) income:
Debt related expenses	—		(9,918)
Loss on Assertio Therapeutics divestiture	(8,174)		—
Interest expense	(3,~~039~~075)		(3,~~380~~039)
Interest income	32,~~221~~665		23,~~403~~221
Other gain, net	~~2,765~~180		~~377~~2,765
Total other income (expense)	2,947		(10,518)
Total other (expense) income	(8,404)		2,947
Net loss before income taxes	(2129,~~529~~940)		(~~254~~21,~~054~~529)
Income tax expense	(52435)		(~~77,888~~52)
Net loss and comprehensive loss	$	(2130,~~581~~375)	$	(~~331~~21,~~942~~581)

4847

Revenues

The following table reflects total revenues, net for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	Year ended December 31,
	2024		2023
	2025		2024
Product sales, net:
ROLVEDON	$	6068,~~090~~225	$	1860,~~175~~090
INDOCIN products	2618,~~761~~905		8726,~~217~~761
Sympazan	1011,~~457~~349		910,~~938~~457
Otrexup	8,842		12,026
SPRIX	7,952		7,624
SPRIX	7,624		9,150
Other products	10,669		15,917
CAMBIA	5,556		8,070
Total product sales, net	117,100		120,849
Other products	1,519		4,875
Royalty revenue	1,613		2,012
Total product sales, net	120,849		149,451
Other revenue	—		2,100
Royalties and milestone revenue	2,012		2,433
Total revenues	$	118,713	$	124,961
Other revenue	2,100		185
Total revenues	$	124,961	$	152,069

Product sales, net

ROLVEDON net product sales ~~were~~increased $608.1 million ~~and~~from $1860.21 million for the ~~years~~year ended December 31, 2024 ~~and~~to ~~2023, respectively~~$68.2 ~~The~~million ~~increase~~for ofthe ~~$41.9~~year ~~million~~ended ~~was~~December 31, 2025, primarily due to higher volume, the ~~acquisition~~adjustment of ~~Spectrum~~a onprior ~~July~~period ~~31,~~returns ~~2023,~~reserve ~~which~~of ~~resulted~~$5.4 million established in aconnection ~~full~~with ~~year~~our ofmerger ~~net~~with ~~product~~Spectrum ~~sales~~(the ~~being~~“Spectrum ~~included~~Merger”), inpartially ~~the~~offset ~~year~~by ~~ended~~lower ~~December~~net ~~31,~~pricing. ~~2024,~~The ~~compared~~higher tovolume ~~five~~reflects ~~months~~large ofpurchases ~~net~~by ~~product~~several ~~sales~~national ~~included~~distributors induring the ~~year~~third ~~ended~~quarter ~~December~~of ~~31,~~2025 ~~2023,~~to inhelp ~~addition~~ensure toconsistent ~~higher~~supply ~~unit~~of ~~volume~~ROLVEDON in the ~~last~~fourth ~~five~~quarter ~~months~~of 2025 and the first quarter of ~~2024~~2026 ~~compared~~as towe complete the ~~same~~integration ~~five~~into ~~months~~Assertio ~~of 2023~~Specialty, ~~and~~as ~~was~~noted ~~partially~~above. ~~offset~~We bydid ~~lower~~not record material net ~~pricing.~~product Wesales ~~expect~~of ~~that~~ROLVEDON during the ~~average~~fourth ~~sales~~quarter ~~price~~of ~~for~~2025 ~~ROLVEDON,~~and ~~which~~do isnot ~~used~~anticipate tomaterial ~~set~~net ~~pricing~~product ~~for~~sales ain ~~significant~~the ~~portion~~first quarter of ~~our~~2026. ~~ROLVEDON~~Sales ~~net~~of ~~product~~the ~~sales,~~newly ~~will~~labeled beROLVEDON ~~impacted~~are ~~due~~expected to ~~increased~~commence ~~discounts,~~at ~~chargebacks,~~a ~~and~~normal ~~rebates~~volume ~~given~~in tothe ~~our~~second ~~customers~~quarter of 2026.

INDOCIN net ~~products~~product sales decreased $607.59 million from $8726.28 million for the year ended December 31, ~~2023~~2024 to $2618.89 million for the year ended December 31, ~~2024~~2025, primarily due to lower volume ~~and~~from ~~pricing~~previously asannounced ~~a result of the August 2023 approval and launch of~~ generic ~~indomethacin suppositories~~competition. In ~~2025~~2026, we expect INDOCIN net product sales to continue to bedecline ~~impacted unfavorably by increasing competition~~ as a result of continued competition from existing generic entrants, as well as new and expected future generic entrants~~, including the new generic entrant that launched in January 2025, and other competitive products~~.

Sympazan net product sales increased $0.59 million from $910.95 million for the year ended December 31, ~~2023~~2024 to $1011.53 million for the year ended December 31, ~~2024~~2025, primarily due to higher volume, partially offset by unfavorable payor mix.

~~Otrexup~~SPRIX net product sales ~~decreased~~increased $30.23 million from $127.06 million for the year ended December 31, ~~2023~~2024 to $8.80 million for the year ended December 31, ~~2024~~2025, primarily due to ~~unfavorable~~favorable payor mix, ~~and~~partially offset by lower volume.

~~SPRIX~~Other net product sales ~~decreased~~for the year ended December 31, 2025 and December 31, 2024 included net product sales of Otrexup of $14.5 million ~~from~~and $98.28 million, ~~for~~respectively, ~~the~~net ~~year~~product ~~ended~~sales ~~December~~of ~~31,~~CAMBIA ~~2023~~of to $5.7 million and $5.6 million, ~~for~~respectively, ~~the~~and ~~year~~net ~~ended~~product ~~December~~sales ~~31,~~of ~~2024~~Zipsor of $0.5 million and $1.5 million, respectively. The year-over-year decrease in other net product sales was primarily due to lower ~~volume~~Otrexup net product sales as a result of ceasing commercialization of Otrexup in July 2025.

~~CAMBIA~~For ~~net~~the ~~product~~year ~~sales~~ended ~~decreased~~December ~~$2.5~~31, ~~million~~2025, ~~from~~the ~~$8.1~~amount ~~million~~recognized for ~~the~~gross-to-net ~~year~~sales ~~ended~~allowances ~~December~~on ~~31,~~product ~~2023~~sales toincreased by $550.68 million ~~for~~compared to the year ended December 31, 2024, primarily due to higher ROLVEDON sales volumes and a ~~decrease~~continued shift in ~~volume~~product ~~caused~~mix bytoward ~~generic~~ROLVEDON, ~~entrants~~which ~~that~~carries ~~began~~a higher contractual rebate rate than our other products. Refer to the Critical Accounting Policies and Significant Estimates section within this Item 7 and Schedule II to the accompanying Consolidated Financial Statements for additional information about amounts charged as a reduction to revenue for product sales allowances, product return allowances, discounts, chargebacks, and rebates. Our products operate in ~~January~~competitive ~~2023~~markets and the impact of competition on net pricing could have an unfavorable impact on the amount of gross-to-net sales allowances recognized.

Other net product sales for the year ended December 31, 2023 of $4.9 million include net product sales for Zipsor of $3.5 million and net product sales for OXAYDO of $1.4 million. As we ceased OXAYDO product sales beginning in September 2023, other net product sales of $1.5 million for the year ended December 31, 2024 represent only net product sales of Zipsor. The decrease in other net product sales of Zipsor of $2.0 million was primarily due to unfavorable payor mix and lower volume.48

~~For~~Royalty the year ended December 31, 2024, the amount recognized for gross-to-net sales allowances on product sales increased by $86.4 million compared to the year ended December 31, 2023, primarily due to a shift in product mix from INDOCIN to ROLVEDON, which resulted in a higher rate of commercial and governmental rebates recognized for Revenue

49 In November 2010, we entered into a license agreement granting Tribune Pharmaceuticals Canada Ltd. (later known as Aralez Pharmaceuticals, Miravo Healthcare, and Searchlight Pharma, or “Searchlight,” now owned by Apotex Inc.) the rights to commercially market CAMBIA in Canada. The counterparty to the license agreement independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. We recognized royalty revenue related to the CAMBIA licensing agreement of $1.6 million and $2.0 million for the years ended December 31, 2025 and 2024, respectively.

~~ROLVEDON.~~The ~~Refer~~patents tounderlying the ~~Critical~~license ~~Accounting~~agreement ~~Policies~~that ~~and~~we ~~Significant~~have ~~Estimates~~with ~~section~~Searchlight ~~within~~expire ~~this~~in ~~Item~~June 72026, and ~~Schedule~~we IIanticipate tothat ~~the~~there ~~accompanying~~will ~~Consolidated~~be ~~Financial~~generic ~~Statements~~competition ~~for~~in ~~additional~~Canada ~~information~~after ~~about~~the ~~amounts~~patents ~~charged~~expire, asor athe ~~reduction~~earlier tonegotiated ~~revenue~~launch ~~for~~of ~~product~~generics ~~sales~~in ~~allowances,~~connection ~~product~~with ~~return~~the ~~allowances,~~settlement ~~discounts,~~of ~~chargebacks~~patent litigation, ~~and~~resulting ~~rebates.~~in ~~Due~~increased tocompetition ~~the~~with ~~competitive~~CAMBIA ~~markets~~upon inpatent ~~which~~expiration. ~~our~~As ~~products~~a ~~compete~~result, we ~~expect~~anticipate ~~our~~the ~~pricing~~amount toof beroyalty ~~impacted~~revenue byearned ~~higher~~under ~~discounts,~~the ~~chargebacks,~~license ~~and~~agreement ~~rebates~~could be reduced to zero beginning in ~~2025~~the asthird ~~compared~~quarter toof ~~2024~~2026.

Royalties & milestone revenue

In November 2010, we entered into a license agreement granting Searchlight the rights to commercially market CAMBIA in Canada. The counterparty to the license agreement independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. We recognized royalties revenue related to the CAMBIA license agreement of $2.0 million for each of the years ended December 31, 2024 and 2023.

We recognized no milestone revenue associated with the completion of certain service milestones for the year ended December 31, 2024 and $0.4 million for the year ended December 31, 2023.

Other revenue

Other revenue consists of sales adjustments for previously divested products, which includes adjustments to reserves for product sales allowances (gross-to-net sales allowances) and can result in a reduction to or an increase to total revenue ~~during~~in the period of recognition. There was no other revenue for the year ended December 31, 2025. Sales adjustments for reserves recorded in prior periods for previously divested products resulted in an increase to total revenue of $2.1 million ~~and $0.2 million~~ for the ~~years~~year ended December 31, 2024 ~~and December 31, 2023, respectively~~.

Cost of Sales

Cost of sales consists of costs of the active pharmaceutical ingredient, contract manufacturing and packaging costs, royalties payable to third parties, inventory write -downs and scrap, product quality testing, ~~internal employee costs related to the manufacturing process,~~ distribution costs, and shipping costs related to our product sales. Cost of sales excludes the amortization of intangible assets. Fair value of inventories acquired through business combinations or asset acquisitions include an inventory step-up within the value of inventories. The inventory step-up value is amortized as the related inventory is sold, and included in cost of sales.

Cost of sales ~~increased~~decreased $123.28 million from $2739.02 million for the year ended December 31, ~~2023~~2024 to $3935.24 million for the year ended December 31, ~~2024~~2025, primarily due to (i) a $6.26 million ~~increase~~decrease in ~~cost~~inventory ofwrite-downs, ~~sales~~primarily ~~related~~for INDOCIN due to ~~changes~~lower indemand ~~product~~for ~~mix~~INDOCIN products, ~~primarily~~(ii) ~~from~~a ~~INDOCIN~~$4.6 tomillion of ROLVEDON inventory step-up amortization included in the year ended December 31, ~~and~~2024, which did not recur in the year ended December 31, 2025, (iii) a $61.09 million decrease in Otrexup cost of ~~higher~~sales ~~inventory~~primarily ~~write-downs~~due to ceasing commercialization of Otrexup in July 2025, ~~primarily~~(iv) ~~for~~a $0.9 million decline in INDOCIN ~~and~~cost ~~ROLVEDON,~~of sales due to lower ~~demand~~INDOCIN ~~for~~sales ~~INDOCIN~~volume, and (v) a $0.2 million decrease in other cost of sales. The decrease was partially offset by a $7.9 million increase from the ~~manufacture~~impact of ~~batches~~higher ROLVEDON volumes on cost of sales driven by the sales of ROLVEDON ~~that~~inventory ~~did~~during ~~not~~the ~~meet~~third ~~our~~quarter ~~quality~~of ~~standards~~2025 noted above, and $2.5 million of one-time costs related to ceasing commercialization of Otrexup in July 2025.

Cost of sales are impacted by both product volume and mix, changes in which will have an impact on Cost of sales recognized by us in future periods. ~~In 2025, we expect Cost of sales, as a percentage of sales, to continue to be negatively affected by changes in product volume and mix.~~

Research and Development Expenses

Research and development expenses include salaries, costs for clinical trials, consultant fees, supplies, and allocations of corporate costs. Research and development expenses were $31.87 million and $23.8 million for the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively, primarily representing costs directly associated with ~~the~~ongoing ~~same-day dosing~~ clinical ~~trial~~activity offor the ROLVEDON, ~~which~~pediatric wesafety ~~concluded~~trial in ~~the~~2025 ~~fourth~~and ~~quarter of~~ 2024., Weas ~~expect~~well ~~expenses~~as ~~associated~~the ~~with~~same-day ~~this~~dosing ~~clinical~~ trial ~~to be significantly reduced~~ in ~~future periods~~2024.

Selling, General and Administrative Expenses

Selling, general and administrative expenses primarily consist of personnel, contract personnel, marketing and promotion expenses, personnel expenses to support our administrative and operating activities, facility costs, and professional expenses, such as legal and accounting fees.

Selling, general, and administrative expenses decreased $3.6.1 million from $7875.61 million for the year ended December 31, ~~2023~~2024 to $7569.10 million for the year ended December 31, ~~2024~~2025, primarily due to: (i) $8.9 million of transaction-related expenses, primarily legal and professional fees, associated with the Spectrum Merger that were recognized in the prior year, of which there were none in the current year, (ii) a $4.17 million ~~decrease~~net ~~in stock-based compensation expense, (iii) a $3.0 million~~ decrease in ~~operating~~legal ~~expenses~~charges ~~from cost savings initiatives implemented following the Spectrum Merger,~~ and ~~(iv)~~settlements ~~a $1.0 million decrease in sales and marketing expenses. These decreases were partially offset by (i) an increase~~ of ~~$6.2~~certain ~~million~~litigation ~~related to higher personnel expenses following the Spectrum Merger~~items, (ii) ~~an increase of~~ $62.04 million ~~in legal-related expenses, and (iii) a net increase~~ of ~~$1.1~~income ~~million~~recognized induring ~~our~~the ~~reserves~~year ~~for~~ended ~~loss~~December ~~contingencies.~~31,

2025 related to the lapsing of the statute of limitations for employee retention tax credits, of which there was none in 2024, (iii) a $1.6 million decrease in stock-based compensation expense, primarily driven by forfeitures related to our 2025 restructuring actions, and (iv) a $0.2 million decrease in other general operating expenses. The decrease was partially offset by $1.7 million of one-time costs related to ceasing commercialization of Otrexup and $1.1 million of costs related to the Therapeutics Transaction recognized in the year ended December 31, 2025.

Change in Fair Value of Contingent Consideration

In connection with the Spectrum Merger, we issued contingent value rights (“CVRs”) that represent a contingent consideration obligation that is measured at fair value. In connection with the merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”), we assumed a contingent consideration obligation for future royalties on annual INDOCIN product net sales that is measured at fair value. Change in fair value of contingent consideration represents the change in fair value, if any, of our contingent consideration obligations which are remeasured each reporting period.

~~Change~~We inrecognized ~~fair~~a ~~value~~benefit of ~~contingent~~$0.3 ~~consideration~~million ~~represents~~and ~~the change in fair value, if any, of our contingent consideration obligations which are remeasured each reporting period~~$0.2 ~~During~~million during the years ended December 31, ~~2024~~2025 and ~~2023~~December 31, ~~we recognized benefits of $0.2 million and $21.6 million~~2024, respectively, for the change in fair value of contingent consideration ~~obligation~~ incurred in the Zyla Merger. We recognized no expense or benefit for the change in fair value of the CVR contingent consideration obligation during the ~~year~~years ended December 31, 2025 or December 31, 2024, ~~and~~as athe ~~benefit~~milestones oftriggering ~~$3.9~~payment ~~million~~of ~~during~~ the ~~year~~obligation ~~ended~~were ~~December~~not ~~31, 2023~~met.

We do not expect to recognize a contingent consideration obligation in future periods nor make any contingent consideration payments related to the above in 2026 or beyond.

Amortization of Intangible Assets

The following table reflects amortization of intangible assets for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	Year ended December 31,
	2024		2023
	2025		2024
Amortization of intangible assets—ROLVEDON	$	617,~~066~~356	$	56,~~270~~066
Amortization of intangible assets—INDOCIN	13,514		11,321
Amortization of intangible assets—Sympazan	1,213		1,212
Amortization of intangible assets—Sympazan	1,212		1,213
Amortization of intangible assets—SPRIX	4,017		3,808
Amortization of intangible assets—Otrexup	1,044		4,592
Amortization of intangible assets—INDOCIN	7,277		13,514
Amortization of intangible assets—SPRIX	3,808		5,131
Amortization of intangible assets—Otrexup	—		1,044
Total amortization of intangible assets	$	2529,~~644~~863	$	2725,~~527~~644

Amortization expense ~~decreased~~increased $14.92 million from $2725.56 million for the year ended December 31, ~~2023~~2024 to $2529.69 million for the year ended December 31, ~~2024~~2025, primarily asdue ato ~~result~~an ofincrease ~~a decrease in amortization expense~~ of $911.43 million ~~attributable~~related to ~~the~~a ~~lower~~change ~~carrying~~in ~~value~~the ofremaining ~~intangible~~estimated ~~assets~~useful ~~due~~life toof ~~impairment~~the ~~charges~~ROLVEDON ~~recognized~~product inrights ~~the~~intangible ~~third~~assets ~~and~~effective ~~fourth~~December ~~quarters~~31, ~~of 2023~~2024, ~~partially~~as ~~offset~~well byas ~~(i)~~a ~~an increase of~~ $0.82 million ~~due~~increase related to ~~additional~~a ~~amortization~~change in the remaining estimated useful life of ~~ROLVEDON~~the SPRIX product rights, ~~acquired~~intangible inassets ~~July~~effective ~~2023~~October 1, ~~and~~2025. ~~(ii)~~This anwas ~~increase~~partially inoffset ~~amortization~~by ~~expense~~a net decrease of $6.72 million, ~~which was~~ due to ~~revisions~~the tofull ~~decrease~~amortization of the remaining ~~estimated~~value ~~useful life~~ of the INDOCIN ~~product rights~~ intangible assets. Wein ~~believe~~ the ~~revised~~second ~~remaining~~quarter ~~estimated~~of ~~useful~~2025 ~~life~~and ~~better~~a ~~reflects~~$1.0 ~~the~~million ~~realization~~decrease ofresulting from the ~~economic~~full ~~benefit~~impairment of the Otrexup intangible asset group in the fourth quarter of 2024.

AsImpairment of ~~December~~Intangible 31, 2024, the estimated undiscounted cash flows of the INDOCIN and SPRIX assets groups exceeded their respective carrying values by approximately 15% and 10%, respectively. The sum of the undiscounted cash flows could continue to decrease in the event of significant unfavorable changes in their estimated undiscounted future cash flows due to increased competition and, in the case of INDOCIN, due to potential future generic entrants. Any significant unfavorable changes in the estimated undiscounted future cash flows may also impact the related assets, such as inventory, leading to Assets

51During each quarter of 2025 and 2024, our market capitalization was below the book value of our equity, which management determined represented an indicator of impairment with respect to our long-lived assets. For the three months ended September 30, 2025, we also recognized an additional indicator of impairment in our SPRIX asset group related to a change in the expected timing of cash flows from SPRIX net product sales. Applying the relevant accounting guidance, we first assessed the recoverability of our long-lived assets at the product level at each date.

~~potential~~For ~~charges~~the inassessment ~~addition~~performed tofor athe ~~potential~~three months ended September 30, 2025, we determined that the undiscounted cash flows and the fair value of the SPRIX asset group were less than its carrying value and recognized an impairment for this asset group of $1.7 ~~Any~~million ~~future~~during ~~impairment~~the third quarter of ~~our~~2025, ~~long-lived~~reducing ~~assets~~its carrying value to $4.6 million. Additionally, ~~including~~effective ~~INDOCIN~~October or1, ~~SPRIX~~2025, ~~may~~we ~~result~~revised inthe ~~material~~remaining ~~charges~~estimated ~~that~~useful ~~could~~life ~~have~~of athe ~~material~~SPRIX ~~adverse~~product ~~effect~~rights onintangible assets to one year, which we believe better reflects the ~~Company’s~~realization ~~business~~of ~~and~~the ~~financial~~economic ~~results~~benefit of the intangible asset.

~~Loss on Impairment of Long-Lived Assets~~ 50

~~During~~For ~~each~~the ofassessment performed for the three months ended December 31, 2024, ~~September 30, 2024, June 30, 2024 and March 31, 2024,~~ we determined that the book value of our equity exceeded our market capitalization, which management determined represented an indicator of impairment with respect to our long-lived assets. Applying the relevant accounting guidance, management first assessed the recoverability of our long-lived assets at the product level at each date. After grouping the long-lived assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities, we estimated ~~the future net~~ undiscounted cash flows ~~expected~~and tofair bevalue ~~generated from the use~~ of the ~~long-lived~~Otrexup asset ~~groups~~group ~~and~~were ~~their~~less ~~eventual~~than ~~disposition~~its atcarrying ~~each~~value ~~impairment~~and ~~testing~~recognized ~~date.~~an Weimpairment ~~then~~for ~~compared~~this ~~the~~asset ~~estimated~~group ~~undiscounted~~of ~~cash~~$5.2 ~~flows~~million toduring the ~~carrying~~fourth ~~amounts~~quarter of ~~the~~2024, ~~long-lived~~reducing ~~asset~~its ~~groups~~carrying atvalue ~~each~~to ~~date~~zero.

For all the ~~assessment~~assessments ~~performed~~ for ~~the~~our ~~three~~other ~~months~~asset ~~ended~~groups ~~December~~performed ~~31,~~during each quarter in 2025 and 2024, we determined that the estimated undiscounted cash flows ~~and~~were ~~fair~~in ~~value~~excess of the ~~Otrexup asset group were less than its~~ carrying ~~value~~amounts ~~and recognized an impairment loss~~ for ~~this asset group of approximately $5.2 million, reducing its carrying value to zero. For~~ all of our ~~other~~long-lived asset groups, ~~the~~at ~~estimated~~each ~~undiscounted~~impairment ~~cash~~testing ~~flows~~date. ~~exceeded their carrying amounts~~Accordingly, ~~and~~ we concluded that the ~~other~~long-lived asset groups were fully recoverable and no adjustment to ~~the~~their carrying values was required.

~~For~~Although the ~~assessments~~SPRIX ~~performed~~asset ~~for~~group ~~each~~was ofwritten ~~the~~down ~~three~~to ~~months~~its ~~ended~~fair value as of September 30, ~~2024~~2025, ~~June~~the ~~30,~~sum ~~2024~~of ~~and~~the ~~March~~undiscounted ~~31,~~cash ~~2024,~~flows wecould ~~determined~~continue ~~that~~to decrease in the event of significant unfavorable changes in their estimated undiscounted future cash flows ~~were~~due to increased competition. Any significant unfavorable changes in ~~excess~~the ofestimated undiscounted future cash flows may also impact the ~~carrying~~related ~~amounts~~assets, ~~for~~such ~~all~~as ofinventory, ~~our~~leading ~~long-lived~~to ~~asset~~potential ~~groups~~charges atin ~~each~~addition ~~impairment~~to ~~testing~~a ~~date~~potential impairment. ~~Accordingly,~~Any wefuture ~~concluded~~impairment ~~that~~of ~~the~~our long-lived ~~asset~~assets ~~groups~~may ~~were~~result ~~fully~~in ~~recoverable~~material ~~and~~charges nothat ~~adjustment~~could tohave ~~their~~a ~~carrying~~material ~~values~~adverse ~~was~~effect ~~required~~on our business and financial results.

During each of the three months ended December 31, 2023 and September 30, 2023, we performed an assessment of the recoverability and impairment of our long-lived assets as a result of the book value of our equity exceeding our market capitalization, which management determined represented an indicator of impairment. Similar to each of the assessments performed in each quarter of 2024, for the three months ended December 31, 2023 management assessed the recoverability of our long-lived assets at the product level at that date. For the three months ended September 30, 2023, management assessed the recoverability of our long-lived assets at the entity level. The change in the identification of asset groups was due to strategic changes to the Company’s operating cost structure through the reduction of shared costs that had occurred by the fourth quarter of 2023. In each case, management determined that the fair value of the identified asset group(s) was not fully recoverable and was less than each of their carrying values and recognized an impairment loss for the asset group(s). For the three months ended December 31, 2023, we recognized an impairment loss for the INDOCIN and Otrexup product asset groups of approximately $36.0 million and $4.8 million, respectively. For the three months ended September 30, 2023, management concluded that the fair value of the entity level asset group was less than its carrying value and recognized an impairment loss of approximately $238.8 million, which was allocated to the intangible assets of the group.

Restructuring Charges

~~Restructuring~~We ~~charges~~regularly ~~were~~evaluate ~~$0.7~~our ~~million~~operations ~~for~~to ~~the~~identify ~~year~~opportunities ~~ended December 31, 2024, compared~~ to ~~$5.5~~streamline ~~million~~operations ~~for the year ended December 31, 2023. In August 2023, we implemented a reorganization plan of our workforce~~ and ~~other~~optimize ~~resources~~operating ~~primarily~~efficiencies ~~designed~~in toanticipation ~~realize the synergies~~ of ~~the~~changes ~~Spectrum~~in ~~Merger (~~the ~~“Spectrum~~business ~~Reorganization Plan”)~~environment. ~~The~~As ~~Spectrum~~such, ~~Reorganization~~Company ~~Plan~~management ~~was~~may ~~primarily~~approve, ~~focused~~from ontime ~~the~~to ~~reduction~~time, ofplans ~~staff~~to atreduce ~~our~~costs ~~headquarters office~~ and ~~the~~improve ~~exit~~efficiencies, ofwhich ~~certain~~may ~~leased~~result ~~facilities.~~in Weincurring docosts ~~not~~associated ~~expect~~with tothose ~~recognize any additional~~ restructuring ~~charges related to the Spectrum Reorganization Plan~~efforts. ~~We expect all cash payments under the Spectrum Reorganization Plan to be completed by the end of 2025.~~

WeRestructuring ~~regularly~~charges ~~evaluate~~related ~~our~~to ~~operations~~employee tocompensation ~~identify~~costs ~~opportunities~~were to$2.9 ~~streamline~~million ~~operations~~and $0.7 million for the years ended December 31, 2025 and ~~optimize~~December ~~operating~~31, ~~efficiencies~~2024, asrespectively. anCash ~~anticipation~~payments during the years ended December 31, 2025 and December 31, 2024 related to ~~changes~~our invarious ~~the~~restructuring ~~business~~efforts ~~environment~~were $1.7 million and $3.9 million, respectively.

52During the fourth quarter of 2025, we recognized $1.2 million in restructuring costs associated with a reduction in our workforce. We may incur additional restructuring charges related to this restructuring effort. All related cash payments are expected to be completed by the fourth quarter of 2026.

Effective as of October 27, 2025, we separated from the service of our former Chief Executive Officer. Pursuant to his then existing Management Continuity Agreement with the Company, he was entitled to severance compensation and benefits of approximately $1.4 ~~Other~~million, ~~Income~~which ~~(Expense)~~were recognized as Restructuring charges during the year ended December 31, 2025. All related cash payments are expected to be completed by the second quarter of 2027. We do not expect to recognize any additional restructuring charges related to his separation from us.

~~The~~During ~~following~~the ~~table~~first ~~reflects~~quarter ~~Other~~of ~~income~~2025, ~~(expense)~~we ~~for~~recognized ~~the~~$0.3 million ~~years~~in ~~ended~~restructuring ~~December~~costs ~~31,~~associated ~~2024~~with improving efficiencies within our sales and ~~2023~~marketing ~~(in~~organization. ~~thousands):~~We do not expect to recognize any additional restructuring charges related to this restructuring effort, and all related cash payments were completed by the third quarter of 2025.

	Year ended December 31,
	2024		2023
Debt related expenses	$	—	$	(9,918)
Interest expense	(3,039)		(3,380)
Interest income	3,221		2,403
Other gain, net	2,765		377
Total other income (expense)	$	2,947	$	(10,518)

Other (Expense) Income

~~Total~~ The ~~other~~following ~~income~~table reflects Other (expense) ~~changed by $13.5 million from expense of $10.5 million for the year ended December 31, 2023 to~~ income ~~of $2.9 million~~ for the ~~year~~years ended December 31, ~~2024,~~2025 ~~primarily~~and ~~due to (i) debt-related expenses incurred in the prior year, (ii) the favorable impact of a $2.6 million customer reimbursement recognized in the year ended December 31,~~ 2024, (~~iii) a $0.2 million favorable impact for the change~~ in ~~the fair value of a derivative liability associated with an embedded derivative feature of our 2027 Convertible Notes, (iv~~thousands) higher interest income due to our investments in short-term investments during the year ended December 31, 2024, which yielded higher investment returns, and (v) lower interest expense for the year ended December 31, 2024 compared to the year ended December 31, 2023, as further discussed below. :

Debt-related expenses for the year ended December 31, 2023 consisted of an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million incurred as a result of the privately negotiated exchange of $30.0 million principal amount of the 2027 Convertible Notes (the “Convertible Note Exchange”) in the first quarter of 2023, as further described below under the headings “Liquidity and Capital Resources” and in “Item 8. Financial Statements and Supplementary Data – Note 6. Debt.” There were no similar debt-related expenses during the year ended December 31, 2024.


	Year ended December 31,
	2025		2024
Loss on Assertio Therapeutics divestiture	$	(8,174)	$	—
Interest expense	(3,075)		(3,039)
Interest income	2,665		3,221
Other gain, net	180		2,765
Total other (expense) income	$	(8,404)	$	2,947

~~The~~Total ~~following~~other ~~table~~(expense) ~~reflects~~income ~~interest~~changed ~~expense~~by $11.4 million from income of $2.9 million for the ~~years~~year ended December 31, 2024 ~~and~~to ~~2023~~expense (of $8.4 million for the year ended December 31, 2025, primarily due to an $8.2 million loss on the divestiture of Assertio Therapeutics recognized during the second quarter of 2025, as described in ~~thousands):~~“Item 8. Financial Statements and

	Year ended December 31,
	2024		2023
Interest on 2027 Convertible Notes	$	2,600	$	2,925
Amortization of debt issuance costs	439		455
Total interest expense	$	3,039	$	3,380

~~Total~~Supplementary ~~interest~~Data ~~expense~~– ~~decreased~~Note $02.3 ~~million~~Divestitures ~~from~~and ~~$3.4~~Strategic ~~million~~Transactions,” ~~for~~and the ~~year~~favorable ~~ended~~impact ~~December~~of ~~31,~~a ~~2023 to~~ $32.06 million ~~for~~customer reimbursement recognized in the year ended December 31, 2024, ~~primarily~~that ~~due~~did tonot arepeat ~~lower~~in ~~principal balance of our outstanding 6~~2025.5% ~~Convertible Senior Notes due 2027 as a result of the Convertible Note Exchange.~~

The following table reflects interest expense for the years ended December 31, 2025 and 2024 (in thousands):


	Year ended December 31,
	2025		2024
Interest on 2027 Convertible Notes	$	2,600	$	2,600
Amortization of debt issuance costs on 2027 Convertible Notes	475		439

Total interest expense	$	3,075	$	3,039

Income Tax Provision

~~During~~We ~~the year ended December 31, 2024, we~~ recorded an income tax expense of $0.4 million and $0.1 million, ~~which~~for ~~represents~~the anyears ~~effective~~ended ~~tax~~December ~~rate~~31, of2025 (0and December 31, 2024, respectively.~~2)%.~~ The difference between the income tax expense ~~of $0.1 million~~ and the tax at the federal statutory rate of 21.0% onin ~~current~~each ~~year~~period ~~operations~~was is primarily due to ~~the~~changes ~~impact~~in of the valuation allowance ~~and~~due ~~net~~to ~~operating~~our ~~losses~~net ~~recognized in the current year~~loss, partially offset by state ~~income~~tax ~~taxes~~expense and the loss recorded on sale of Assertio Therapeutics. As of December 31, 2025 and December 31, 2024, we concluded that it is not more likely than not that ~~we will realize~~ the net deferred tax asset recorded as of ~~December~~those ~~31,~~dates ~~2024~~will be realized. As a result, we ~~have~~ recorded a full valuation allowance against ~~the~~our net deferred tax asset as of both December 31, 2025 and December 31, 2024.

~~During~~On ~~the~~July ~~year ended December 31~~4, ~~2023~~2025, wethe ~~recorded~~President ~~an income tax expense~~ of ~~$77.9~~the ~~million,~~United ~~which~~States ~~represents~~signed anHouse ~~effective~~Resolution ~~tax~~1 ~~rate of~~ (30“H.~~7)%~~R. ~~The~~1”), ~~difference~~which ~~between~~made ~~the~~a ~~income~~number ~~tax expense~~ of ~~$77.9~~changes ~~million~~to ~~and the~~ tax atlaw ~~the~~in ~~statutory rate of 21.0% was principally due to~~ the ~~recording~~Internal ofRevenue aCode, ~~full~~including ~~valuation allowance during~~ the ~~year~~reinstatement ~~ended December 31, 2023. As part~~ of ~~our~~immediate ~~valuation~~expensing ~~allowance~~for ~~assessment~~domestic asresearch ofand ~~December~~development ~~31,~~expenditures ~~2023,~~and wemodifications ~~were no longer able~~ to ~~rely~~the onbusiness ~~our~~interest ~~projected~~expense ~~availability~~limitation. ofThe ~~future~~changes ~~taxable~~to ~~income~~tax ~~from~~law ~~pre-tax~~promulgated ~~income~~under ~~forecasts~~H.R. As1 ~~such,~~did wenot ~~primarily~~have ~~relied~~a onmaterial ~~our~~impact ~~reversing~~on ~~taxable temporary differences to assess~~ our ~~valuation~~income ~~allowance,~~tax ~~which~~expense ~~resulted~~or inincome ~~recording~~tax ofaccount ~~the~~balances ~~full valuation allowance~~ for the year ended December 31, ~~2023~~2025. The December 31, 2023 income tax expense also included the valuation allowance for utilization of our deferred tax assets to offset the deferred tax liabilities of Spectrum recorded through acquisition accounting.

LIQUIDITY AND CAPITAL RESOURCES

We have financed, and continue to finance, our operations and business development efforts primarily from product sales, ~~public sales of equity securities, including convertible debt securities, and~~ the proceeds of secured borrowings~~. In addition~~, ~~we have financed,~~ and ~~may~~public ~~consider~~sales ~~financing in the future, our operations through the sale~~ of ~~rights~~equity ~~to future royalties and milestones~~securities, ~~licenses~~including ~~with~~convertible ~~upfront~~debt ~~and milestone fees, and fees from collaborative and license partners~~securities.

We believe that our existing cash, cash equivalents and short-term investments, which totaled $~~100~~63.14 million at December 31, ~~2024~~2025, will be sufficient to fund our operations and make the required payments under our debt agreements due for the next 12 months from the date of this filing. We base this expectation on our current operating plan, which may change as a result of many factors.

Our cash needs may vary materially from our current expectations because of ~~differences between the actual cash impacts and our expected impacts related to~~ numerous factors, including:

•~~expenditures~~reductions ~~related~~in tonet ~~the~~product ~~commercialization~~sales ofand ~~our~~gross ~~products,~~margin ~~including~~in ~~our~~the ~~efforts~~first toquarter ~~manage~~of ~~supply~~2026 ~~costs~~due ~~and~~to ~~enhance~~ the ~~long-term~~transition ~~prospects~~ of ROLVEDON ~~product~~from ~~sales~~Spectrum to Assertio Specialty;

•changes in our working capital needs, including the timing of ~~our~~ purchases ofand ~~inventory~~manufacturing ~~pursuant~~of to our ~~supply agreements~~inventories, ~~such as~~ the ~~increased~~timing ~~purchases~~of payment of ~~ROLVEDON~~our ~~inventory~~accounts ~~that~~payable ~~occurred~~and inaccrued ~~2024~~rebates, returns and discounts, and the ~~impact~~timing ~~this~~of ~~may~~accounts ~~have~~receivable oncollections, ~~our~~due ~~inventory~~to the large purchases of ROLVEDON inventory by several national distributors in ~~future~~the ~~periods~~third quarter of 2025 noted above;

•declines in sales of our marketed products, including those resulting from the entry and sales of generics and/or other products competitive with any of our products;

•potential additional expenses relating to any litigation matters, as discussed in “Item 8. Financial Statements and Supplementary Data - Note 8. Commitments and Contingencies”;

•milestone and royalty revenue we receive under our collaborative development arrangements;

•interest and principal payments on our current and future indebtedness;

•our level of expenditures related to the commercialization of our products, including our efforts to manage supply costs and enhance the long-term prospects of ROLVEDON product sales;

•the timing of our purchases of inventory pursuant to our supply agreements, including those that may be required under the Amendment to the Hanmi Agreement, and the impact this may have on our inventory purchases in future periods;

•declines in sales of our marketed products, including those resulting from the entry and sales of generics and/or other products competitive with any of our products;

•potential additional expenses relating to any litigation matters, as discussed in “Item 8. Financial Statements and Supplementary Data - Note 8. Commitments and Contingencies;”

•potential payments required as a result of ceasing commercialization of Otrexup in July 2025;

•potential payments for income and other taxes to the extent that they cannot be offset against our net operating loss (“NOL”) carryforwards;

•acquisitions or licenses of complementary businesses, products, technologies or companies;

•financial terms of definitive license agreements or other commercial agreements we may enter into;

•milestone and royalty revenue we receive under our collaborative development arrangements;

•changes in the focus and direction of our business strategy and/or research and development programs;

•potential expenses, including termination expenses if a decision is made to cease development of Spectrum’s de-prioritized development asset poziotinib; and

•expenditures related to future clinical trial costs.

We expect our cash needs will be met by our existing cash, cash equivalents, and short-term investments, including funding our future operations, ~~ongoing~~payments ~~legal~~due ~~expenses~~under ~~and~~our ~~settlement~~debt ~~payments~~agreement, ~~payments~~ongoing ~~due~~legal ~~under~~expenses ~~our~~and ~~debt~~settlement ~~agreement~~payments, or product acquisitions and strategic transactions that we may pursue. We expect that ongoing legal expenses will, and any settlements that we are able to negotiate may, continue to be a significant usage of cash in ~~2025~~2026. We may be required to raise additional capital if our cash needs ~~vary~~increase significantly from current expectations. ~~The inability to raise any additional capital that may be required for any of the above items could have a material adverse effect on the Company.~~

On August 22, 2022, we issued $70.0 million aggregate principal amount of ~~2027~~convertible ~~Convertible~~senior ~~Notes~~notes which mature on September 1, 2027 and bear interest at a rate of 6.5% per annum, payable semi-annually in arrears on March 1 and September 1 of each year (the “2027 Convertible Notes”). On February 27, 2023, we completed ~~the~~a ~~Convertible~~privately ~~Note~~negotiated ~~Exchange.~~exchange ~~Pursuant to the Convertible Note Exchange, 6,990,000 shares~~ of ~~the Company’s common stock, plus an additional~~ $1030.50 million inprincipal ~~cash,~~amount ~~were issued in a partial settlement~~ of the 2027 Convertible Notes.

The terms of the 2027 Convertible Notes are governed by an indenture dated August 25, 2022 (the “2027 Convertible Note Indenture”). Pursuant to the terms of the 2027 Convertible Note Indenture, we and our restricted subsidiaries must comply with certain covenants, including mergers, consolidations, and divestitures; guarantees of debt by subsidiaries; issuance of preferred and/or disqualified stock; and liens on our properties or assets. We were in compliance with our covenants with respect to the 2027 Convertible Notes as of December 31, ~~2024~~2025.

54The following table reflects summarized cash flow activities for the years ended December 31, 2025 and 2024 (in thousands):

The following table reflects summarized cash flow activities for the years ended December 31, 2024 and 2023 (in thousands):


	Year ended December 31,
	2025		2024
Net cash (used in) provided by operating activities	$	(28,182)	$	26,408
Net cash used in investing activities	(11,988)		(48,911)
Net cash used in financing activities	(189)		(350)
Net decrease in cash and cash equivalents	(40,359)		(22,853)
Cash and cash equivalents at beginning of year	50,588		73,441
Cash and cash equivalents at end of year	$	10,229	$	50,588

	Year ended December 31,
	2024		2023
Net cash provided by operating activities	$	26,408	$	49,604
Net cash (used in) provided by investing activities	(48,911)		3,097
Net cash used in financing activities	(350)		(44,201)
Net (decrease) increase in cash and cash equivalents	(22,853)		8,500
Cash and cash equivalents at beginning of year	73,441		64,941
Cash and cash equivalents at end of year	$	50,588	$	73,441

Cash Flows from Operating Activities

Cash ~~provided~~used byin operating activities was $2628.42 million for the year ended December 31, ~~2024~~2025 compared to cash provided by operating activities of $4926.64 million for the year ended December 31, ~~2023,~~2024. The change was primarily due to ~~lower~~higher net ~~product~~working ~~sales~~capital needs and alower ~~change~~net in product ~~mix for the year ended December 31, 2024 compared to the year ended December 31, 2023~~sales.

~~For~~Operating ~~the~~assets ~~year~~and ~~ended~~liabilities ~~December~~resulted ~~31,~~in ~~2024,~~a net ~~loss~~cash ~~was~~use ~~$21.6 million compared to net loss~~ of $~~331~~45.93 million for the year ended December 31, ~~2023.~~2025 ~~Excluding~~compared ~~the~~to ~~non-~~net cash ~~items~~provided of $425.82 million ~~and $381.4 million~~ for the ~~years~~year ended December 31, 2024. ~~and~~The ~~2023,~~change ~~respectively,~~was ~~cash~~primarily ~~provided by operating activities decreased~~ due to ~~lower~~a ~~cash~~$59.5 ~~contributions~~million ~~from~~increase ~~net~~in ~~product~~accounts ~~sales~~receivable ~~and~~primarily anassociated ~~unfavorable~~with ~~change~~the inlarge ~~product~~purchases ~~mix,~~of ~~partially~~ROLVEDON ~~offset~~ by anseveral ~~increase~~national distributors in ~~cash~~the ~~generated~~third byquarter ~~working~~of ~~capital.~~2025, ~~Net~~which ~~cash~~included ~~generated~~extended bypayment ~~working~~terms ~~capital~~provided ~~increased~~to ~~$5.1~~ROLVEDON ~~million~~customers ~~from~~as ~~$0.1~~further ~~million~~discussed ~~for~~above ~~the~~in ~~year~~“COMPANY ~~ended December 31~~OVERVIEW,” ~~2023~~as towell ~~$5.2~~as ~~million~~higher ~~for~~settlements ~~December~~of ~~31,~~accrued ~~2024~~liabilities, ~~primarily~~particularly ~~due to higher accruals for~~ accrued ~~rebates~~legal costs, ~~returns~~ and ~~discounts~~accounts payable due to timing. ~~and~~This ~~the~~was ~~impact of sales product mix,~~ partially offset by ~~decreased~~lower ~~cash~~inventory ~~from accounts receivable payments and higher~~ purchases, ofparticularly ~~inventory. Cash provided by operating activities~~ for the ~~year~~ROLVEDON ~~ended~~active ~~December~~pharmaceutical 31ingredient, ~~2024~~and ~~also~~higher ~~included~~accruals afrom ~~$1.7~~the ~~million~~timing ~~payment~~of ~~made~~settlements ~~for contingent consideration in excess~~ of ~~the~~accrued ~~INDOCIN contingent consideration liability recognized at the acquisition date. Prior to this~~rebates, ~~payments~~returns ~~made~~and ~~for~~discounts ~~contingent~~related ~~consideration up~~ to the ~~INDOCIN~~sale ~~contingent~~of ~~consideration~~ROLVEDON ~~liability~~inventory ~~recognized~~ at the ~~acquisition~~end ~~date~~of ~~were~~the ~~classified~~third asquarter ~~cash~~of ~~flows from financing activities~~2025.

Cash flows from operating activities are impacted by, among other things, product revenue, operating profit and changes in working capital. Fluctuations in any of these will impact our cash flows from operating activities recognized in future periods. Due to the large purchases of ROLVEDON by several national distributors in the third quarter of 2025, the timing of related cash collections and payments is expected to reduce cash flows from operating activities in the first quarter of 2026, with cash flows from operating activities expected to increase in the second quarter of 2026.

Cash Flows from Investing Activities

Cash used in investing activities was $4812.90 million for the year ended December 31, ~~2024~~2025, which consisted of $98119.62 million of purchases of short-term investments, ~~partially~~and ~~offset~~an by $498.7 2 million ofinvesting ~~proceeds~~outflow from ~~maturities~~cash oftransferred ~~short-term investments. Beginning~~ in the ~~second~~Therapeutics ~~quarter of 2024~~Transaction, weoffset ~~began purchasing and holding highly liquid marketable securities with maturities dates at purchase of more than three months and less than one year. Cash provided~~ by ~~investing activities was~~ $3115.1 4 million ~~for the year ended December 31, 2023, which primarily consisted~~ of ~~$2.2 million of~~ proceeds from ~~the~~maturities ~~sale~~ of ~~marketable~~short-term ~~securities~~investments. ~~that~~Refer weto ~~acquired~~Note ~~in the Spectrum Merger and $~~2.0 ~~million~~Divestitures ofand ~~net~~Strategic ~~cash~~Transactions ~~acquired~~included in ~~the~~“Item ~~Spectrum~~8. ~~Merger,~~Financial ~~partially~~Statements ~~offset~~and bySupplemental ~~cash~~Data ~~paid~~ for ~~the~~details ~~transaction~~regarding ~~costs incurred with~~ the ~~acquisition~~Therapeutics ~~of Sympazan and cash paid for purchases of property and equipment~~Transaction.

Cash used in investing activities was $48.9 million for the year ended December 31, 2024, which consisted of $98.6 million of purchases of short-term investments, partially offset by $49.7 million of proceeds from maturities of short-term investments. Beginning in the second quarter of 2024, we began purchasing and holding highly liquid marketable securities with maturities dates at purchase of more than three months and less than one year.

Cash Flows from Financing Activities

Cash used in financing activities for the year ended December 31, ~~2024,~~2025 ~~was~~and ~~$0.4 million, which consisted entirely of cash used for employees’ withholding tax liability upon the vesting of stock awards. Cash used in financing activities for the year ended~~ December 31, ~~2023,~~2024 was $440.2 million, ~~which~~and ~~primarily consisted of (i) a~~ $240.24 million ~~payment for contingent consideration related to INDOCIN~~, ~~(ii) $10.5 million in cash payments related to the partial settlement of the 2027 Convertible Notes in the Convertible Note Exchange~~respectively, ~~(iii) $1.1 million of direct transaction cost payments made in connection with the Convertible Note Exchange,~~ and ~~(iv)~~consisted ~~cash~~entirely ~~payments related to the vesting and settlement~~ of ~~equity awards, of which $2.6 million related to the~~ cash ~~settlement of the vested performance RSUs, $3.4 million related to the total cash payment of taxes for the net share settlement of the vested performance RSUs, and $1.9 million related to cash~~ used ~~for~~from employees’ withholding tax liability upon the vesting of ~~stock~~employee ~~awards, net of cash received from~~ stock ~~option exercises~~awards.

Contractual Obligations

Our principal material cash requirements consist of obligations related to our ~~debt,~~payments ~~our~~for ~~contingent~~rebates, ~~consideration~~returns ~~obligations~~and discounts, payments for ~~rebates~~debt, ~~returns~~non-cancelable ~~and~~leases ~~discounts~~for our office space, non-cancelable contractual obligations for our purchase commitments, and cash payments for our restructuring activities. Refer to “Item 8. Financial Statements and Supplemental Data - Note 1, Note 6, Note 7, Note 8 and Note 16,” respectively. We generally expect to satisfy these requirements and commitments with cash on hand and cash provided by operating activities.

and non-cancelable leases for our office space. Refer to “Item 8. Financial Statements and Supplemental Data - Note 6, Note 13, Note 1, Note 8 and Note 7,” respectively. We generally expect to satisfy these requirements and commitments with cash on hand and cash provided by operating activities.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT ESTIMATES

Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and SEC regulations for annual reporting. Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements. The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. OnWe anevaluate ~~ongoing~~our ~~basis,~~estimates weon ~~evaluate~~an ~~our~~ongoing ~~estimates~~basis. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions. We believe the following critical accounting policies reflect the more significant ~~judgements~~judgments and estimates used in the preparation of our consolidated financial statements.

A more detailed discussion of our significant accounting policies may be found in “Note 1. Organization and Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, and the impact and risks associated with our accounting policies are discussed throughout this Annual Report on Form 10‑K and in the Notes to the Consolidated Financial Statements.

Revenue Recognition

Product sales revenue is recognized when the customer has control of the product, which is when title has transferred to the customer and the customer has assumed the risks and rewards of ownership. These conditions typically occur upon delivery to the customer. Our performance obligation is to deliver product to the customer, and the performance obligation is typically completed upon delivery. The transaction price consists of a fixed invoice price and variable product sales allowances, which include rebates, discounts and returns. Product sales revenues are recorded net of applicable sales tax and reserves for these product sales allowances (also referred to as gross-to-net sales allowances).

Product sales allowances consist primarily of provisions for product returns, managed care rebates, commercial rebates, and government rebates (managed care rebates, commercial rebates and government rebates are collectively referred to as “rebates”), wholesaler and pharmacy discounts, prompt pay discounts, patient discount programs, and chargebacks. We consider product sales allowances to be variable consideration and estimate and recognize product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on actual or estimated amounts owed on the related sales. These estimates take into consideration the terms of our agreements with customers, historical returns, rebates or discounts taken by product, estimated levels of inventory in the distribution channel, the shelf life of the product, and specific known market events, such as competitive pricing and new product introductions. We use the most likely method in estimating product sales allowances. If actual future results vary from our estimates, we may need to adjust the estimates, which could have an effect on product sales and earnings in the period of adjustment.

Our estimates related to gross‑to‑net sales adjustments for product return allowances and rebates are judgmental and are subject to change based on our historical experience and certain quantitative and qualitative factors. We believe that our estimates related to gross‑to‑net sales adjustments for wholesaler and pharmacy fees and discounts, prompt payment discounts, patient discount programs and chargebacks do not have a high degree of estimation complexity or uncertainty, as the related amounts are settled within a relatively short period of time. The timing of ultimate settlement of returns and chargebacks-related allowances can be prolonged by our process to validate such adjustments before settlement is finalized.54

~~Product~~consider ~~Returns~~product -sales Weallowances ~~allow customers~~ to ~~return~~be ~~product~~variable ~~for~~consideration ~~credit~~and ~~with~~estimate ~~respect~~and torecognize ~~that~~ product ~~within~~sales ~~six~~allowances ~~months~~as ~~before~~a ~~and~~reduction upof toproduct 12sales ~~months~~in ~~after~~the same period the ~~product~~related ~~expiration~~revenue ~~date~~is recognized. WeProduct ~~estimate~~sales ~~product~~allowances ~~returns~~are based on ~~historical~~actual ~~return~~or ~~trends~~estimated byamounts ~~product~~owed oron bythe ~~return~~related ~~trends~~sales. ofThese ~~similar~~estimates ~~products,~~take ~~taking~~ into consideration the ~~shelf~~terms ~~life~~ of ~~the~~our ~~product~~agreements atwith ~~the~~customers, ~~time~~historical ~~of shipment~~returns, ~~shipment~~rebates ~~and~~or ~~prescription~~discounts ~~trends~~taken by product, estimated ~~distribution~~levels ~~channel~~of inventory ~~levels~~in ~~and~~the ~~consideration~~distribution ofchannel, the ~~introduction~~shelf life of ~~competitive~~the ~~products.~~product, Weand dospecific ~~not~~known ~~assume~~market ~~financial~~events, ~~responsibility~~such ~~for~~as ~~returns~~competitive ofpricing ~~any~~and ofnew ~~our~~product ~~currently~~introductions. ~~marketed~~We ~~products~~use ifthe ~~those~~most ~~returns~~likely ~~relate~~method toin estimating product sales ofallowances. ~~that~~If ~~product~~actual ~~prior~~future toresults orvary ~~after~~from ~~the~~our ~~period~~estimates, ofwe ~~our~~may ~~ownership~~need ofto adjust the ~~respective product~~estimates, which ~~are~~could ~~identified~~affect byproduct ~~specific~~sales ~~lot~~and ~~numbers~~earnings in the period of adjustment.

56Our estimates related to gross‑to‑net sales adjustments for product return allowances and rebates are judgmental and are subject to change based on our historical experience and certain quantitative and qualitative factors. We believe that our estimates related to gross‑to‑net sales adjustments for wholesaler and pharmacy discounts, prompt payment discounts, patient discount programs and chargebacks do not have a high degree of estimation complexity or uncertainty, as the related amounts are settled within a relatively short period of time. The timing of ultimate settlement of returns- and chargebacks-related allowances can be prolonged by our process to validate such adjustments before settlement is finalized.

~~Shelf~~Product ~~lives~~Returns ~~for~~- ~~our~~We ~~products,~~allow ~~from~~customers ~~the~~to ~~respective~~return ~~manufacture~~product ~~dates,~~for ~~range~~credit ~~from~~with 24respect to that product generally within six months tobefore 48and 12 months after the product expiration date. ~~Because~~We ofestimate ~~the~~product ~~shelf~~returns ~~life~~based ofon ~~our~~historical ~~products~~return ~~and~~trends ~~our~~by product or by return ~~policy~~trends of ~~issuing~~similar ~~credits~~products, ~~with~~taking ~~respect~~into toconsideration ~~product~~the ~~that~~shelf islife ~~returned~~of ~~within~~the ~~six~~product ~~months~~at ~~before~~the ~~and~~time upof toshipment, 12shipment ~~months~~and ~~after~~prescription ~~our~~trends, ~~product~~estimated ~~expiration~~distribution ~~date,~~channel ~~there~~inventory ~~may~~levels beand aconsideration ~~significant~~of ~~period~~the introduction of ~~time~~competitive ~~between~~products. ~~when~~We ~~the~~do ~~product~~not isassume ~~shipped~~financial ~~and~~responsibility ~~when~~for wereturns ~~issue~~of ~~credit~~any onof aour ~~returned~~currently ~~product.~~marketed ~~Accordingly,~~products weacquired ~~may~~through ~~have~~product torights ~~adjust~~acquisitions ~~these~~if ~~estimates,~~those ~~which~~returns ~~could~~relate ~~have~~to ansales ~~effect~~of onthat product ~~sales~~prior ~~and~~to ~~earnings~~or inafter the period of ~~adjustments~~our ownership of the respective product, which are identified by specific lot numbers.

Shelf lives for our products, from the respective manufacture dates, range from 24 months to 48 months. Because of the shelf life of our products and our return policy of issuing credits with respect to product that is returned within six months before and 12 months after our product expiration date, there may be a significant period of time between when the product is shipped and when we issue credit on a returned product. Accordingly, we may have to adjust these estimates, which could affect product sales and earnings in the period of adjustments.

Managed Care Rebates - We offer discounts under contracts with certain managed care providers. We generally pay managed care rebates one to three months after prescriptions subject to the rebate are filled.

Commercial Rebates - We offer certain group purchasing organization (“GPO”) rebates for end-user purchases made under contractual rebate percentage tier programs. Commercial rebates are based on (i) our estimates of end-user purchases through a GPO, (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. We generally pay commercial rebates two to 12 months after qualifying purchases are made.

Government Rebates - We offer discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, including Centers for Medicare & Medicaid Services’ Medicaid Drug Rebate Program, ~~and~~ Medicare Part B Program and Medicare Part D Coverage Gap Discount Programs. We generally pay government rebates three to 12 months after prescriptions subject to the rebate are filled. These rebates are subject to our active participation in the respective programs.

~~The following table reflects activity relating to the Company’s provision for product sales allowances as of December 31, 2024 and 2023 (in thousands):~~55

	Product Returns		Rebates (1)		Other Sales Allowances (2)		Total(4)
Balance as of December 31, 2022	$	31,287	$	7,685	$	11,340	$	50,312
Provisions made in current period to Product Sales, net (3)	7,842		24,901		51,782		84,525
Provisions made in current period to Other revenue (4)	—		—		(185)		(185)
Payments and credits made in current period	(9,340)		(18,083)		(48,183)		(75,606)
Balance as of December 31, 2023	$	29,789	$	14,503	$	14,754	$	59,046
Provisions made in current period to Product Sales, net (3)	5,796		59,107		105,998		170,901
Provisions made in current period to Other revenue (4)	(2,100)		—		—		(2,100)
Payments and credits made in current period	(11,130)		(52,696)		(86,553)		(150,379)
Balance as of December 31, 2024	$	22,355	$	20,914	$	34,199	$	77,468

The following table reflects activity relating to the Company’s provision for product sales allowances as of December 31, 2025 and 2024 (in thousands):


	Product Returns		Rebates (1)		Other Sales Allowances (2)		Total(5)
Balance as of December 31, 2023	$	29,789	$	14,503	$	14,754	$	59,046
Provisions made in current period to Product Sales, net (3)	5,796		59,107		105,998		170,901
Provisions made in current period to Other revenue (4)	(2,100)		—		—		(2,100)
Payments and credits made in current period	(11,130)		(52,696)		(86,553)		(150,379)
Balance as of December 31, 2024	$	22,355	$	20,914	$	34,199	$	77,468
Provisions made in current period to Product Sales, net (3)	(1,644)		80,267		143,077		221,700

Payments and credits made in current period	(4,165)		(79,560)		(113,095)		(196,820)
Balance as of December 31, 2025	$	16,546	$	21,621	$	64,181	$	102,348

(1)Rebates consist of managed care rebates, commercial rebates and government rebates.

(2)Other Sales Allowances consist of wholesaler and pharmacy discounts, prompt pay discounts, patient discount programs, and chargebacks.

(3)Includes adjustments to revenue recognized as a result of changes in estimates for the Company’s gross-to-net sales allowances for products sold in previous periods, which were approximately 37% and 3% for the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. In addition, ROLVEDON net product sales for the year ended December 31, 2025 included the adjustment of a prior period returns reserve of $5.4 million established in connection with the Spectrum Merger.

(4)Consists of sales adjustments for previously divested products recognized in Other revenue in the Consolidated Statements of Comprehensive Loss.

(5)Balance includes allowances for cash discounts for prompt payment of $13.20 million and $01.92 million as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, which are recognized in Account receivable, net in the Company’s Consolidated Balance Sheets. The remaining balance of $7699.34 million and $5876.13 million as of December 31, ~~2024~~2025 and ~~2023~~2024, respectively, is recognized in Accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.

Impairment of Long-lived Assets

We evaluate long-lived assets, including property and equipment and acquired intangible assets consisting of product rights, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment ~~loss~~ would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The impairment ~~loss~~ is calculated as the excess of the carrying amount over the fair value. Estimating future cash flows and fair value related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment ~~loss~~ or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. Refer to “Results of Operations – Impairment of Intangible Assets” within this Item 7 and “Item 8. Financial Statements and Supplemental Data – Note 5. Intangible Assets” for a discussion of the results of our 2025 and 2024 assessments of the recoverability and impairment of our long-lived assets.

Item 7 and “Item 8. Financial Statements and Supplemental Data – Note 5, Intangible Assets” for a discussion of the results of our 2023 and 2024 assessments of the recoverability and impairment of our long-lived assets.

Income Taxes

We record the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in our accompanying consolidated balance sheets, as well as operating loss and tax credit carryforwards. We follow the guidelines set forth in the applicable accounting guidance regarding the recoverability of any tax assets recorded on the consolidated balance sheet and provide any necessary allowances as required. Determining necessary allowances requires us to make assessments about the timing of future events, including the probability of expected future taxable income and available tax planning opportunities. When we determine that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in the future, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that we determine is more-likely-than-not to be realized.

We are subject to examination of our income tax returns by various tax authorities on a periodic basis. We regularly assess the likelihood of adverse outcomes resulting from such examinations to determine the adequacy of our provision for income taxes. We have applied the provisions of the applicable accounting guidance on accounting for uncertainty in income taxes, which requires application of a more‑likely‑than‑not threshold to the recognition and derecognition of uncertain tax positions. If the recognition threshold is met, the applicable accounting guidance permits us to recognize a tax benefit measured at the largest amount of tax benefit that, in our judgment, is more than 50% likely to be realized upon settlement. It further requires that a change in judgment related to the expected ultimate resolution of uncertain tax positions be recognized in earnings in the period of such change.

As of December 31, 2024, we have recorded a full valuation allowance against our net deferred tax assets. In evaluating our ability to realize our deferred tax assets, we consider available positive and negative evidence, including past operating results and forecasts of future taxable income, and the potential Internal Revenue Code section 382 limitation on the net operating loss carryforwards due to a change in control. In determining future taxable income, we make assumptions to forecast U.S. federal and state operating income, the reversal of temporary differences, and the implementation of any feasible and prudent tax planning strategies.56

~~These~~As ~~assumptions require significant judgment regarding the forecasts~~ of ~~the~~December ~~future~~31, ~~taxable~~2025, ~~income in each tax jurisdiction and are consistent with the forecasts used to manage our business. It should be noted that~~ we have ~~generated~~recorded a ~~top-line~~full ~~and~~valuation ~~as-adjusted~~allowance ~~cumulative~~against ~~loss~~our ~~for~~net ~~the~~deferred ~~thirty-six~~tax ~~month~~assets. ~~period~~In ~~ended~~evaluating ~~December~~our ~~31,~~ability ~~2024.~~to ~~All~~realize of our deferred tax assets, ~~(“DTA”)~~we ~~are~~consider ~~recorded~~available bypositive ~~our~~and ~~U.S.~~negative ~~operations~~evidence, ~~and~~including ~~the~~past ~~U.S.~~operating ~~does~~results ~~not~~and ~~permit~~forecasts ~~carryback~~ of ~~losses.~~future Astaxable ~~such~~income, weand ~~can~~the ~~only~~potential ~~rely~~Internal onRevenue ~~the~~Code ~~reversal~~section of382 ~~existing~~limitation ~~taxable~~on ~~temporary~~NOL ~~differences~~carryforwards due to bea ~~considered~~change ~~as positive evidence~~ in ~~analyzing future use of existing DTAs~~control. WeIn ~~analyzed~~determining ~~the~~future ~~existing~~ taxable ~~temporary differences~~income, ~~but~~we ~~determined~~make ~~they~~assumptions ~~were~~to ~~insufficient~~forecast ~~for~~U.S. ~~generating~~federal ~~future~~and ~~taxable~~state operating income, tothe ~~permit~~reversal ~~full use~~ of ~~the~~temporary ~~existing DTAs. Additionally~~differences, weand ~~noted no tax planning strategies or tax planning actions which would allow for~~ the ~~use~~implementation of ~~the~~any ~~net~~feasible ~~domestic~~and ~~DTAs~~prudent ~~recorded~~tax asplanning ~~of December 31, 2024~~strategies.

WeThese ~~recognize~~assumptions ~~tax~~require ~~liabilities~~significant injudgment ~~accordance~~regarding ~~with~~the ~~ASC~~forecasts ~~Topic~~of ~~740,~~the ~~Tax~~future ~~Provisions,~~taxable income in each tax jurisdiction and weare ~~adjust~~consistent ~~these~~with ~~liabilities~~the ~~when~~forecasts used to manage our ~~judgment~~business. ~~changes~~We ashave generated a ~~result~~top-line ofand as-adjusted cumulative loss for the ~~evaluation~~three ofyear ~~new~~period ~~information~~ended ~~not~~December ~~previously~~31, ~~available~~2025. ~~Due~~All toour deferred tax assets (“DTA”) are recorded by our U.S. operations, and the ~~complexity~~U.S. ofdoes ~~some~~not permit carryback of ~~these~~losses. ~~uncertainties~~As such, we can only rely on the ~~ultimate~~reversal ~~resolution~~of ~~may~~existing ~~result~~taxable intemporary adifferences ~~payment~~to ~~that~~be isconsidered ~~materially~~as ~~different~~positive ~~from~~evidence ~~our~~in ~~current~~analyzing ~~estimate~~future use of existing DTAs. We analyzed the ~~tax~~existing ~~liabilities.~~taxable ~~These~~temporary differences, ~~are~~but ~~reflected~~determined asthey ~~increases~~were orinsufficient ~~decreases~~for togenerating future taxable income ~~tax~~to ~~expense~~permit infull use of the ~~period~~existing inDTAs. ~~which~~Additionally, ~~they~~we ~~are~~did ~~determined.~~not ~~Refer~~identify toany ~~“Note~~tax ~~14.~~planning ~~Income~~strategies ~~Taxes”~~or intax ~~the~~planning ~~Notes~~actions towhich ~~the~~would ~~Consolidated~~allow ~~Financial~~for ~~Statements~~the ~~included~~use inof ~~Part~~the ~~II,~~net ~~Item~~domestic 8DTAs recorded as of ~~this~~December ~~report~~31, 2025.

~~Acquisitions~~We recognize tax liabilities in accordance with Accounting Standards Codification Topic 740, Income Taxes, and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences are reflected as increases or decreases to income tax expense in the period in which they are determined.

WeSee ~~account~~“Item ~~for~~8. ~~acquired~~Financial ~~businesses~~Statements ~~using the acquisition method of accounting under ASC 805, which requires that assets acquired~~ and ~~liabilities~~Supplemental ~~assumed~~Data be- ~~recorded~~Note ~~at date of acquisition at their respective fair values~~14. ~~The~~Income ~~fair~~Taxes” ~~value~~for ofadditional ~~the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values~~information. ~~Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.~~

Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to calculate the present value of expected future net cash flows, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate

acquisition date fair values to assets acquired and liabilities assumed, and the resulting timing and amounts charged to or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.

On July 31, 2023, we completed the Spectrum Merger, which was accounted for under ASC 805. See “Note 2. Acquisitions” in the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this annual report.

RECENT ACCOUNTING PRONOUNCEMENTS

See “Item 8. Financial Statements and Supplemental Data - Note 1. Organization and Summary of Significant Accounting Policies” for additional information on recent accounting pronouncements.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and therefore are not required to provide the information called for by this Item 7A in this report.

5957

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ASSERTIO HOLDINGS, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248) Consolidated Balance Sheets as of December 31, ~~2024~~2025 and ~~2023~~2024 Consolidated Statements of Comprehensive Loss for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 Consolidated Statements of Shareholders’ Equity for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 Consolidated Statements of Cash Flows for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 Notes to Consolidated Financial Statements Schedule II: Valuation and Qualifying Accounts

6058

Report of Independent Registered Public Accounting Firm

Board of Directors and Shareholders

Assertio Holdings, Inc.

Opinion on the financial statements

We have audited the accompanying consolidated balance sheets of Assertio Holdings, Inc. (a Delaware corporation) and subsidiaries (the “Company”) as of December 31, ~~2024~~2025 and ~~2023~~2024, the related consolidated statements of comprehensive loss, shareholders’ equity, and cash flows for each of the two years in the period ended December 31, ~~2024~~2025, and the related notes and financial statement schedule included under Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, ~~2024~~2025 and ~~2023~~2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, ~~2024~~2025, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, ~~2024~~2025, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), and our report dated March 1216, ~~2025~~2026 expressed an unqualified opinion.

Change in accounting principle

As discussed in Note 1 to the consolidated financial statements, the Company has adopted new accounting guidance in 2025 related to income tax disclosures due to the adoption of ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The adoption was prospectively applied.

Basis for opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical audit ~~matter~~ matters

The critical audit ~~matter~~matters communicated below isare amatters ~~matter~~ arising from the current period audit of the financial statements that ~~was~~were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit ~~matter~~matters below, providing a separate ~~opinion~~opinions on the critical audit ~~matter~~matters or on the accounts or disclosures to which itthey ~~relates~~relate.

~~Allowance~~Divestiture ~~for~~of ~~Product~~Assertio ~~Returns~~Therapeutics

As described further in Note 12 to the consolidated financial statements, during 2025 the Company ~~estimates~~transferred ~~product~~all ~~returns~~of ~~based~~the onequity ~~historical~~interests ~~return~~in ~~trends~~Assertio byTherapeutics ~~product~~to oran byestablished ~~return~~purchaser ~~trends~~ of ~~similar~~legacy ~~products~~litigation matters, ~~taking~~resulting ~~into~~in ~~consideration~~Assertio ~~the~~Therapeutics ~~shelf~~being ~~life~~owned ofby the ~~product~~purchaser’s atrelated ~~the time of shipment~~company, ~~shipment~~ATIH ~~and~~Industries ~~prescription~~LLC. ~~trends,~~In ~~estimated~~connection ~~distribution~~with ~~channel inventory levels and consideration of~~ the ~~introduction of competitive products. As of December 31~~divestiture, ~~2024,~~ the Company ~~had accrued product returns of $22.4 million. We identified the estimate for future product returns as a critical audit matter.~~

The principal considerations for our determination that accrued product returns is a critical audit matter are (i) the significant judgment by management when developing the accrual, and (ii) a high degree of auditor judgement, subjectivity and effort in performing procedures and evaluating the assumptions related to estimated percentages of future product returns.59

61recognized a net loss of approximately $8.2 million. The divestiture of Assertio Therapeutics involved unique and complex facts and circumstances and required management to apply significant judgment in determining the appropriate accounting treatment, financial statement presentation, and related disclosures. We identified the divestiture of Assertio Therapeutics as a critical audit matter. The principal considerations for our determination that the divestiture of Assertio Therapeutics is a critical audit matter are the unique nature of the transaction and the high degree of auditor judgment, subjectivity, and effort required to evaluate the application of relevant accounting principles, including the recognition and measurement of the loss on divestiture and the appropriateness of the related financial statement presentation and disclosures.

Our audit procedures related to the ~~allowance~~divestiture ~~for~~of ~~product~~Assertio ~~returns~~Therapeutics included: the following, among others:

•We obtained an understanding ~~and~~of, ~~tested~~evaluated the design of, and tested the operating effectiveness of ~~relevant~~internal controls ~~within~~over the Company’s ~~process~~accounting ~~to prepare estimates~~ for ~~future~~the ~~product returns~~divestiture.

•We ~~developed~~evaluated anmanagement’s ~~independent~~accounting ~~estimated~~conclusions ~~product~~related ~~return~~to ~~rate~~the byrecognition ~~utilizing~~and ~~audited~~measurement ~~historical~~of ~~data~~the ~~and~~loss ~~comparing~~on divestiture. We involved national office resources to ~~management’s~~assist ~~estimate~~in assessing the appropriateness of the accounting treatment and financial statement presentation of the transaction.

•We substantively tested, onthe acalculation ~~sample~~of ~~basis,~~the ~~product~~loss ~~returns~~recognized ~~processed~~in byconnection with the ~~Company~~divestiture.

•We ~~performed~~assessed athe ~~retrospective~~sufficiency ~~analysis~~and clarity of management’s ~~estimate~~presentation ~~for accrued product returns~~ and ~~performed~~disclosures arelated ~~sensitivity analysis~~ to ~~determine if~~ the ~~accrual was reasonable~~divestiture.

Estimate of Gross-to-Net Accruals for Rolvedon Held by Wholesalers

As described further in Note 1 to the consolidated financial statements, the Company establishes provisions for chargebacks, rebates, and other sales allowances in the same period that product is sold to wholesalers. As of December 31, 2025, the Company recorded gross‑to‑net accruals of approximately $38.4 million related to Rolvedon inventory sold to wholesalers but not yet sold to end customers. These accruals primarily relate to estimated rebates and chargebacks offered to group purchasing organizations (“GPOs”). We identified the estimate of gross‑to‑net accruals for Rolvedon held by wholesalers as a critical audit matter. The principal considerations for our determination that the estimate of gross‑to‑net accruals for Rolvedon held by wholesalers is a critical audit matter are the significant judgment and estimation uncertainty involved in determining rebate and chargeback rates applicable to future sales of product held by wholesalers, including management’s assumptions related to historical wholesaler sales trends and anticipated changes in contractual terms and the high degree of auditor judgement, subjectivity, and effort required to evaluate the assumption and resulting impact on net revenues and the related portion of “accrued rebates, returns and discounts”.

Our audit procedures related to the estimate of gross-to-net accruals for Rolvedon held by wholesalers included the following, among others:

•We obtained an understanding of, evaluated the design of, and tested the operating effectiveness of controls over management’s process for estimating gross-to-net accruals for Rolvedon held by wholesalers.

•We tested the completeness and accuracy of historical rebate, chargeback, and wholesaler sales data used by management in developing the estimate.

•We inspected relevant contractual arrangements with GPOs and chargeback provisions applicable to future end-user sales.

•We assessed the reasonableness of management’s assumptions related to anticipated pricing, utilization trends, and end-user mix, and evaluated the impact of those assumptions on the estimated rebates and chargebacks.

/s/ GRANT THORNTON LLP

We have served as the Company’s auditor since 2021.

Chicago, Illinois

March 1216, ~~2025~~2026

6260

ASSERTIO HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	December 31,
	2024		2023
	2025		2024
ASSETS
Current assets:
Cash and cash equivalents	$	5010,~~588~~229	$	7350,~~441~~588
Short-term investments	4953,~~466~~176		—49,466
Accounts receivable, net	~~54,~~120,110		4754,~~663~~120
Inventories, net	3824,~~308~~120		3738,~~686~~308
Prepaid and other current assets	109,~~067~~011		1210,~~272~~067
Total current assets	~~202~~216,~~549~~646		~~171~~202,~~062~~549
Property and equipment, net	~~586~~444		~~770~~586
Intangible assets, net	8048,~~471~~908		~~111~~80,~~332~~471
Other long-term assets	~~1,126~~972		31,~~255~~126
Total assets	$	~~284~~266,~~732~~970	$	~~286~~284,~~419~~732
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	149,~~736~~014	$	1314,~~439~~736
Accrued rebates, returns and discounts	7699,~~304~~366		5876,~~137~~304
Accrued liabilities	1814,~~847~~282		18,~~213~~847
Contingent consideration, current portion	~~726~~—		~~2,700~~726
Other current liabilities	4,~~075~~851		~~954~~4,075
Total current liabilities	~~114~~127,~~688~~513		93114,~~443~~688
Long-term debt	3839,~~813~~124		38,~~514~~813
Other long-term liabilities	106,~~150~~381		1610,~~459~~150
Total liabilities	~~163~~173,~~651~~018		~~148~~163,~~416~~651
Commitments and contingencies (Note 8)
Shareholders’ equity:
Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,536,990 and 94,668,523 shares issued and outstanding as of December 31, 2024 and 2023, respectively	9		9
Common stock, $0.0001 par value, 200,000,000 shares authorized; 6,421,899 and 6,369,133 shares issued and outstanding as of December 31, 2025 and 2024, respectively*	1		1
Additional paid-in capital	794,196		789,537
Additional paid-in capital*	797,450		794,204
Accumulated deficit	(~~673~~703,~~124~~499)		(~~651~~673,~~543~~124)
Total shareholders’ equity	~~121~~93,~~081~~952		~~138~~121,~~003~~081
Total liabilities and shareholders' equity	$	~~284~~266,~~732~~970	$	~~286~~284,~~419~~732

* Shares issued and outstanding, common stock and additional paid-in capital as of December 31, 2024 have been adjusted to reflect the 1-for-15 reverse stock split effected on December 26, 2025.

The accompanying notes are an integral part of these consolidated financial statements.

6361

ASSERTIO HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands, except per share data)

	Year Ended December 31,
	2024		2023
	2025		2024
Revenues:
Product sales, net	$	~~120~~117,~~849~~100	$	~~149~~120,~~451~~849
Royalties and milestones	2,012		2,433
Royalty revenue	1,613		2,012
Other revenue	~~2,100~~—		~~185~~2,100
Total revenues	~~124~~118,~~961~~713		~~152~~124,~~069~~961
Costs and expenses:
Cost of sales	3935,~~227~~383		2739,~~020~~227
Research and development expenses	31,~~822~~690		23,~~843~~822
Selling, general and administrative expenses	7569,~~051~~000		7875,~~638~~051
Change in fair value of contingent consideration	(~~244~~276)		(~~25,538~~244)
Amortization of intangible assets	2529,~~644~~863		2725,~~527~~644
Loss on impairment of intangible assets	5,217		279,639
Impairment of intangible assets	1,700		5,217
Restructuring charges	~~720~~2,889		~~5,476~~720
Total costs and expenses	~~149~~140,~~437~~249		~~395~~149,~~605~~437
Loss from operations	(2421,~~476~~536)		(~~243~~24,~~536~~476)
Other income (expense):
Other (expense) income:
Debt related expenses	—		(9,918)
Loss on Assertio Therapeutics divestiture	(8,174)		—
Interest expense	(3,~~039~~075)		(3,~~380~~039)
Interest income	32,~~221~~665		23,~~403~~221
Other gain, net	~~2,765~~180		~~377~~2,765
Total other income (expense)	2,947		(10,518)
Total other (expense) income	(8,404)		2,947
Net loss before income taxes	(2129,~~529~~940)		(~~254~~21,~~054~~529)
Income tax expense	(52435)		(~~77,888~~52)
Net loss and comprehensive loss	$	(2130,~~581~~375)	$	(~~331~~21,~~942~~581)
Basic and diluted net loss per share	$	(0.23)	$	(4.67)
Basic and diluted net loss per share*	$	(4.74)	$	(3.40)
Shares used in computing basic and diluted net loss per share	95,271		71,031
Shares used in computing basic and diluted net loss per share*	6,403		6,351

* Basic and diluted net loss per share and shares used in computing basic and diluted net loss per share for the year ended December 31, 2024 have been adjusted to reflect the 1-for-15 reverse stock split effected on December 26, 2025.

The accompanying notes are an integral part of these consolidated financial statements.

6462

ASSERTIO HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands)

	Common Stock			Additional Paid-In Capital*		AccumulatedDeficit		Shareholders’Equity
	Shares	Amount
	Shares*	Amount*
Balances as of December 31, 2022	48,320	$	5	$	545,321	$	(319,601)	$	225,725
Balances as of December 31, 2023	6,311	$	1	$	789,545	$	(651,543)	$	138,003
Issuance of common stock upon exercise of options	133	—		210		—		210
Common stock issuance and other impacts of the vesting and settlement of equity awards	58	—		(350)		—		(350)
Common stock issuance and other impacts of the vesting and settlement of equity awards	1,218	—		(8,108)		—		(8,108)
Induced exchange of convertible notes - (see Note 11)	6,990	—		26,699		—		26,699
Issuance of common stock in connection with the Spectrum Merger, net of fractional shares settlement	38,008	4		216,257		—		216,261
Stock-based compensation	—	—		9,158		—		9,158
Net loss and comprehensive loss	—	—		—		(331,942)		(331,942)
Balances as of December 31, 2023	94,669	9		789,537		(651,543)		138,003
Common stock issuance and other impacts of the vesting and settlement of equity awards	868	—		(350)		—		(350)
Stock-based compensation	—	—		5,009		—		5,009
Net loss and comprehensive loss	—	—		—		(21,581)		(21,581)
Net loss	—	—		—		(21,581)		(21,581)
Balances as of December 31, 2024	956,~~537~~369	$1	9	$794,204	~~794,196~~	$(673,124)	~~(673,124)~~	$121,081	~~121,081~~
Common stock issuance and other impacts of the vesting and settlement of equity awards	53	—		(189)		—		(189)
Stock-based compensation	—	—		3,454		—		3,454
Reverse stock split fractional shares settlement	—	—		(19)		—		(19)
Net loss	—	—		—		(30,375)		(30,375)
Balances as of December 31, 2025	6,422	$	1	$	797,450	$	(703,499)	$	93,952

* Adjusted to reflect the 1-for-15 reverse stock split effected on December 26, 2025.

The accompanying notes are an integral part of these consolidated financial statements.

6563

ASSERTIO HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Year Ended December 31,
	2024		2023
	2025		2024
Operating Activities
Net loss	$	(2130,~~581~~375)	$	(~~331~~21,~~942~~581)
Adjustments to reconcile net loss to net cash provided by operating activities:
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	2530,~~829~~005		2825,~~229~~829
Amortization of debt issuance costs and Royalty Rights	439		455
Amortization of debt issuance costs	475		439
Accretion of interest income from short-term investments	~~(542)~~93		—(542)
Loss on impairment of intangible assets	5,217		279,639
Impairment of intangible assets	1,700		5,217
Recurring fair value measurements of assets and liabilities	(397)		(25,482)
Loss on Assertio Therapeutics divestiture	8,174		—
Payment of contingent consideration	(1,730)		—
Recurring fair value measurements of assets and liabilities	(435)		(397)
Debt-related expenses	—		9,918
Payment of contingent consideration	(450)		(1,730)
Stock-based compensation	53,~~009~~454		95,~~158~~009
Provisions for inventory	84,~~960~~510		38,~~288~~960
Deferred income taxes	—		76,201
Changes in assets and liabilities, net of acquisition:
Accounts receivable	(665,~~457~~990)		48(6,~~669~~457)
Inventories	(9,~~583)~~678		(49,~~973~~583)
Prepaid and other assets	41,~~334~~209		(14,~~169)~~334
Accounts payable and other accrued liabilities	(113,~~256~~292)		(291,~~348~~256)
Accrued rebates, returns and discounts	1823,~~166~~062		~~(12~~18,~~313)~~166
Interest payable	—		(726)
Net cash (used in) provided by operating activities	(28,182)		26,408
Net cash provided by operating activities	26,408		49,604
Investing Activities
Purchases of short-term investments	(98,605)		—
Assertio Therapeutics divestiture	(8,174)		—
Proceeds from maturities of short-term investments	49115,~~694~~383		—49,694
Proceeds from the sale of investments	—		2,194
Purchases of short-term investments	(119,197)		(98,605)
Net cash acquired in Spectrum Merger	—		1,950
Net cash used in investing activities	(11,988)		(48,911)
Purchases of property and equipment	—		(628)
Purchase of Sympazan	—		(419)
Net cash (used in) provided by investing activities	(48,911)		3,097
Financing Activities
Payments related to the vesting and settlement of equity awards, net	(~~350~~189)		(~~7,898~~350)
Payment of contingent consideration	—		(24,194)
Net cash used in financing activities	(189)		(350)
Payments in connection with 2027 Convertible Notes	—		(10,500)
Net decrease in cash and cash equivalents	(40,359)		(22,853)
Payment of direct transaction costs related to convertible debt inducement	—		(1,119)
Cash and cash equivalents at beginning of year	50,588		73,441
Payment of Royalty Rights	—		(459)
Cash and cash equivalents at end of year	$	10,229	$	50,588
Other financing activities	—		(31)
Net cash used in financing activities	(350)		(44,201)
Net (decrease) increase in cash and cash equivalents	(22,853)		8,500
Cash and cash equivalents at beginning of year	73,441		64,941
Cash and cash equivalents at end of year	$	50,588	$	73,441
Supplemental Disclosure of Cash Flow Information
Net cash paid for income taxes	$	1,594	$	4,031
Cash paid for interest	$	2,600	$	2,600
Cash paid for interest	$	2,600	$	3,651

The accompanying notes are an integral part of these consolidated financial statements.

6664

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Assertio Holdings, Inc., or the Company, is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. The Company’s focus is on supporting patients by marketing products primarily in the oncology, ~~neurology, and pain management~~market.

The Company has built its product portfolio through the acquisition or licensing of approved products, including its lead product, ~~ROLVEDON~~ROLVEDONTM. The Company’s ~~commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s~~ primary marketed products include ~~ROLVEDONTM~~ROLVEDON (elflapegrastim-xnst) injection for subcutaneous use, Sympazan® (clobazam) oral film, INDOCIN® (indomethacin) Suppositories, INDOCIN® (indomethacin) Oral Suspension, ~~Otrexup® (methotrexate) injection for subcutaneous use,~~ SPRIX® (ketorolac tromethamine) Nasal Spray, and CAMBIA® (diclofenac potassium for oral solution). ToIn ~~date~~July 2025, ~~substantially all of~~ the Company’s ~~revenues~~ceased ~~are~~commercializing ~~related~~Otrexup to(see ~~product~~Note ~~sales~~2. inDivestitures ~~the~~and ~~United~~Strategic ~~States (“U.S.”~~Transactions).

Unless otherwise noted or required by context, use of “Assertio,” the “Company,” “we,” “our” and “us” refer to Assertio Holdings and/or its applicable subsidiary or subsidiaries. Reference to “Assertio Specialty” refers to Assertio Specialty Pharmaceuticals, LLC, and “Spectrum” refers to Spectrum Pharmaceuticals, Inc., and/or its applicable subsidiary or subsidiaries. Both Assertio Specialty and Spectrum are wholly-owned subsidiaries of the Company. Additionally, the use of “Assertio Therapeutics” ~~or “Depomed”~~ refers to Assertio Therapeutics, Inc., and/or its applicable subsidiary or subsidiaries. Assertio Therapeutics was divested on May 9, 2025 (see Note 2. Divestitures and Strategic Transactions).

Basis of Presentation

The Company’s consolidated financial statements are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and U.S. Securities and Exchange Commission (“SEC”) regulations for annual reporting. During 2024, the Company began to reclassify interest income from Other gain (loss) to Interest income on the Company’s Consolidated Statements of Comprehensive Loss. Prior period amounts have been reclassified to conform with the current period presentation.

In ~~connection~~preparing ~~with~~ the ~~preparation of the~~ financial statements for the year ended December 31, ~~2024~~2025, the Company evaluated whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to the entity's ability to continue as a going concern within 12 months after the date of the issuance of these financial statements, ~~noting~~and concluded that ~~there~~no ~~did not appear to be evidence of~~ substantial doubt ~~of the entity's ability to continue as a going concern for a period of 12 months after the date these financial statements were issued~~exists.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Reverse Stock Split

On December 26, 2025, the Company effected a 1-for-15 reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company’s stockholders received one share of common stock for every 15 shares held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company’s issued and outstanding shares of common stock equally. Any fractional shares remaining as a result of the Reverse Stock Split were paid to the shareholder in cash. The par value and number of authorized shares of the Company's common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company’s outstanding stock-based awards and convertible senior notes due 2027 and resulted in the shares underlying such instruments being reduced and the exercise or conversion price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying stock-based awards and the convertible senior notes due 2027 included in these consolidated financial statements, including the exercise price of equity instruments or conversion price of the convertible senior notes due 2027, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used in determining items such as product returns, rebates, the evaluation of impairment of intangible assets, the fair value of contingent consideration obligations, and income taxes. Estimates are also used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities as well as subsequent fair value measurements. Although management believes these estimates are based upon reasonable assumptions within the bounds of its knowledge of the Company, actual results could differ materially from these estimates.

Estimates are used in determining items such as product returns, rebates, the evaluation of impairment of intangible assets, the fair value of contingent consideration obligations, and income taxes. Estimates are also used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities as well as subsequent fair value measurements. Although management believes these estimates are based upon reasonable assumptions within the bounds of its knowledge of the Company, actual results could differ materially from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity date ofat purchase of three months or less to be cash equivalents. Cash and cash equivalents generally consist of cash on ~~deposits~~deposit with banks, money market instruments, U.S. Agency discount notes, commercial paper and corporate debt securities. The Company invests its cash in money market funds and marketable securities including U.S. Treasury and government agency securities, commercial paper, and higher quality debt securities of financial and commercial institutions. There may be times when the Company's cash and cash equivalents on deposit exceed the Federal Deposit Insurance Corporation insurance limits, which potentially exposes the Company to a concentration of credit risk. The Company maintains its cash and cash equivalents principally with accredited financial institutions with high credit ratings.

concentration of credit risk. The Company maintains its cash and cash equivalents principally with accredited financial institutions of high-credit standing.

Short-Term Investments

The Company considers all highly liquid investments with a maturity date at purchase of more than three months but less than one year to be short-term investments. The Company’s short-term investments consist of marketable securities, which could include commercial paper and U.S. Treasury securities. The Company has classified its short-term investments as trading securities. The short-term investments are recorded at fair value using Level 2 inputs, as the inputs used to value these instruments are directly observable or can be corroborated by observable market data for substantially the full term of the assets. Gains and losses on short-term investments are included in Interest income in the Consolidated Statements of Comprehensive Loss.

Accounts Receivable

Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment. To date, the Company has not recorded an allowance for estimated expected credit losses since the majority of its product revenue comes from sales to a limited number of financially sound companies who have historically paid their balances timely, with resulting credit losses not historically being material. The need for an allowance for estimated expected credit losses is evaluated each reporting period based on the Company’s assessment of the creditworthiness of its customers or any other potential circumstances that could result in an allowance for estimated expected credit losses.

Inventories

Cost of sales includes the cost of inventory sold or reserved, which includes manufacturing and supply chain costs, product shipping and handling costs, and product royalties.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, as follows:


Furniture and office equipment			3 - 5 years
Machinery and equipment			5 - 7 years
Laboratory equipment			3 - 5 years
Leasehold improvements			Shorter of estimated useful life or lease term

Intangible Assets

Intangible assets consist of product rights that are accounted for as definite-lived intangible assets subject to amortization. The Company determines the fair value of acquired intangible assets as of the acquisition date. Discounted cash flow models are typically used in these valuations, which require the use of significant estimates and assumptions, including but not limited to, developing appropriate discount rates and estimating future cash flows from product sales and related expenses. The fair value recorded is amortized on a straight-line basis over the estimated useful life of the asset. The Company estimates the useful life of the assets by considering competition by products prescribed for the same indication, the expected lives of the patents held by the Company for the products, the likelihood and estimated future entry of non-generic and generic competition for the same or similar indication, and other related factors.

Impairment of Long-lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Pursuant to Accounting Standards Codification (“ASC”) 360, Property, Plant and Equipment (“ASC 360”), the Company groups its long-lived assets at the product level, which is the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities. The Company estimates the future net undiscounted cash flows expected to be generated from the use of the long-lived asset group and its eventual disposition. An impairment would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The impairment is calculated as the excess of the carrying amount over the fair value.

Impairment Testing: Long Lived Assets Classified as Held and Used (“ASC 360”), the Company groups its long-lived assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities. The Company estimates the future net undiscounted cash flows expected to be generated from the use of the long-lived asset group and its eventual disposition. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The impairment loss is calculated as the excess of the carrying amount over the fair value.

Acquisitions

The Company accounts for acquired businesses using the acquisition method of accounting under ASC 805, Business Combinations (“ASC 805”), which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to calculate the present value of expected future net cash flows, the assessment of each asset’s life cycle, and impact of competitive trends on each asset’s life cycle, and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amounts charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.

Any changes in the fair value of contingent consideration resulting from a change in the underlying inputs is recognized in operating expenses until the contingent consideration arrangement is settled. Changes in the fair value of contingent consideration resulting from the passage of time are recorded within interest expense until the contingent consideration is settled.

If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the cost to acquire the group of assets, including transaction costs, is allocated to the individual assets acquired or liabilities assumed based on their relative fair values. In addition, amounts allocated to acquired in-process research and development with no alternative future use is charged to expense at the acquisition date.

Revenue Recognition

Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation, when (or as) the performance obligation is satisfied. The Company assesses the term of the contract based upon the contractual period in which the Company has enforceable rights and obligations.

Variable consideration arising from sales or usage-based royalties, promised in exchange for a license of the Company’s intellectual property, is recognized at the later of (i) when the subsequent product sales occur or (ii) the performance obligation, to which some or all of the sales-based royalty has been allocated, has been satisfied.

Product Sales

The Company sells commercial products to wholesale distributors and specialty pharmacies. Product sales revenue is recognized when the customer has control of the product, which is when title has transferred to the customer and the customer has assumed the risks and rewards of ownership. These conditions typically occur upon delivery to the customer. The Company’s performance obligation is to deliver product to the customer, and the performance obligation is typically completed upon delivery. The transaction price consists of a fixed invoice price and variable product sales allowances, which include rebates, discounts and returns. Product sales revenues are recorded net of applicable sales tax and reserves for these product sales allowances. Receivables related to product sales are typically collected one to two months after delivery. As a result, the Company has elected to apply the practical expedient to not recognize a significant financing element for its contracts where the period between the customer obtaining control of the product and the customer paying for its product is one year or less. Receivables may also include customer deductions for returns and chargebacks that are pending Company validation.

The Company considers product sales allowances to be variable consideration and estimates and recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on actual or estimated amounts owed on the related sales. These estimates take into consideration the terms of the Company’s agreements with customers, historical product returns, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. The Company uses the most likely method in estimating product sales allowances. If actual future results vary from the Company’s estimates, the Company may need to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment.

the distribution channel, the shelf life of the product and specific known market events, such as competitive pricing and new product introductions. The Company uses the most likely method in estimating product sales allowances. If actual future results vary from the Company’s estimates, the Company may need to adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment.

The Company’s product sales allowances include:

Product Returns - The Company allows customers to return product for credit with respect to that product generally within six months before and ~~up to~~ 12 months after the product expiration date. The Company estimates product returns based on historical return trends by product or by return trends of similar products, taking into consideration the shelf life of the product at the time of shipment, shipment and prescription trends, estimated distribution channel inventory levels and consideration of the introduction of competitive products. The Company does not assume financial responsibility for returns of any of its currently marketed products acquired through product rights acquisitions if those returns relate to sales of that product prior to the period of the Company’s ownership of the respective product, which are identified by specific lot numbers.

Shelf lives for the Company’s products, from the respective manufacture dates, for the Company’s products range from 24 months to 48 months. Because of the shelf life of the Company’s products and its return policy of issuing credits with respect to product that is returned within six months before and ~~up to~~ 12 months after its product expiration date, there may be a significant period of time between when the product is shipped and when the Company issues credit on a returned product. Accordingly, the Company may have to adjust these estimates, which could have an effect on net product sales and earnings in the period of adjustments.

Managed Care Rebates - The Company offers discounts under contracts with certain managed care providers. The Company generally pays managed care rebates one to three months after prescriptions subject to the rebate are filled.

Commercial Rebates - The Company offers certain group purchasing organization (“GPO”) rebates for end-user purchases made under contractual rebate percentage tier programs. Commercial rebates are based on (i) an estimate of end-user purchases through a GPO, (ii) the corresponding contractual rebate percentage tier the Company expects each GPO to achieve, and (iii) the Company’s estimate of the impact of any prospective rebate program changes made by the Company. The Company generally pays commercial rebates two to 12 months after qualifying purchases are made.

Government Rebates - The Company offers discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, including Centers for Medicare and Medicaid Services’ Medicaid Drug Rebate Program and Medicare Part B Program and Medicare Part D Coverage Gap Discount Programs. The Company generally pays government rebates three to 12 months after prescriptions subject to the rebate are filled. These rebates are subject to the Company’s active participation in the respective programs.

Wholesaler and Pharmacy Discounts— - The Company offers contractually determined discounts to certain wholesale distributors and specialty pharmacies that purchase directly from it. These discounts are either taken off invoice at the time of shipment or paid to the customer on a quarterly basis one to two months after the quarter in which the product was shipped to the customer.

Prompt Pay Discounts - The Company offers cash discounts to its customers (generally 2% of the sales price) as an incentive for prompt payment. Based on the Company’s experience, the Company expects its customers to meet the payment terms to earn the cash discount.

Patient Discount Programs - The Company offers patient discount co-pay assistance programs in which patients receive certain discounts off their prescriptions at participating retail and specialty pharmacies. The discounts are reimbursed by the Company to program administrators approximately one month after the prescriptions subject to the discount are filled.

Chargebacks - The Company provides discounts to authorized users of the U.S. Department of Veterans Affairs’ Federal Supply Schedule Program and the Health Resources and Services ~~Administrations’~~Administration's 340B Drug Pricing Program. These federal and 340B entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current retail price and the price the federal entity paid for the product. These discounts are subject to the Company’s active participation in the respective programs.

~~All~~The ~~of the~~ Company’s product sales allowances are included in Accrued rebates, returns and discounts on the Consolidated Balance Sheets, except for prompt pay discounts, which are included as a reduction in Accounts receivable, net, on the Consolidated Balance Sheets.

~~Royalties and Milestone Revenue~~68

Royalty Revenue

For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalties revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty that has been allocated has been satisfied (or partially satisfied). The Company currently receives royalties based on sales of CAMBIA in Canada, which are recognized as revenue when the related sales occur as there are no continuing performance obligations by the Company under those agreements.

For arrangements that include milestones, the Company recognizes such revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestone and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.

Loss Contingencies

The Company is currently involved in various lawsuits, claims, investigations, and other legal proceedings that arise in the ordinary course of business. The Company recognizes a loss contingency provision in its financial statements when it concludes that a contingent liability is probable, and the amount thereof is estimable. For matters where a loss is not probable, or a probable loss cannot be reasonably estimated, no liability has been recorded. For the matters described in Note 8,. Commitments and Contingencies, in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss is provided, if material. Costs associated with the Company’s involvement in legal proceedings are expensed as incurred. Amounts accrued for legal contingencies are based on management’s best estimate of a loss based upon the status of the cases, assessments of the likelihood of damages, and the advice of counsel, and often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. Provisions for loss contingencies are recorded in Selling, general and administrative expense in the Company’s Consolidated Statements of Comprehensive Loss and the related accruals are recorded in Accrued liabilities in the Company’s Consolidated Balance Sheets.

Contingent Consideration Obligations

The Company has issued contingent value rights (“CVRs”) as part of the Spectrum acquisition in July 2023 (the “Spectrum Merger”) and future royalties to an affiliate of CR Group L.P. as part of the Company’s merger with Zyla Life Sciences (“Zyla”) in May 2020 (the “Zyla Merger”). See Note ~~2, Acquisitions and Note~~ 13,. Fair Value, for further details. Both are contingent consideration obligations of the Company.

The fair values of each of the contingent consideration obligations are remeasured each reporting period, with changes in the fair values resulting from changes in the respective underlying inputs being recognized in operating expenses until both the contingent arrangements are settled. Both are based on significant inputs not observable in the market and thus represent Level 3 measurements.

Leases

In accordance with ASC 842, Leases, the Company assesses contracts for lease arrangements at inception. Operating right-of-use (“ROU”) assets and lease liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease.

The Company accounts for operating leases with an initial term of 12 months or less on a straight-line basis over the lease term in the Consolidated Statements of Comprehensive Loss. ROU assets and liabilities are not recorded for these leases.

Stock-Based Compensation

The Company’s stock-based compensation generally includes time-based restricted stock units (“RSU”) and options, and from time to time also includes performance-based RSUs and options. The Company accounts for forfeitures as they occur for each type of award. Stock-based compensation expense related to time-based RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The determination of the fair value of stock-based payment awards on the date of grant using an option valuation model is affected by the Company’s stock price as well as various assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate, and expected dividends over the expected term of the award. The Company uses historical option exercise data to estimate the expected term of the options. The Company estimates the volatility of its common stock price by using the historical volatility over the expected term of the options. The Company bases the risk-free interest rate on U.S. Treasury zero coupon issues with terms similar to the expected term of the options as of the date of grant. The Company does not anticipate paying any cash dividends in the foreseeable future, and therefore, uses an expected dividend yield of zero in the option valuation model. For performance-based options granted with vesting subject to performance conditions, the fair value of the award is determined at grant date using the Black-Scholes option valuation model, and expense is recognized ratably over the requisite performance period regardless of whether or not the performance condition is satisfied.

coupon bonds with terms similar to the expected term of the options as of the date of grant. The Company does not anticipate paying any cash dividends in the foreseeable future, and therefore, uses an expected dividend yield of zero in the option valuation model. For performance-based options granted with vesting subject to performance conditions, the fair value of the award is determined at grant date using the Black-Scholes option valuation model, and expense is recognized ratably over the requisite performance period regardless of whether or not the performance condition is satisfied.

Advertising Costs

Costs associated with advertising are expensed as incurred. Advertising expense for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 was $1.83 million and $41.48 million, respectively. Advertising costs are included in Selling, general and administrative expenses within the Consolidated Statements of Comprehensive Loss.

Income Taxes

The Company records the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in its Consolidated Balance Sheets, as well as net operating loss and tax credit carryforwards. The Company follows the guidelines set forth in the applicable accounting guidance regarding the recoverability of any tax assets recorded on the Consolidated Balance Sheets and provides any necessary allowances as required. Determining necessary allowances requires the Company to make assessments about the timing of future events, including the probability of expected future taxable income and available tax planning opportunities. When it is determined that it is more likely than not that some portion or all of the deferred tax assets will not be realized in the future, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount determined isto be more likely than not to be realized.

The Company is subject to examination of its income tax returns by various tax authorities on a periodic basis. The Company regularly assesses the likelihood of adverse outcomes resulting from such examinations to determine the adequacy of its provision for income taxes. The Company has applied the provisions of the applicable accounting guidance on accounting for uncertainty in income taxes, which requires application of a more‑likely‑than‑not threshold to the recognition and derecognition of uncertain tax positions. If the recognition threshold is met, the applicable accounting guidance permits the Company to recognize a tax benefit measured at the largest amount of tax benefit that, in its judgment, is more than 50% likely to be realized upon settlement. It further requires that a change in judgment related to the expected ultimate resolution of uncertain tax positions be recognized in earnings in the period of such change.

The Company recognizes tax liabilities in accordance with ASC Topic 740, Income Taxes (“ASC 740”), and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company’s current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.

complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.

Restructuring

The Company accounts for restructuring costs in accordance with ASC 420, Exit or Disposal Cost Obligations (“ASC 420”) and ASC 712, Compensation - Nonretirement Postemployment Benefits (“ASC 712”). One-time termination benefits are recorded at the time restructuring is communicated to the affected employees. Ongoing termination benefits are recognized when they are probable and estimable. Payments under one-time and ~~probable~~ongoing termination benefits are made over the period to which the former employee is entitled to the benefit under the termination agreement.

Concentrations of Risk

The Company is subject to credit risk from its accounts receivable related to product sales. The three large, national wholesale distributors represent the majority of the Company’s business and represented the following percentage of consolidated revenue ~~by customer~~ and ~~the percentage of~~ accounts receivable by customer related to product ~~shipments~~sales for the years ended December 31, ~~2024~~2025 and ~~2023~~2024.

	Consolidated revenue				Accounts receivable related to product sales
	Year Ended December 31,					As of December 31,
	2024		2023			2024		2023
	2025		2024			2025		2024
Cencora (formerly AmerisourceBergen Corporation)	40	%	35	%		33	%	57	%
Cencora	45	%	40	%		44	%	33	%
McKesson Corporation	3031	%	2130	%		4239	%	1242	%
Cardinal Health	810	%	188	%		610	%	146	%
Other significant customer	7	%	10	%		13	%	10	%
All others	14	%	22	%		7	%	19	%
All others	15	%	16	%		6	%	7	%
Total	100	%	100	%		100	%	100	%

InThe ~~addition, the~~ Company is ~~dependent~~also ~~upon~~subject ~~third-party manufacturers~~ to ~~supply~~risk ~~product~~from ~~for commercial use. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with~~ its ~~requirements~~concentration ~~for all commercialized products. Such production arrangements could be adversely affected by a significant interruption which would negatively impact the supply~~ of ~~final drug~~ product. ~~The~~sales ~~Company~~in ~~mitigates~~ROLVEDON, ~~potential~~as ~~supply~~further ~~risks~~discussed ~~for~~in ~~all~~Note of3. ~~its marketed products through inventory management and through exploring additional manufacturers to provide the Company’s marketed products~~Revenue.

In addition, the Company is dependent upon third-party manufacturers to supply product for commercial use. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for all commercialized products. Such production arrangements could be adversely affected by a significant interruption which would negatively impact the supply of final drug product. The Company mitigates potential supply risks for its marketed products through inventory management and through exploring additional manufacturers to provide the Company’s marketed products.

Recently Adopted Accounting Pronouncements

In ~~November~~December 2023, the FASB issued ASU No. 2023-0709, ~~Segment~~Income ~~Reporting~~Taxes (Topic ~~280~~740): Improvements to ~~Reportable~~Income ~~Segment~~Tax Disclosures (“"ASU 2023-~~07”~~09"), which isprescribes ~~intended~~standard tocategories ~~improve~~for ~~reportable~~the ~~segment~~components ~~disclosure~~of ~~requirements,~~the ~~primarily~~effective ~~through~~tax ~~enhanced~~rate ~~disclosures~~reconciliation ~~about~~and ~~significant~~requires ~~segment expenses. The~~ disclosure ~~requirements~~of ~~included~~additional ininformation ~~ASU~~for ~~2023-07~~reconciling ~~are~~items ~~required~~meeting ~~for~~certain ~~all~~quantitative ~~public entities~~thresholds, ~~including~~requires ~~those~~disclosure ~~with~~of adisaggregated ~~single~~income ~~reportable~~taxes ~~segment. ASU 2023-07 is effective for fiscal years beginning after December 15~~paid, ~~2023,~~ and ~~interim~~modifies ~~periods~~certain ~~within~~other ~~fiscal~~income ~~years~~tax-related ~~beginning after December 15, 2024, with early adoption permitted~~disclosures. The Company adopted ASU 2023-0709 in the fourth quarter of ~~2024~~2025 prospectively. ~~The~~Adoption ~~adoption~~ of ~~this~~ASU ~~guidance~~2023-09 resulted in additional financial statement disclosures and had no impact on the Company’s results of operations or financial condition. See Note ~~15,~~14. ~~Segments~~Income Taxes, ~~for~~which includes the disclosures resulting from the adoption of ASU 2023-0709.

Recently Issued Accounting Pronouncements

In ~~December~~November ~~2023~~2024, the FASB issued ASU No. ~~2023~~2024-0903, Income ~~Taxes~~Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (~~Topic~~Subtopic ~~720~~220-40): ~~Improvements~~Disaggregation toof Income ~~Tax~~Statement ~~Disclosures~~Expenses ("ASU ~~2023~~2024-0903"), which ~~prescribes~~is ~~standard~~intended ~~categories~~to ~~for~~improve disclosures about a public business entity’s expenses by requiring disaggregated disclosure, in the ~~components~~notes to the financial statements, of certain categories of expenses included in the ~~effective~~financial ~~tax~~statements. ~~rate~~As ~~reconciliation~~clarified ~~and~~by ~~requires~~ASU ~~disclosure~~2025-01, ofIncome ~~additional~~Statement ~~information~~- ~~for~~Reporting ~~reconciling~~Comprehensive ~~items~~Income ~~meeting~~- ~~certain~~Expense ~~quantitative~~Disaggregation ~~thresholds~~Disclosures (Subtopic 220-40): Clarifying the Effective Date, ~~requires~~ASU ~~disclosure~~2024-03 ofis ~~disaggregated~~effective ~~income~~for ~~taxes~~fiscal ~~paid~~years beginning after December 15, 2026, and ~~modifies~~interim ~~certain~~periods ~~other~~within ~~income~~fiscal ~~tax-related~~years ~~disclosures~~beginning after December 15, 2027. ASU ~~2023~~2024-0903 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU ~~2023~~2024-0903 on its consolidated financial statement disclosures.

73In November 2024, the FASB issued ASU No. 2024-04, Debt - Debt with Conversions and Other Options (Subtopic 470-20) ("ASU 2024-04"), which is intended to clarify requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. ASU 2024-04 is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual periods. ASU 2024-04 may be applied either on a prospective or retrospective basis, and early adoption is permitted. While the Company believes that ASU 2024-04 will not have a material impact on its consolidated financial statements or its disclosures, the Company has convertible notes (see Note 6. Debt, for further information) and has induced a conversion on those convertible notes in the past.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which is intended to improve disclosures about a public business entity’s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.71

InNOTE ~~November 2024, the FASB issued ASU No~~2. ~~2024-04,~~DIVESTITURES ~~Debt~~AND -STRATEGIC Debt with Conversions and Other Options (Subtopic 470-20) ("ASU 2024-04"), which is intended to clarify requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. ASU 2024-04 is effective for fiscal years beginning after December 15, 2025, and interim periods within those annual periods. ASU 2024-04 may be applied either on a prospective or retrospective basis, and early adoption is permitted. While the Company believes that ASU 2024-04 will not have a material impact on its consolidated financial statement disclosures, the Company has convertible notes (see Note 6, Debt, for further information) and has induced a conversion on those convertible notes in the past.TRANSACTIONS

~~NOTE~~Assertio 2.Therapeutics ~~ACQUISITIONS~~Divestiture

~~Spectrum~~On ~~Pharmaceuticals~~May 9, 2025, the Company transferred all the equity interests in Assertio Therapeutics to an established purchaser of legacy litigation matters, resulting in Assertio Therapeutics being owned by the purchaser’s related company, ATIH Industries, LLC (the “Therapeutics Transaction”). At the closing of the Therapeutics Transaction, Assertio Therapeutics held approximately $8.2 million in cash, insurance and retained a single-digit royalty based on net income derived from INDOCIN. In addition, Assertio Therapeutics retained certain legal liabilities, including those related to opioid litigation (see Note 8. Commitments and Contingencies for further information). As a result of the Therapeutics Transaction, neither the Company nor any of its current subsidiaries are defendants in any opioid-related litigation.

OnThe ~~July 31, 2023, (the “Effective Date”), the~~ Company ~~completed~~recognized ~~the~~a ~~acquisition~~net loss of ~~Spectrum Pharmaceuticals, Inc~~$8.2 ~~(“Spectrum”),~~million ~~a commercial stage biopharmaceutical company focused~~ on ~~novel~~the ~~and~~Therapeutics ~~targeted~~Transaction ~~oncology~~during ~~products (~~the ~~“Spectrum~~second ~~Merger”).~~quarter ~~The~~of ~~Spectrum~~2025, ~~Merger~~which ~~was~~is ~~completed~~shown ~~pursuant~~as toLoss anon ~~Agreement~~Assertio ~~and~~Therapeutics ~~Plan~~divestiture ofin ~~Merger (~~the ~~“Merger~~Company’s ~~Agreement”),~~Consolidated ~~dated~~Statements as of ~~April~~Comprehensive ~~24,~~Loss. ~~2023,~~The ~~through~~Therapeutics aTransaction ~~merger~~is ofreflected aas ~~wholly-owned~~cash ~~subsidiary~~used ofin ~~the~~investing ~~Company~~activities ~~with~~for ~~and into Spectrum, with Spectrum surviving~~ the ~~merger~~year asended aDecember ~~wholly-owned~~31, ~~subsidiary~~2025 ofin the Company.’s ~~The~~Consolidated ~~Company~~Statements ~~accounted for the Spectrum Merger using the acquisition method~~ of ~~accounting~~Cash ~~under ASC 805 and is considered the accounting acquirer~~Flows.

~~Pursuant~~Otrexup to the Merger Agreement, each issued and outstanding share of Spectrum common stock as of the Effective Date was converted into the right to receive (i) 0.1783 shares of the Company’s common stock and (ii) one CVR representing a contractual right to receive future conditional payments worth up to an aggregate maximum amount of $0.20, settleable in cash, additional shares of Assertio common stock or a combination of cash and additional shares of Assertio common stock at the Company’s sole discretion, upon the achievement of certain sales milestones related to Spectrum’s product ROLVEDON. Subject to adjustments, each CVR represents the right to receive up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and up to $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $225 million during the calendar year ending December 31, 2025. In addition, upon consummation of the Spectrum Merger, Spectrum’s outstanding employee stock awards and other warrants that were outstanding immediately prior to the Effective Date automatically vested (if unvested) or were cancelled, as applicable, which generally resulted in the issuance of shares of the Company’s common stock and/or CVRs to the holders of such stock awards or other warrants, in each case as dictated by the terms of the Merger Agreement. These shares and CVRs issued are considered part of the consideration transferred, and no compensation expense was recognized because the settlement was a condition of the Merger Agreement and other existing individual agreements, no future performance is required by the holders, and the fair value of the shares and CVRs is equivalent to the fair value of the existing employee stock awards and other warrants.Decommercialization

74As part of its ongoing commercial portfolio assessment, the Company ceased commercialization of Otrexup in July 2025. As a result of this decision, the Company incurred $4.2 million of expenses during the year ended December 31, 2025, of which $2.5 million was recognized in Cost of sales and $1.7 million was recognized in Selling, general and administrative expenses in the Company’s Consolidated Statements of Comprehensive Loss. These costs were primarily associated with the write-off of inventory (including inventory held at the Company’s contract manufacturers for Otrexup), the write-off of certain prepaid assets and the recognition of an accrual for a settlement in principle to settle any claims associated with the Company ceasing commercialization of Otrexup. (see Note 8. Commitments and Contingencies, for further details).

The following table reflects the components of the consideration transferred in the Spectrum Merger (in thousands, except per share data):

Assertio shares issued	38,013
Assertio closing price per share as of the Effective Date	$	5.69
Fair value of Assertio shares issued	$	216,294
Repayment of Spectrum's long-term debt(1)	32,647
CVRs (2)	3,932
Total fair value of consideration transferred	$	252,873

(1)Represents settlement of Spectrum’s existing long-term debt in connection with the close of the transaction. The Company concluded it did not assume the debt, therefore the amount paid to settle the debt has been accounted for and included as part of the consideration transferred.

(2)Represents the Effective Date fair value of 223,397 CVRs at $0.0176 per CVR issued to holders of Spectrum common stock, employee stock awards and warrants.

The CVRs represent a contingent consideration obligation measured at fair value and classified as a liability on the Company’s Consolidated Balance Sheets. The fair value of the CVR contingent consideration is determined using a Monte Carlo simulation model under the income approach and is based on Level 3 inputs. Refer to Note 13, Fair Value, for additional information. Fair value is based on the probability of achievement of 2024 and 2025 annual ROLVEDON net sales milestones. Significant assumptions include the discount rate and the probability assigned to the achievement of the net sales milestones. Achievement of both the 2024 and 2025 annual ROLVEDON net sales milestones would obligate the Company to transfer a maximum of approximately $44.7 million of additional consideration. No additional consideration would be paid by the Company if neither the 2024 nor 2025 annual ROLVEDON net sales milestones are achieved.

The following table reflects the fair values of the assets acquired and liabilities assumed at the Effective Date (in thousands). The fair values were based on management’s estimates and assumptions. Management’s determination of the fair values of the assets acquired and liabilities assumed was completed as of March 31, 2024.

	Initial Preliminary Purchase Price Allocation to Fair Value		Adjustments to Purchase Price Allocation to Fair Value (2)		Adjusted Preliminary Purchase Price Allocation to Fair Value
Assets:
Cash and cash equivalents	$	34,600	$	—	$	34,600
Marketable securities	2,194		—		2,194
Accounts receivable	50,975		—		50,975
Inventories	22,244		61		22,305
Prepaid and other current assets	1,287		698		1,985
Property and equipment	100		—		100
Intangible assets	234,000		(13,500)		220,500
Other long-term assets	1,396		—		1,396
Total	$	346,796	$	(12,741)	$	334,055
Liabilities:
Accounts payable	$	10,108	$	—	$	10,108
Accrued rebates, returns and discounts	21,025		—		21,025
Accrued liabilities	36,509		(2,343)		34,166
Other current liabilities	784		—		784
Deferred taxes	34,250		(30,254)		3,996
Other long-term liabilities	11,103		—		11,103
Total	$	113,779	$	(32,597)	$	81,182
Total Spectrum net assets acquired (1)	$	233,017	$	19,856	$	252,873
Goodwill	$	19,856	$	(19,856)	$	—

(1)Application of the acquisition method required the Company to adjust Spectrum assets and liabilities as of the Effective Date, including certain liabilities for variable consideration associated with ROLVEDON, to reflect conformity of Spectrum’s accounting policies to those of Assertio. Liabilities assumed include certain bonuses owed to former Spectrum executives under the terms of existing employment agreements triggered by the consummation of the Spectrum Merger.

(2)Adjustments made to the preliminary purchase price allocation to fair value primarily reflect completion of studies and other analyses necessary to determine the income tax effects of the net identifiable assets acquired and further refinement of the assumptions used in the valuation supporting the ROLVEDON product rights. These adjustments did not materially impact the Consolidated Statement of Comprehensive Loss in the period from July 31, 2023 through March 31, 2024.

The income approach was primarily used to value the acquired intangible assets, representing rights to Spectrum’s product ROLVEDON. Significant assumptions included the amount and timing of projected future cash flows; the discount rate selected to measure the inherent risk of future cash flows; and the assessment of the product’s life cycle and the competitive trends impacting the product. As of the Effective Date, the ROLVEDON product rights were to be amortized on a straight-line basis over its estimated useful life of 10 years.

There were no acquisition costs related to the Spectrum Merger recognized for the year ended December 31, 2024. Acquisition costs related to the Spectrum Merger were approximately $8.9 million for the year ended December 31, 2023.

The following unaudited pro forma information represents the Company’s results of operations as if the Spectrum Merger had been completed as of January 1, 2023 (in thousands) and includes nonrecurring adjustments for additional costs of sales from the fair value step-up of inventories and transaction costs. The disclosure of pro forma total revenues and net loss does not purport to indicate the results that would actually have been obtained had the Spectrum Merger been completed on the assumed date for the period presented, or which may be realized in the future. The unaudited pro forma information does not reflect any operating efficiencies or cost savings that may be realized from the integration of the acquisition.

	Year Ended
	December 31, 2023
Total revenues	$	192,513
Net loss	$	(380,272)

NOTE 3. REVENUE

Disaggregated Revenue

The following table reflects total revenues for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	Year ended December 31,
	2024		2023
	2025		2024
Product sales, net:
ROLVEDON	$	6068,~~090~~225	$	1860,~~175~~090
INDOCIN products	2618,~~761~~905		8726,~~217~~761
Sympazan	1011,~~457~~349		910,~~938~~457
Otrexup	8,842		12,026
SPRIX	7,952		7,624
SPRIX	7,624		9,150
Other products	10,669		15,917
CAMBIA	5,556		8,070
Total product sales, net	$	117,100	$	120,849
Other products	1,519		4,875
Royalty revenue	1,613		2,012
Total product sales, net	$	120,849	$	149,451
Other revenue	—		2,100
Royalties and milestone revenue	2,012		2,433
Total revenues	$	118,713	$	124,961
Other revenue	2,100		185
Total revenues	$	124,961	$	152,069

Product Sales, Net

AsProduct asales, ~~result~~net, consist of sales of the ~~Spectrum~~Company’s ~~Merger~~products as listed above. Other product sales, net, represent product sales for Otrexup, CAMBIA and Zipsor. During the ~~Company~~first ~~began~~quarter ~~recognizing~~of ~~ROLVEDON~~2025, the Company reclassified product sales from Otrexup and CAMBIA to the Other products line in ~~August~~the ~~2023~~table above. Prior period amounts were reclassified herein to conform with the current period presentation. As discussed in Note 2. Divestitures and Strategic Transactions, the Company ceased commercialization of Otrexup in July 2025.

~~Other~~In ~~product~~the ~~sales~~third quarter of 2025, ~~net~~the ~~for~~Company advanced key integration efforts to consolidate operations and align its products, including ROLVEDON, under a single subsidiary, Assertio Specialty. Sales of ROLVEDON in 2025 reflected normal demand through the ~~year~~first ~~ended~~nine ~~December~~months 31of 2025, ~~2023~~as ~~include~~well ~~product~~as ~~sales~~large ~~for~~purchases ~~OXAYDO~~by several national distributors to help ensure consistent supply of ROLVEDON during the fourth quarter of 2025 and ~~Zipsor.~~first Asquarter of 2026 as the Company ~~ceased~~completes ~~OXAYDO~~the ~~product~~integration ~~sales~~of ~~beginning~~ROLVEDON ininto ~~September~~Assertio ~~2023,~~Specialty. ~~other~~The Company did not record material net product sales, ~~net~~of ~~for~~ROLVEDON during the ~~year~~fourth ~~ended~~quarter ~~December~~of ~~31,~~2025 ~~2024~~and ~~represent~~does ~~only~~not anticipate material net product sales in the first quarter of ~~Zipsor~~2026. Sales of the newly labeled ROLVEDON are expected to commence at a normal volume in the second quarter of 2026.

~~Royalties~~To facilitate the large purchases of ROLVEDON by several national distributors in the third quarter of 2025, the Company provided its customers with higher-than-historical levels of discounts and ~~Milestone~~extended ~~Revenue~~payment terms. The related discounts and payment terms were accounted for in accordance with ASC 606 and met the accounting criteria for applying the practical expedient to not recognize a significant financing element.

InThe ~~November~~Company ~~2010~~reviews its estimates related to its accrued rebates, returns and discounts, including those recorded in prior periods, on a frequent basis and makes adjustments to those allowances as needed. Those adjustments to revenue for products sold in prior periods were approximately 7% and 3% of Total product sales, net, for the ~~Company~~years ~~entered~~ended ~~into~~December 31, 2025 and 2024, respectively. The adjustment to revenue for the year ended December 31, 2025 included the adjustment of a ~~license~~prior ~~agreement~~period ~~granting~~returns ~~Tribune~~reserve ~~Pharmaceuticals~~of ~~Canada~~$5.4 ~~Ltd~~million established in connection with the Spectrum Merger.

~~(later~~The ~~known~~following astable ~~Aralez~~reflects ~~Pharmaceuticals,~~Accrued ~~Miravo Healthcare~~rebates, returns and ~~now~~discounts Searchlight Pharma, or “Searchlight,” now owned by Apotex Inc.) the rights to commercially market CAMBIA in Canada. Searchlight independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalties revenue related to the CAMBIA licensing agreement $2.0 million for ~~each of~~ the years ended December 31, 2025, 2024 and 2023. (in thousands):

Under the license agreement, the Company’s royalties on net sales are reduced upon the launch of a generic version of CAMBIA in Canada. On February 22, 2024, Searchlight commenced a patent infringement action in Canadian federal court against a generic company seeking approval of a generic version of CAMBIA in Canada. On June 9, 2024, Searchlight


	December 31,
	2025		2024		2023

Accrued rebates, returns and discounts	$	99,366	$	76,304	$	58,137

77Royalty Revenue

~~commenced~~In November 2010, the Company entered into a ~~second~~license ~~patent~~agreement ~~infringement~~granting ~~action~~Tribune inPharmaceuticals ~~Canadian~~Canada ~~federal~~Ltd. ~~court~~(later ~~against~~known aas ~~second~~Aralez ~~generic~~Pharmaceuticals, ~~company~~Miravo ~~seeking~~Healthcare, ~~approval~~and ofSearchlight aPharma, ~~generic~~or ~~version~~“Searchlight,” ofowned by Apotex Inc.) the rights to commercially market CAMBIA in Canada. ~~The~~Searchlight ~~Company’s~~independently ~~royalties~~contracts ~~from~~with ~~Searchlight’s~~manufacturers ~~net~~to ~~sales~~produce ofa specific CAMBIA formulation in Canada. ~~will~~The beCompany ~~reduced~~recognized ifroyalties ~~Searchlight’s~~revenue ~~patent~~related ~~infringement~~to ~~litigations~~the ~~fail~~CAMBIA tolicensing ~~keep~~agreement ~~the~~licensing ~~generic~~agreement ~~from~~of ~~launching~~$1.6 ~~before~~million and $2.0 million for the ~~relevant~~years ended December 31, 2025 and 2024, respectively. The patents underlying the license agreement that the Company has with Searchlight expire in June 2026.

The Company recognized no Milestone revenue associated with the completion of certain service milestones for the year ended December 31, 2024 and $0.4 million for the year ended December 31, 2023.

Other Revenue

Other revenue consists of adjustments to reserves for product sales allowances (gross-to-net sales allowances) for previously divested products and can result in a reduction to, or an increase to, total revenues during the period. There was no other revenue recognized for the year ended December 31, 2025. Sales adjustments for reserves recorded in prior periods for previously divested products increased total revenue by $2.1 million ~~and $0.2 million~~ for the ~~years~~year ended December 31, 2024 ~~and December 31, 2023, respectively~~.

Additionally, adjustments to revenue recognized as a result of changes in estimates for the Company’s gross-to-net sales allowances for products sold in previous periods were approximately 3% and 3% of Total product sales, net, for the years ended December 31, 2024 and 2023, respectively. 73

NOTE 4. SUPPLEMENTAL BALANCE SHEET DETAILS

Accounts Receivable, Net

AsThe offollowing ~~December~~table ~~31,~~reflects ~~2024~~Accounts ~~and 2023, accounts~~ receivable, net, ~~consisted~~for ~~entirely~~the ofyears ~~receivables~~ended ~~related~~December to31, ~~product sales~~2025, ~~net~~2024 ~~of allowances for cash discounts for prompt payment of $1.2 million~~ and ~~$0.9~~2023 ~~million,~~(in ~~respectively.~~ thousands):


	December 31,
	2025		2024		2023
Accounts receivable, net	$	120,110	$	54,120	$	47,663

The increase in Accounts receivable, net from December 31, 2024 to December 31, 2025 primarily relates to large purchases of ROLVEDON by several national distributors in the third quarter of 2025, whereby the Company provided its customers with extended payment terms (see Note 3. Revenue, for further information).

As of December 31, 2025 and 2024, accounts receivable, net, consisted entirely of receivables related to product sales, net of allowances for cash discounts for prompt payment, of $3.0 million and $1.2 million, respectively.

Inventories, Net

The following table reflects the components of inventories, net, as of December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	December 31,
	2024		2023
	2025		2024
Raw materials	$	15,~~524~~173	$	1015,~~537~~524
Work-in-process	46,~~900~~051		24,~~239~~900
Finished goods	172,~~884~~896		2417,~~910~~884
Total inventories, net	$	3824,~~308~~120	$	3738,~~686~~308

The ~~Company~~decrease ~~writes~~in ~~down~~finished ~~the~~goods ~~value~~from ofDecember ~~inventory~~31, ~~for~~2024 ~~potential~~to ~~excess~~December or31, ~~obsolete~~2025 ~~inventories~~primarily ~~based~~relates onto anthe ~~analysis~~large purchases of ~~inventory~~ROLVEDON onby ~~hand~~several ~~and~~national ~~projected~~distributors ~~demand.~~in Asthe third quarter of ~~December~~2025 ~~31,~~(see ~~2024~~Note 3. Revenue for further information) and ~~2023,~~the write-off of Otrexup inventory ~~reserves~~in ~~were~~the $8second quarter of 2025 due to ceasing commercialization of Otrexup (see Note 2.7 ~~million~~Divestitures and ~~$6.8~~Strategic ~~million,~~Transactions ~~respectively~~for further information).

The Company writes down the value of inventory for potential excess, obsolete or defective inventories based on an analysis of inventory on hand and projected demand. As of December 31, 2025 and 2024, inventory reserves were $9.2 million and $8.7 million, respectively.

Prepaid and Other Current Assets

The following table reflects prepaid and other current assets as of December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	December 31,
	2024		2023
	2025		2024
Prepaid assets and deposits	$	98,~~764~~667	$	119,~~973~~764
Other current assets	~~303~~344		~~299~~303
Total prepaid and other current assets	$	109,~~067~~011	$	1210,~~272~~067

Other current assets includes the Company’s investment in NES Therapeutic, Inc. (“NES”). In August 2018, the Company entered into a Convertible Secured Note Purchase Agreement (the “Note Agreement”) with NES. Pursuant the terms of the Note Agreement, the Company purchased, for total consideration of $3.0 million, a Convertible Secured Promissory Note of $3.0 million in aggregate principal (the “NES Note”) which accrues interest annually at a rate of 10%. Both the aggregate 74

principal and accrued interest were due at maturity on August 2, 2024, which was subsequently amended to mature on May 16, 2025. Pursuant to the Note Agreement, the NES Note is convertible into equity based on (i) U.S. Food and Drug Administration (“FDA”) acceptance of its New Drug Application (“NDA”), (ii) initiation of any required clinical trials by NES, or (iii) a qualified financing event by NES, as defined in the Note Agreement. This investment is accounted as a loan receivable and is valued at amortized cost. As of both December 31, 2024 and 2023, the Company has assessed an estimated $3.5 million expected credit loss on its investment, representing the entire aggregate principal amount and outstanding interest on the NES Note, based on its evaluation of probability of default that exists.

Property and Equipment, Net

The following table reflects property and equipment, net as of December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	December 31,
	2024		2023
	2025		2024
Furniture and office equipment	$	1,412	$	1,~~908~~412
Laboratory equipment	20		20
Leasehold improvements	2,551		2,~~945~~551
Construction in progress	—		528
	3,983		3,983
	3,983		5,401
Less: Accumulated depreciation	(3,539)		(3,397)
Less: Accumulated depreciation	(3,397)		(4,631)
Property and equipment, net	$	444	$	586
Property and equipment, net	$	586	$	770

Depreciation expense was $0.21 million and $0.72 million for the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. Depreciation expense is recognized in Selling, general and administrative expenses in the Company’s Consolidated Statements of Comprehensive Loss.

Other Long-Term Assets

The following table reflects other long-term assets as of December 31, 2024 and 2023 (in thousands):

	December 31,
	2024		2023
Operating lease right-of-use assets	$	1,125	$	1,269
Prepaid asset and deposits	1		1,289
Other	—		697
Total other long-term assets	$	1,126	$	3,255

Accrued Liabilities

The following table reflects accrued liabilities as of December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	December 31,
	2024		2023
	2025		2024
Accrued compensation	$	32,~~260~~721	$	23,~~438~~260
Accrued restructuring (See Note 16)	12,~~187~~400		41,~~378~~187
Other accrued liabilities	12,310		9,492
Interest payable	867		867
Accrued royalties	~~1,223~~594		1,~~038~~223
Total accrued liabilities	$	18,847	$	18,213
Other accrued liabilities	7,700		12,310
Total accrued liabilities	$	14,282	$	18,847

Other Long-Term Liabilities

The following table reflects other long-term liabilities as of December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	December 31,
	2024		2023
	2025		2024
ROLVEDON product royalties	$	53,~~479~~074	$	95,~~224~~479
Noncurrent operating lease liabilities	~~1,122~~889		1,~~470~~122
Liability for uncertain tax provisions	2,~~337~~418		42,~~553~~337
Deferred employee retention credits	~~1,212~~—		1,212
Total other long-term liabilities	$	106,~~150~~381	$	1610,~~459~~150

In the second quarter of 2025, the statute of limitations for the deferred employee retention credits lapsed. The Company recognized $2.4 million of income in Selling, general, and administrative expenses in the Company’s Consolidated Statements of Comprehensive Loss for the year ended December 31, 2025, comprised of the $1.2 million noted in the table above and an additional $1.2 million of employee retention tax credits received during the second quarter of 2025 associated with claims filed by Spectrum prior to the Spectrum Merger.

NOTE 5. INTANGIBLE ASSETS

Intangible Assets

The following table reflects the gross carrying amounts and net book values of intangible assets as of December 31, ~~2024~~2025 and ~~2023~~2024 (dollar amounts in thousands):

	December 31, 2024									December 31, 2023
	December 31, 2025									December 31, 2024
Product rights	RemainingUseful Life(In years)	GrossCarryingAmount		AccumulatedAmortization		Impairment		Net BookValue		GrossCarryingAmount		AccumulatedAmortization		Impairment		Net BookValue
ROLVEDON	32.0	$	63,405	$	(1128,~~336~~692)	$	—	$	5234,~~069~~713	$	~~220~~63,~~500~~405	$	(511,~~270~~336)	$	~~(157,095)~~—	$	5852,~~135~~069
INDOCIN	0.5	65,605		(58,328)		—		7,277		154,100		(44,814)		(88,494)		20,792
Sympazan	8.8	14,550		(3,840)		—		10,710		14,550		(2,627)		—		11,923
Sympazan	9.8	14,550		(2,627)		—		11,923		14,550		(1,415)		—		13,135
SPRIX	0.7	32,673		(27,488)		(1,700)		3,485		32,673		(23,471)		—		9,202
Otrexup	0.0	16,364		(11,147)		(5,217)		—		44,086		(10,103)		(27,723)		6,260
INDOCIN	0.0	65,605		(65,605)		—		—		65,605		(58,328)		—		7,277
SPRIX	2.4	32,673		(23,471)		—		9,202		39,000		(19,663)		(6,327)		13,010
Otrexup	0.0	—		—		—		—		16,364		(11,147)		(5,217)		—
Total Intangible Assets		$	~~192~~176,~~597~~233	$	(~~106~~125,~~909~~625)	$	(51,~~217~~700)	$	8048,~~471~~908	$	~~472~~192,~~236~~597	$	(81106,~~265~~909)	$	(~~279~~5,~~639~~217)	$	~~111~~80,~~332~~471

Amortization expense was $2529.69 million and $2725.56 million for the years ended December 31, ~~2024~~2025 and ~~2023~~2024, respectively. Effective December 31, 2024, the Company revised the remaining estimated useful life of the ROLVEDON product rights intangible asset to three years. In addition, effective October 1, 2025, the Company revised the remaining estimated useful life of the SPRIX product rights intangible assets to one year.

Effective April 1, 2024, the Company revised the remaining estimated useful life of the INDOCIN product rights intangible asset to 1.3 years, which the Company believes better reflects the realization of the economic benefit of the intangible asset. The impact of this change in estimate is reflected in the Company’s expected future amortization expense disclosed below.

Effective December 31, 2024, the Company revised the remaining estimated useful life of the ROLVEDON product rights intangible asset to three years, which the Company believes better reflects the realization of the economic benefit of the intangible asset. The impact of this change in estimate is reflected in the Company’s expected future amortization expense disclosed below.

The following table reflects future amortization expense the Company expects for its intangible assets (in thousands):

Year Ending December 31,	EstimatedAmortizationExpense
2025	$	29,653
2026	$	22,054
2026	22,377
2027	18,569
2027	20,155
2028	1,213
2029	1,213
Thereafter	5,860
2030	1,213
Total	$	80,471
Thereafter	4,646
Total	$	48,908

During each quarter of ~~the~~2025 ~~three months ended December 31, 2024, September 30, 2024, June 30, 2024~~ and ~~March 31,~~ 2024, the Company’s ~~determined~~market ~~that~~capitalization was below the book value of the Company’s equity ~~exceeded its market capitalization~~, which management determined represented an indicator of impairment with respect to its long-lived assets. For the three months ended September 30, 2025, the Company also recognized an additional indicator of impairment with respect to its SPRIX asset group related to a change in the expected timing of cash flows from SPRIX net product sales. Applying the relevant accounting guidance, the Company first assessed the recoverability of its long-lived assets at the product level at each date. After grouping the long-lived assets at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows of other assets and liabilities, the Company estimated the future net undiscounted cash flows expected to be generated from the use of the long-lived asset groups and their eventual disposition at each impairment testing date. The Company then compared the estimated undiscounted cash flows to the carrying amounts of the long-lived asset groups at each date.

For the assessment performed for the three months ended ~~December~~September 3130, ~~2024~~2025, the Company determined that the undiscounted cash flows and the fair value of the ~~Otrexup~~SPRIX asset group ~~was~~were less than its carrying value and recognized an impairment ~~loss~~ for this asset group of ~~approximately~~ $51.27 million, ~~reducing~~during ~~its carrying value to zero. This impairment charge is classified within Loss on impairment of intangible assets in~~ the ~~Consolidated~~third ~~Statements~~quarter of ~~Comprehensive Loss. The fair values of the Otrexup asset group was determined using an income approach and used Level 3 inputs~~2025, ~~which~~reducing ~~included~~its ~~estimates of forecasted cash flows for each product. For all of the Company’s other asset groups, the estimated undiscounted cash flows exceeded their~~ carrying ~~amounts,~~value ~~and~~to ~~the Company concluded that the other asset groups were fully recoverable~~$4.6 ~~Accordingly, no adjustment to the carrying values of these other asset groups was required~~million.

For the ~~assessments~~assessment performed for ~~each of~~ the three months ended ~~September~~December ~~30, 2024, June 30, 2024 and March~~ 31, 2024, the Company determined that the estimated undiscounted cash flows ~~were~~and infair ~~excess~~value of the ~~carrying~~Otrexup ~~amounts~~asset ~~for~~group ~~all~~were ofless ~~the~~than ~~Company’s~~its ~~long-lived~~carrying ~~asset~~value ~~groups~~and atrecognized ~~each~~an impairment ~~testing~~for ~~date.~~this ~~Accordingly,~~asset ~~the~~group ~~Company~~of ~~concluded~~$5.2 ~~that~~million during the ~~long-lived~~fourth ~~asset~~quarter ~~groups~~of ~~were~~2024, ~~fully~~reducing ~~recoverable~~its ~~and~~carrying novalue ~~adjustment~~ to ~~their carrying values was required~~zero.

During each of the three months ended December 31, 2023 and September 30, 2023, the Company performed an assessment of the recoverability and impairment of its long-lived assets as a result of the book value of the Company’s equity exceeding its market capitalization, which management determined represented an indicator of impairment. Similar to each of the assessments performed in each quarter of 2024, for the three months ended December 31, 2023 management assessed the recoverability of its long-lived assets at the product level. For the three months ended September 30, 2023, management assessed the recoverability of its long-lived assets at the entity level. The change in the identification of asset groups was due to strategic changes to the Company’s operating cost structure through the reduction of shared costs that had occurred by the fourth quarter of 2023. In each case, management determined that the fair value of the identified asset group(s) was not fully recoverable and was less than each of their carrying values and recognized an impairment loss for the asset group(s). For the three months ended December 31, 2023, the Company recognized an impairment loss for the INDOCIN and Otrexup product asset groups of approximately $36.0 million and $4.8 million, respectively. For the three months ended September 30, 2023, management concluded that the fair value of the entity level asset group was less than its carrying value and recognized an impairment loss of approximately $238.8 million, which was allocated to the intangible assets of the group.76

81Both the SPRIX and Otrexup impairment charges were classified within Impairment of intangible assets in the Company’s Consolidated Statements of Comprehensive Loss. The fair values of the SPRIX asset group as of September 30, 2025, and the Otrexup asset group as of December 31, 2024, were determined using an income approach and Level 3 inputs, which included estimates of forecasted cash flows.

For all the assessments for the Company’s other asset groups performed during each quarter in 2025 and 2024, the Company determined that the estimated undiscounted cash flows were in excess of the carrying amounts for all its long-lived asset groups at each impairment testing date. Accordingly, the Company concluded that the long-lived asset groups were fully recoverable and no adjustment to their carrying values was required.

NOTE 6. DEBT

As of December 31, ~~2024~~2025 and ~~2023~~2024, long-term debt, net, consisted entirely of the carrying value of the Company’s 6.5% Convertible Senior Notes due 2027 (the “2027 Convertible Notes”) of $3839.81 million and $38.58 million, respectively.

6.5% Convertible Senior Notes due 2027

On August 22, 2022, Assertio entered into a purchase agreement (the “Purchase Agreement”), with U.S. Bank Trust Company as the trustee of the initial purchasers (the “Initial Purchasers”) to issue $60.0 million in aggregate principal amount of the 2027 Convertible Notes. Under the Purchase Agreement, the Initial Purchasers were also granted an overallotment option to purchase up to an additional $10.0 million aggregate principal amount of the 2027 Convertible Notes solely to cover overallotment (the “Overallotment Option”) within a 13-day period from the date the initial 2027 Convertible Notes were issued. On August 24, 2022, the Initial Purchasers exercised the Overallotment Option in full for the $10.0 million aggregate principal amount of additional 2027 Convertible Notes. The 2027 Convertible Notes are senior unsecured obligations of the Company.

On February 27, 2023, the Company completed a privately negotiated exchange of $30.0 million principal amount of the 2027 Convertible Notes ~~(the “Convertible Note Exchange”)~~. As a result of the Convertible Note Exchange in the first quarter of 2023, the Company recorded an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million, the total of which is reported in Debt-related expenses in the Company’s Consolidated Statements of Comprehensive Loss for the year ended December 31, 2023. The induced conversion expense represents the fair value of the consideration transferred in the Convertible Note Exchange in excess of the fair value of common stock issuable under the original terms of the 2027 Convertible Notes.

The terms of the 2027 Convertible Notes are governed by an indenture dated August 25, 2022 (the “2027 Convertible Note Indenture”). The terms of the 2027 Convertible Notes allow for conversion into the Company’s common stock, cash, or a combination of cash and common stock, at the Company’s election only, at an initial conversion rate of ~~244~~16.~~2003~~28002 shares of the Company’s common stock per $1,000 principal amount (equal to an initial conversion price of approximately $461.0942 per share), subject to adjustments specified in the 2027 Convertible Note Indenture. The 2027 Convertible Notes will mature on September 1, 2027, unless earlier repurchased or converted. ~~Starting~~The ~~on September 8, 2025, the~~ Company may ~~also~~ redeem the 2027 Convertible Notes for cash equal to the principal amount, plus accrued and unpaid interest, if the closing price of the Company’s common stock has been at least 130% of the conversion price noted above then in effect for at least 20 trading days during any 30 consecutive trading day period.

Pursuant to the terms of the 2027 Convertible Note Indenture, the Company and its restricted subsidiaries must comply with certain covenants, including mergers, consolidations, and divestitures; guarantees of debt by subsidiaries; issuance of preferred and/or disqualified stock; and liens on the Company’s properties or assets. The Company was in compliance with its covenants with respect to the 2027 Convertible Notes as of December 31, ~~2024~~2025.

The 2027 Convertible Notes bear interest at a rate of 6.5% per annum payable semiannually in arrears on March 1 and September 1 of each year.

The following table reflects the carrying balance of the 2027 Convertible Notes as of December 31, ~~2024~~2025 and ~~2022~~2024 (in thousands):

	December 31,
	2024		2023
	2025		2024
Principal balance	$	40,000	$	40,000
Derivative liability for embedded conversion feature	~~168~~4		~~308~~168
Unamortized debt issuance costs	(~~1,355~~880)		(1,~~794~~355)
Carrying balance	$	3839,~~813~~124	$	38,~~514~~813

The debt issuance costs incurred related to the 2027 Convertible Notes are recognized as a debt discount and are being amortized as interest expense over the term of the 2027 Convertible Notes using the effective interest method with an effective interest rate determined to be 7.8%. During each of the years ended December 31, 2024 and 2023, the Company amortized $0.4 million of the debt discount on the 2027 Convertible Notes. 77

82The debt issuance costs incurred related to the 2027 Convertible Notes are recognized as a debt discount and are being amortized as interest expense over the term of the 2027 Convertible Notes using the effective interest method with an effective interest rate determined to be 7.8%. During the years ended December 31, 2025 and 2024, the Company amortized $0.5 million and $0.4 million of the debt discount on the 2027 Convertible Notes, respectively.

The Company determined that an embedded conversion feature included in the 2027 Convertible Notes required bifurcation from the host contract and torecognition ~~be recognized~~ as a separate derivative liability carried at fair value. See Note 13,. Fair Value, for further ~~details~~discussion ~~around~~of the estimated fair value of the derivative liability. All of the other embedded features of the 2027 Convertible Notes were clearly and closely related to the debt host and did not require bifurcation as a derivative liability, or the fair value of the bifurcated features was immaterial to the Company’s consolidated financial statements.

Interest Expense

The following table reflects debt-related interest included in Interest expense in the Company’s Consolidated Statements of Comprehensive Loss as of December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

	Year ended December 31,
	2024		2023
	2025		2024
Interest on 2027 Convertible Notes	$	2,600	$	2,~~925~~600
Amortization of debt issuance costs	439		455
Amortization of debt issuance costs on 2027 Convertible Notes	475		439
Total interest expense	$	3,~~039~~075	$	3,~~380~~039

NOTE 7. LEASES

The Company has a non-cancelable operating lease through December 31, 2030 for its corporate office, which is located in Lake Forest, Illinois. ~~(the~~Additionally, ~~“Lake~~in ~~Forest~~connection ~~Lease”).~~with Onthe ~~May~~Spectrum 1Merger, ~~2023,~~ the Company ~~amended~~assumed ~~the~~leases ~~Lake~~for ~~Forest~~two ~~Lease~~facilities to(whose ~~reduce~~terms ~~the~~ended ~~size~~in ~~of leased premises and extend~~ the ~~term~~third quarter of ~~the~~2025) ~~lease~~and ~~through~~certain ~~December~~office ~~31,~~equipment ~~2030.~~(which ~~Additionally,~~term ends in ~~connection with~~ the ~~Spectrum~~third ~~Merger,~~quarter ~~the~~of ~~Company~~2026) ~~assumed leases~~ for ~~two facilities and certain office equipment~~ which Spectrum had previously been the lessee ~~(See Note 16, Restructuring Charges)~~.

The following table reflects lease expense ~~and sublease income~~ for the years ended December 31, ~~2024~~2025 and ~~2023~~2024 (in thousands):

Year ended December 31,

Financial Statement Classification

~~2024~~2025

~~2023~~2024

Operating lease cost

Selling, general and administrative expenses

~~256~~241

~~229~~256

The following table reflects supplemental cash flow information related to leases for the years ended December 31, 2025 and 2024 (in thousands):

	Year ended December 31,
	2024		2023
	2025		2024
Cash paid for amounts included in measurement of liabilities:
Operating cash flows used in operating leases	$	~~1,058~~412	$	~~717~~1,058

~~The following table reflects supplemental balance sheet information related to leases as of December 31, 2024 and 2023 (in thousands):~~78

		December 31,
	Financial Statement Classification	2024		2023
Assets
Operating lease right-of-use assets	Other long-term assets	$	1,125	$	1,269
Liabilities
Current operating lease liabilities	Other current liabilities	$	331	$	928
Noncurrent operating lease liabilities	Other long-term liabilities	1,122		1,470
Total lease liabilities		$	1,453	$	2,398

The following table reflects supplemental balance sheet information related to leases as of December 31, 2025 and 2024 (in thousands):


		December 31,
	Financial Statement Classification	2025		2024
Assets
Operating lease right-of-use assets	Other long-term assets	$	971	$	1,125
Liabilities
Current operating lease liabilities	Other current liabilities	$	240	$	331
Noncurrent operating lease liabilities	Other long-term liabilities	889		1,122
Total lease liabilities		$	1,129	$	1,453

The following table reflects other operating lease information as of December 31, ~~2024~~2025 and ~~2023~~2024:

	December 31,
	2024		2023
	2025		2024
Weighted-average remaining lease term (years):	5.2		4.6
Weighted-average remaining lease term (years)	4.7		5.2
Weighted-average discount rate:	6.8	%	5.7	%
Weighted-average discount rate	7.2	%	6.8	%

The following table reflects future minimum lease payments under the Company’s non-cancelable operating leases as of December 31, ~~2024~~2025 (in thousands):

	Lease Payments
2025	$	412
2026	$	307
2026	307
2027	243
2028	253
2029	263
Thereafter	274
2030	274
Total lease payments	$	1,~~752~~340
Less: Interest	~~299~~211
Present value of lease liabilities	$	1,~~453~~129

NOTE 8. COMMITMENTS AND CONTINGENCIES

COMMITMENTS

Jubilant HollisterStier Manufacturing and Supply Agreement

In connection with the Zyla Merger, the Company assumed a Manufacturing and Supply Agreement (the “Jubilant HollisterStier Agreement”) with Jubilant HollisterStier LLC (“JHS”) pursuant to which the Company engaged JHS to provide certain services related to the manufacture and supply of SPRIX for the Company’s commercial use. ~~Under~~In ~~the~~February ~~Jubilant HollisterStier Agreement~~2025, ~~JHS is responsible for supplying a minimum of 75% of~~ the Company’s ~~annual~~amended ~~requirements~~the ofJubilant ~~SPRIX.~~HollisterStier ~~The~~Agreement ~~Company agreed~~ to ~~purchase~~reduce athe minimum number of batches of SPRIX ~~per~~required to be purchased for calendar ~~year~~years ~~from~~2024 ~~JHS~~and ~~over~~2025. ~~the~~The ~~term~~Company ofmet ~~the~~its ~~Jubilant~~purchase ~~HollisterStier~~commitment ~~Agreement.~~from JHS for 2025.

InOn ~~February~~January ~~2025~~2, 2026, the Company ~~amended~~entered into an amendment (the “JHS Amendment”) of the Jubilant HollisterStier Agreement. toThe ~~reduce~~JHS Amendment sets the minimum number of batches of SPRIX required to be purchased for the two year period ending December 31, 2027 and is consistent with the minimum number of batches for the two year period ended December 31, 2025. ~~Commitments~~Total commitments to JHS for ~~the~~2026 ~~2024~~ and ~~2025~~2027 ~~calendar~~as ~~years~~a result of the JHS Amendment are approximately $12.50 million ~~in total~~.

Antares Supply Agreement

In connection with the Otrexup acquisition, the Company entered into a supply agreement with Antares ~~Pharma, Inc. (“Antares”)~~ pursuant to which Antares will manufacture and supply the finished Otrexup products (the “Antares Supply Agreement”). Under the Antares Supply Agreement, the Company has agreed to annual minimum purchase obligations from Antares, which are approximately $2.01 million annually. The Antares Supply Agreement has an initial term through December 2031 and can be renewed thereafter.

As discussed in Note 2. Divestitures and Strategic Transactions, the Company ceased commercialization of Otrexup in July 2025. Pursuant to the Antares Supply Agreement’s termination provisions, amounts due upon termination are only payable if the Antares Supply Agreement is formally terminated by written notice. In December 2025, the Company and Antares reached a settlement in principle to settle any claims associated with the Company ceasing commercialization of Otrexup. The settlement in principle requires the Company to pay $1.2 million as of December 31, 2025, and would result in the termination of the Antares Supply Agreement. Accordingly, an accrual of $1.2 million was accrued in accordance with ASC 450-20-25, Loss Contingencies (“ASC 450-20”) as of December 31, 2025.

Hanmi Supply Agreement

In connection with the Spectrum Merger, the Company assumed a Manufacturing and Supply Agreement (the “Hanmi Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) pursuant to which the Company engaged Hanmi to provide certain services related to the manufacture and supply of ROLVEDON for the Company’s commercial use. The Company ~~has~~ agreed to purchase a minimum number of batches totaling approximately $19.1 million in 2024 and $3.8 million in 2025. The Company ~~purchased~~met ~~$21.1~~its ~~million~~purchase ofcommitment ~~inventory~~ from Hanmi ~~during~~for ~~the year ended December 31, 2024~~2025.

84On October 7, 2025, the Company, through its wholly owned subsidiary Spectrum, entered into an amendment and restatement of the Hanmi Agreement (the “Amendment”). Subsequently, on December 18, 2025, Spectrum assigned the Amendment to Assertio Specialty as part of the Company’s efforts to consolidate operations and align its products, including ROLVEDON, under a single subsidiary. The Amendment fixes the price that the Company pays for the remaining term of its license agreement with Hanmi and amends the payment timing for certain product royalties due to Hanmi, which were fully accrued and resulted in an immaterial reclassification between Other current liabilities and Other long-term liabilities in the Company’s Consolidated Balance Sheet during the third quarter of 2025. While the Company will not have any minimum purchase requirements for ROLVEDON under the Amendment, if it includes any orders in any annual forecasted purchase plan provided to Hanmi under the Amendment, it must designate at least 50 percent of such orders as binding.

CONTINGENCIES

General

The Company is currently involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business. The Company continues to monitor each matter and adjust accruals as warranted based on new information and further developments in accordance with ASC 450-20~~-25~~.

Other than the matters disclosed below, the Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of its business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims and other matters. ~~The Company may also become party to further litigation in federal and state courts relating to opioid drugs.~~ Although actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, other than the matters set forth below, the Company is not currently involved in any matters that the Company believes may have a material adverse effect on its business, results of operations, cash flows or financial condition. However, regardless of the outcome, litigation can have an adverse impact on the Company because of associated cost and diversion of management time.

Glumetza Antitrust Litigation

Direct purchaser antitrust class actions were filed in the U.S. District Court for the Northern District of California against the Company and several other defendants relating to the Company’s former drug Glumetza®. On February 3, 2022, the U.S District Court for the Northern District of California issued its final order approving a settlement of the direct purchaser class plaintiffs’ claims against the Company in return for $3.85 million.

Humana Inc. (“Humana”) was initially a plaintiff in the direct purchaser class action in the U.S. District Court for the Northern District of California, but withdrew its claims and filed claims under state law against the Company and the same defendants in the Superior Court of the State of California for the County of Alameda (“California Superior Court of Alameda”) in February 2021. Health Care Service Corporation (“HCSC”) filed a similar complaint in the California Superior Court of Alameda in April 2022.

These antitrust cases arise out of a Settlement and License Agreement (the “Settlement”) that the Company, Santarus, Inc. (“Santarus”) and Lupin Limited (“Lupin”) entered into in February 2012 to resolve patent infringement litigation filed by the Company against Lupin regarding Lupin’s Abbreviated New Drug Application for generic 500 mg and 1000 mg tablets of Glumetza. The antitrust plaintiffs alleged, among other things, that the Settlement violated the antitrust laws because it included a “reverse payment” in the form of an alleged agreement not to launch an authorized generic version of Glumetza for a certain period that caused Lupin to delay market entry of its generic version of Glumetza. The antitrust plaintiffs allege that the defendants, which include Lupin as well as Bausch Health (the alleged successor in interest to Santarus), are liable for damages under the antitrust laws for overcharges that the antitrust plaintiffs allege they paid when they purchased the branded version of Glumetza due to delayed generic entry. Plaintiffs seek treble damages for alleged past harm, attorneys’ fees and costs.

During the third quarter of 2024, the Company reached an agreement in principle to settle the claims asserted by Humana and HCSC in the California state court lawsuits, the terms of which are confidential. A liability has been recorded for the agreement in principle, which will not have a material impact to the Company’s Consolidated Financial Statements. The trial in these lawsuits has been removed from the court’s calendar pending finalization of the definitive settlement agreement.

Opioid-Related Request and Subpoenas

As a result of the greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers generally by federal, state, and local regulatory and governmental agencies. In March 2017, Assertio Therapeutics received a letter from then-Sen. Claire McCaskill (D-MO), the then-Ranking Member on the U.S. Senate Committee on Homeland Security and Governmental Affairs, requesting certain information regarding Assertio Therapeutics’ historical commercialization of opioid products. Assertio Therapeutics voluntarily furnished information responsive to Sen. McCaskill’s request. Since 2017, Assertio Therapeutics has received and responded to subpoenas from the U.S. Department of Justice (“DOJ”) seeking documents and information regarding its historical sales and marketing of opioid products. Assertio Therapeutics has also received and responded to subpoenas or civil investigative demands focused on its historical promotion and sales of Lazanda, NUCYNTA, and NUCYNTA ER from various state attorneys general seeking documents and information regarding Assertio Therapeutics’ historical sales and marketing of opioid products. In addition, Assertio Therapeutics received and responded to a subpoena from the State of California Department of Insurance (“CDI”) seeking information relating to its historical sales and marketing of Lazanda. The CDI subpoena also sought

information on Gralise, a non-opioid product formerly in Assertio Therapeutics’ portfolio. In addition, Assertio Therapeutics received and responded to a subpoena from the New York Department of Financial Services seeking information relating to its historical sales and marketing of opioid products. The Company has also received a subpoena from the New York Attorney General in May 2023, pursuant to which the New York Attorney General is seeking information concerning the sales and marketing of opioid products (Lazanda, NUCYNTA, NUCYNTA ER, and OXAYDO) by Assertio Therapeutics and Zyla. The Company also from time to time receives and responds to subpoenas from governmental authorities related to investigations primarily focused on third parties, including healthcare practitioners. The Company is cooperating with the foregoing governmental investigations and inquiries.

In July 2022, the Company became aware that DOJ issued a press release stating that it had settled claims against a physician whom DOJ alleged had received payments for paid speaking and consulting work from two pharmaceutical companies, including Depomed, Inc. (“Depomed,” now known as Assertio Therapeutics), in exchange for prescribing certain of the companies’ respective products. As part of the settlement, the physician did not admit liability for such claims and the press release stated that there has been no determination of any liability for such claims. The Company denies any wrongdoing and disputes DOJ’s characterization of the payments from Depomed.

Multidistrict and Other Federal Opioid Litigation

A number of pharmaceutical manufacturers, distributors and other industry participants have been named in numerous lawsuits around the country brought by various groups of plaintiffs, including city and county governments, hospitals, individuals and others. In general, the lawsuits assert claims arising from defendants’ manufacturing, distributing, marketing and promoting of FDA-approved opioid drugs. The specific legal theories asserted vary from case to case, but the lawsuits generally include federal and/or state statutory claims, as well as claims arising under state common law. Plaintiffs seek various forms of damages, injunctive and other relief and attorneys’ fees and costs.

For such cases filed in or removed to federal court, the Judicial Panel on Multi-District Litigation issued an order in December 2017, establishing a Multi-District Litigation court (“MDL Court”) in the Northern District of Ohio (In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804). Since that time, more than 2,000 such cases that were originally filed in U.S. District Courts, or removed to federal court from state court, have been filed in or transferred to the MDL Court. Assertio Therapeutics is currently involved in a subset of the lawsuits that have been filed in or transferred to the MDL Court. Assertio Holdings has also been named in six such cases. In April 2022, the Judicial Panel on Multi-District Litigation issued an order stating that it would no longer transfer new opioid cases to the MDL Court. Since that time, Assertio Therapeutics has been named in lawsuits pending in federal courts outside of the MDL Court (one of which remains pending in Georgia). Plaintiffs may file additional lawsuits in which the Company may be named, and plaintiffs may also seek leave to add the Company to lawsuits already on file. Plaintiffs in the pending federal cases involving Assertio Therapeutics or Assertio Holdings include individuals; county, municipal and other governmental entities; employee benefit plans, health insurance providers and other payors; hospitals, health clinics and other health care providers; Native American tribes; and non-profit organizations who assert, for themselves and in some cases for a putative class, federal and state statutory claims and state common law claims, such as conspiracy, nuisance, fraud, negligence, gross negligence, negligent and intentional infliction of emotional distress, deceptive trade practices, and products liability claims (defective design/failure to warn). In these cases, plaintiffs seek a variety of forms of relief, including actual damages to compensate for alleged personal injuries and for alleged past and future costs such as to provide care and services to persons with opioid-related addiction or related conditions, injunctive relief, including to prohibit alleged deceptive marketing practices and abate an alleged nuisance, establishment of a compensation fund, establishment of medical monitoring programs, disgorgement of profits, punitive and statutory treble damages, and attorneys’ fees and costs. No trial date has been set for any of these lawsuits, which are at an early stage of proceedings. Assertio Therapeutics and Assertio Holdings intend to defend themselves vigorously in these matters.

State Opioid Litigation

Related to the federal cases noted above, there have been hundreds of similar lawsuits filed in state courts around the country, in which various groups of plaintiffs assert opioid-drug related claims against similar groups of defendants. Assertio Therapeutics is currently named in a subset of those cases, including cases in Delaware, Missouri, New York, Pennsylvania, Texas and Utah. Plaintiffs may file additional lawsuits in which the Company may be named. In the pending cases involving Assertio Therapeutics, plaintiffs are asserting state common law and statutory claims against the defendants, and the majority of those cases are similar in nature to the claims asserted in the MDL cases. Plaintiffs are seeking actual damages, disgorgement of profits, injunctive relief, punitive and statutory treble damages, and attorneys’ fees and costs. Assertio Therapeutics has reached a confidential settlement with the plaintiff in one of the state court cases (Tarnopol, et al. v. Janssen Pharmaceuticals, Inc, et al., Case No. 002584, in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania, Civil Trial Division), which did not have a material impact on the Company’s Consolidated Financial Statements. The other state lawsuits

in which Assertio Therapeutics has been served are generally each at an early stage of proceedings. Assertio Therapeutics intends to defend itself vigorously in these matters.

Qui Tam Litigation

The Company has learned that on October 30, 2017, a qui tam lawsuit was filed against Depomed in the United States District Court for the District of Columbia (United States of America ex rel. Webb, et al. v. Depomed, Inc., Case No. 1:17-cv-02309-JDB). The case was filed under seal and remained under seal until after an order was entered by the district court on July 12, 2024, which followed a notice from DOJ electing to intervene, in part, and declining to intervene, in part, and which granted DOJ’s request to unseal the complaint, DOJ’s notice concerning intervention, and DOJ’s proposed order concerning its intervention. The district court order gave DOJ and the relator until October 10, 2024, to serve their respective complaints on Depomed.

The relator’s complaint alleges that Depomed violated the federal False Claims Act, 31 U.S.C. § 3729, as well as similar laws in California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Jersey, New Mexico, New York, North Carolina, Oklahoma, Rhode Island, Tennessee, Texas, Vermont, Virginia, Washington, and the District of Columbia; the federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7(b)(2)(B); the United States Food, Drug and Cosmetic Act, 21 U.S.C. §§ 331(d), 355(a); and laws in California and Illinois concerning fraudulent insurance claims. The relator’s complaint generally alleges that Depomed marketed off-label uses for its drugs Gralise and Lazanda, which were divested in 2020 and 2017, respectively, and that Depomed paid illegal kickbacks to physicians to induce them to write Gralise and Lazanda prescriptions. The relator also alleges that Depomed retaliated against her for complaining about Depomed’s alleged unlawful conduct. On behalf of herself, the United States, the several states whose laws the Complaint alleges to have been violated, and certain unnamed insurance companies, the relator seeks, among other things, actual damages, treble damages, back pay, two times back pay, special damages, civil penalties, pre- and post-judgment interest, attorneys’ fees, costs, and expenses.

DOJ filed its notice of intervention on July 3, 2024, stating that the United States was intervening on the allegations that Depomed knowingly marketed Lazanda in a manner that caused the submission of false claims for Lazanda to Medicare and TRICARE. DOJ noted that the United States declined to intervene on all other allegations not related to Lazanda. Therefore, DOJ has declined to intervene with respect to the relator’s allegations concerning Gralise. DOJ stated that it would file its complaint in intervention within 90 days of its notice. The Company is not currently aware of any involvement in the lawsuit of any of the governments of the states (or the District of Columbia) on whose behalf the relator purports to act.

Assertio Therapeutics and DOJ entered negotiations around a potential settlement of the qui tam lawsuit, leading to a mediation on December 2, 2024. Following the conclusion of the mediation, Assertio Therapeutics and DOJ reached a settlement in principle. On December 9, 2024, DOJ filed a motion with the district court requesting a 90-day stay of the qui tam lawsuit to allow the parties to finalize settlement terms and obtain the necessary approvals. An expense and liability has been recorded for this settlement in principle to the Company’s consolidated financial statements for the year ended December 31, 2024.

Insurance Litigation

On April 1, 2022, Assertio Therapeutics filed a complaint against its former insurance broker, Woodruff-Sawyer & Co. (“Woodruff”), in the California Superior Court of Alameda (Case No. 22CV009380). Assertio Therapeutics alleged claims for negligence and breach of fiduciary duty in connection with Woodruff’s negotiation and procurement of products liability insurance coverage for Assertio Therapeutics.

During the second quarter of 2024, Assertio Therapeutics settled with Woodruff and received $1.9 million in connection with its claims for insurance reimbursement for previous opioid-related legal expenses, which was recognized within Selling, general and administrative expenses in the Company’s Consolidated Statements of Comprehensive Loss for the year ended December 31, 2024. Pursuant to the terms of the settlement, the complaint filed against Woodruff was dismissed with prejudice.

Stockholder Actions

Shapiro v. Assertio Holdings, Inc., et al., U.S. District Court, Northern District of Illinois, Case No. 1:24-cv-00169. On January 5, 2024, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Assertio and certain of its current and former executive officers made false or misleading statements and failed to disclose material facts regarding the likely impact of INDOCIN sales and the Spectrum Merger on Assertio’s profitability (the “Shapiro class action”). On April 11, 2024, the court appointed Continental General Insurance Company as the lead plaintiff. The plaintiff filed an amended complaint on June 10, 2024, that names as defendants Assertio and certain of its current and former officers and directors, and Spectrum and certain of its former officers and directors. It alleges violations of Sections 10(b) (and Rule 10b-5

8780

court appointed Continental General Insurance Company as the lead plaintiff. The plaintiffs filed an amended complaint on June 10, 2024, that names as defendants Assertio and certain of its current and former officers and directors, and Spectrum and certain of its former officers and directors. It alleges violations of Sections 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) between March 9, 2023 and January 3, 2024, and violations of Sections 14(a) and 20(a) of the Exchange Act in connection with the proxy statement issued in connection with the Spectrum Merger. The amended complaint seeks damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the ~~Court~~court. The defendants filed their motion to dismiss on August 9, 2024; the ~~plaintiffs~~plaintiff filed ~~their~~its opposition brief on October 10, 2024; and the defendants filed their reply brief on November 14, 2024. The Company intends to vigorously defend itself in this matter.

~~Edwards~~In v.re Assertio Holdings, Inc. Derivative Litigation, U.S. District Court, Delaware, Case No. 1:24-cv-00383-UNA. Two putative stockholder derivative actions (Jung v. Peisert, et al., U.S. District Court, ofDelaware, ~~Chancery~~Case ofNo. ~~the~~1:24-cv-00383-UNA, ~~State~~filed ofon March 26, 2024, and Hollin v. Mason, et al., U.S. District Court, Delaware, Case No. ~~2024~~1:24-~~0151.~~cv-00785-UNA, Onfiled ~~February~~on 19July 3, 2024,) ~~this~~were ~~putative~~filed ~~securities~~against ~~class~~the ~~action~~Company ~~lawsuit~~(as ~~was~~a ~~filed~~nominal bydefendant) aand ~~purported~~certain ~~shareholder~~of its current and former executive officers and directors. The stockholder derivative complaints allege, ~~alleging~~inter alia, that (1) certain of the Company’s current and former executive officers and directors are liable to the Company, pursuant to Section 10(b) and 21(d) of ~~Spectrum~~the Exchange Act for contribution and indemnification, relating to the same underlying claims as the Shapiro class action, (2) certain of the Company’s current and former officers and directors breached their fiduciary duties, inand ~~connection~~committed ~~the~~acts ~~Spectrum~~of ~~Merger~~gross ~~and~~mismanagement, ~~that~~abuse ~~Guggenheim~~of ~~Securities~~control, ~~LLC~~or ~~and~~were ~~Assertio~~unjustly ~~aided~~enriched, and ~~abetted~~(3) certain of the Company’s directors negligently violated Section 14(a) of the Exchange Act, by allegedly causing such ~~fiduciary~~false ~~duty~~or ~~breaches~~misleading statements to be issued and/or failing to disclose material facts about such matters. The ~~court~~plaintiffs ~~heard~~generally ~~oral~~seek ~~argument~~corporate onreforms, ~~the~~damages, ~~defendants~~interest, costs, attorneys’ ~~motion~~fees, toand ~~dismiss~~other onunspecified ~~January~~equitable 7relief. On September 5, ~~2025~~2024, ~~and~~the ~~entered~~court anconsolidated ~~order~~the ~~granting~~two stockholder derivative actions under the ~~defendants’~~caption ~~motion~~In onre ~~January~~Assertio 8Holdings, ~~2025~~Inc. ~~The~~Derivative ~~plaintiff’s~~Litigation. ~~deadlines~~On toNovember ~~seek~~4, ~~reconsideration~~2024, ~~and~~the parties filed a stipulation agreeing to ~~appeal~~stay the ~~dismissal~~consolidated ~~order~~action ~~passed~~pending ~~without~~proceedings ~~any~~in ~~further~~the Shapiro class action. byOn November 5, 2024, the ~~plaintiff~~court entered an order staying the consolidated action pursuant to the parties’ stipulation.

InJung rev. ~~Assertio Holdings~~Lebel, ~~Inc~~et al., ~~Derivative~~Court ~~Litigation,~~of ~~U.S.~~Chancery ~~District~~of ~~Court,~~the State of Delaware, Case No. ~~1:24~~2024-~~cv-00383-UNA.~~0821 ~~Two~~and ~~putative stockholder derivative actions (~~Jung v. ~~Peisert~~Turgeon, et al., ~~U.S.~~Court ~~District~~of ~~Court,~~Chancery of the State of Delaware, Case No. ~~1:24~~2024-~~cv-00383-UNA,~~0822. ~~filed~~On onAugust ~~March 26~~5, 2024, ~~and~~alleged ~~Hollin~~former v.Spectrum ~~Mason,~~stockholder etand ~~al.,~~current ~~U.S.~~Assertio ~~District~~stockholder ~~Court,~~Jung ~~Delaware,~~(the ~~Case~~same ~~No.~~plaintiff ~~1:24-cv-00785-UNA,~~who previously filed onJung ~~July~~v. 3Peisert, ~~2024)~~et. ~~were~~al., ~~filed~~in ~~against~~Delaware ~~the~~federal ~~Company~~court, (as adiscussed ~~nominal defendant~~above) ~~and~~filed ~~certain~~two ~~of its current and former executive officers and directors. The~~ stockholder derivative complaints ~~allege,~~in ~~inter~~the ~~alia,~~Delaware ~~that~~Chancery ~~(1)~~Court against certain ~~of the Company’s current and~~ former ~~executive~~Spectrum officers and directors ~~are~~and ~~liable~~naming toboth ~~the~~Assertio ~~Company, pursuant to Section 10(b)~~ and ~~21(d)~~Spectrum ofas ~~the~~nominal ~~Exchange~~defendants. ~~Act~~The ~~for~~complaints ~~contribution~~are, ~~and indemnification~~respectively, ~~relating~~largely toduplicative of the ~~same~~allegations ~~underlying~~in ~~claims~~(1) as the ~~Shapiro~~ongoing Ayoub shareholder class action ~~(discussed~~in ~~above),~~the ~~(2)~~Southern ~~certain~~District of ~~the~~New ~~Company’s~~York, ~~current~~ and ~~former~~(2) ~~officers~~the ~~and~~now-resolved ~~directors~~Luo ~~breached~~shareholder ~~their~~class ~~fiduciary~~action ~~duties,~~in ~~and~~the ~~committed~~District ~~acts~~ of ~~gross~~Nevada ~~mismanagement,~~(both ~~abuse~~cases ofdiscussed ~~control,~~below). orJung ~~were~~previously ~~unjustly~~raised ~~enriched,~~these ~~and~~allegations ~~(3)~~in ~~certain~~demand ofletters ~~the~~to ~~Company~~Assertio’s ~~directors~~Board, ~~negligently~~demanding ~~violated~~that ~~Section 14(a) of~~ the ~~Exchange~~Board ~~Act,~~take bylegal ~~allegedly~~action ~~causing~~against ~~such~~the ~~false~~individuals ornow ~~misleading~~named ~~statements~~in tothese becomplaints. ~~issued~~In ~~and/or~~response ~~failing~~ to ~~disclose~~Jung’s ~~material~~demand ~~facts~~letters, ~~about~~the ~~such~~Board ~~matters.~~retained ~~The~~independent ~~plaintiffs generally seek corporate reforms~~counsel, ~~damages,~~considered ~~interest, costs, attorneys~~Jung’s ~~fees~~demands, and ~~other~~provided ~~unspecified~~a ~~equitable~~substantive ~~relief.~~response Onexplaining ~~September~~the 5,Board’s ~~2024,~~reasons ~~the~~for ~~court~~denying ~~consolidated~~Jung’s ~~the~~demands. ~~two~~These ~~stockholder~~complaints ~~derivative~~now ~~actions~~allege ~~under~~that the ~~caption~~Board Inwrongfully rerefused ~~Assertio~~his ~~Holdings, Inc~~demands. ~~Derivative~~The ~~Litigation.~~individual Ondefendants ~~November~~have 4,not ~~2024,~~yet ~~the~~been ~~parties~~served ~~filed~~with aeither ~~stipulation~~complaint. ~~agreeing~~Assertio toand ~~stay~~Spectrum ~~the~~have ~~consolidated~~been ~~action~~served ~~pending~~with ~~proceedings~~and inmoved ~~the~~to ~~Shapiro~~dismiss ~~class~~both ~~action~~complaints. OnBriefing ~~November~~schedules 5,on ~~2024,~~ the ~~court~~motions ~~entered~~to andismiss ~~order~~have ~~staying~~not ~~the~~been ~~consolidated action pursuant to the parties’ stipulation~~set.

~~Jung~~Luo v. ~~Lebel~~Spectrum Pharmaceuticals, Inc., et al., ~~Court~~U.S. ofDistrict ~~Chancery~~Court, ofDistrict ~~the State~~ of ~~Delaware~~Nevada, Case No. ~~2024~~2:21-~~0821~~cv-01612. ~~and~~On ~~Jung~~August v.31, ~~Turgeon~~2021, etthis ~~al.~~putative securities class action lawsuit was filed by a purported shareholder, ~~Court~~alleging that Spectrum and certain of ~~Chancery~~its former executive officers and directors made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its Biologic License Application (“BLA”) to the ~~State~~FDA for ROLVEDON in violation of ~~Delaware,~~Section ~~Case~~10(b) ~~No.~~(and ~~2024~~Rule 10b-~~0822~~5 promulgated thereunder) and 20(a) of the Exchange Act. On ~~August~~July 528, ~~2024~~2022, ~~alleged~~the ~~former~~court ~~Spectrum~~appointed ~~stockholder~~a ~~and~~lead ~~current~~plaintiff ~~Assertio~~and ~~stockholder~~counsel ~~Jung~~for (the ~~same~~putative ~~plaintiff~~class. ~~who~~On ~~previously~~September ~~filed~~26, ~~Jung~~2022, v.an ~~Peisert~~amended complaint was filed alleging, ~~et.~~inter ~~al.~~alia, infalse ~~Delaware~~and ~~federal~~misleading ~~court,~~statements aswith ~~discussed~~respect ~~above)~~to ~~filed~~ROLVEDON ~~two~~manufacturing ~~stockholder~~operations ~~derivative~~and ~~complaints~~controls inand ~~the~~adding ~~Delaware~~allegations ~~Chancery~~that ~~Court~~defendants ~~against~~misled ~~certain~~investors ~~former~~about ~~Spectrum~~the ~~officers~~efficacy ~~and~~of, ~~directors~~clinical trial data and ~~naming~~market ~~both~~need ~~Assertio~~for ~~and~~poziotinib ~~Spectrum~~during asa ~~nominal~~Class ~~defendants~~Period of March 7, 2018 to August 5, 2021. The ~~complaints~~amended ~~are~~complaint sought damages, ~~respectively~~interest, ~~largely~~costs, ~~duplicative~~attorneys’ offees, and such other relief as may be determined by the ~~allegations~~court. inOn ~~(1)~~October 7, 2024, the ~~ongoing~~court ~~Christiansen~~granted ~~shareholder~~in ~~class~~part ~~action~~and denied in part the ~~Southern~~defendants’ ~~District~~motion to dismiss. Some of ~~New~~the ~~York~~claims ~~(discussed~~were ~~below)~~dismissed with prejudice, and ~~(2)~~some ~~the~~claims ~~ongoing~~plaintiffs ~~Luo~~were ~~shareholder~~permitted ~~class~~to ~~action~~re-plead. inOn April 10, 2025, the ~~District~~parties ofprovided ~~Nevada~~a ~~(discussed~~joint ~~below).~~notice ~~Jung~~to ~~previously~~the ~~raised~~court ~~these~~that ~~allegations~~they inreached ~~demand~~an ~~letters~~agreement in principle to ~~Assertio’s~~settle ~~Board~~this ofmatter, ~~Directors~~and ~~(“the~~on ~~Board”)~~May 9, ~~demanding~~2025, ~~that~~ the ~~Board~~parties ~~take~~submitted ~~legal~~formal ~~action~~settlement ~~against~~papers to the ~~individuals~~court ~~now~~for ~~named~~preliminary approval. As identified in ~~these~~the ~~complaints.~~settlement Inpapers ~~response~~submitted to ~~Jung’s~~the ~~demand letters~~court, the ~~Board~~parties ~~retained~~agreed ~~independent~~to ~~counsel~~a settlement of $16.0 million, ~~considered~~of ~~Jung’s~~which ~~demands~~the Company was responsible for paying approximately $2.7 million, ~~and~~with ~~provided~~insurance acovering ~~substantive~~the ~~response~~remainder. ~~explaining~~During the ~~Board’s~~second ~~reasons~~quarter ~~for~~of ~~denying~~2025, ~~Jung’s~~the ~~demands~~$16.0 ~~These~~million ~~complaints~~liability ~~now~~was ~~allege~~recorded ~~that~~in Accrued liabilities, while the ~~Board~~$13.3 ~~wrongfully~~million ~~refused~~insurance ~~his~~receivable ~~demands.~~was ~~The~~recorded ~~individual~~in ~~defendants~~Prepaid ~~have~~and ~~not~~other ~~yet~~current ~~been~~assets, ~~served~~in ~~with~~the ~~either~~Company’s ~~complaint~~Consolidated Balance Sheets. ~~Assertio~~In June 2025, the court entered an order preliminarily approving the settlement, and ~~Spectrum~~thereafter ~~have~~in ~~been~~July ~~served~~2025, ~~with~~the Company and ~~moved~~the toinsurers ~~dismiss~~funded ~~both~~an ~~complaints~~escrow account with the settlement proceeds, resulting in derecognition of the insurance receivable and liability. ~~Briefing~~The ~~schedules~~court ongranted final approval of the ~~motions~~settlement toat ~~dismiss~~a ~~have~~hearing ~~not~~on ~~been~~October ~~set~~20, 2025.

Luo v. Spectrum Pharmaceuticals, Inc., et al., U.S. District Court, District of Nevada, Case No. 2:21-cv-01612. On August 31, 2021, this putative securities class action lawsuit was filed by a purported shareholder, alleging that Spectrum and certain of its former executive officers and directors made false or misleading statements and failed to disclose material facts about Spectrum’s business and the prospects of approval for its Biologic License Application (“BLA”) to the FDA for ROLVEDON in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act. On July 28, 2022, the Court appointed a lead plaintiff and counsel for the putative class. On September 26, 2022, an amended complaint was filed alleging, inter alia, false and misleading statements with respect to ROLVEDON manufacturing operations and controls and adding allegations that defendants misled investors about the efficacy of, clinical trial data and market need for poziotinib during a Class Period of March 7, 2018 to August 5, 2021. The amended complaint seeks damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. On October 7, 2024, the Court granted in part and denied in part the defendants’ motion to dismiss. Some of the claims were dismissed with prejudice, and some claims plaintiffs are permitted to replead. The parties have scheduled mediation for March 20, 2025 (the “March 20 mediation”). Pursuant to the current scheduling order in the case, the parties are engaged in certain defined discovery prior to the March 20 mediation. If the 81

88Ayoub v. Spectrum Pharmaceuticals, Inc. et al., Case No. 1:22-cv-10292. On December 5, 2022, a class action lawsuit was filed in the U.S. District Court for the Southern District of New York (the “New York Action”). Three additional related putative securities class action lawsuits were subsequently filed by Spectrum shareholders against Spectrum and certain of its former executive officers in the U.S. District Court for the Southern District of New York: Osorio-Franco v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10292 (filed December 5, 2022); Cummings v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10677 (filed December 19, 2022); and Carneiro v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:23-cv-00767 (filed January 30, 2023). These three additional New York lawsuits allege that Spectrum and certain of its former executive officers made false or misleading statements about, inter alia, the safety and efficacy of and clinical trial data for poziotinib in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act, and seek remedies including damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the court. The court consolidated the three additional New York lawsuits and entered an order designating Christiansen as the lead plaintiff. Lead plaintiff Christiansen filed an amended consolidated complaint in the New York Action under the caption Christiansen v. Spectrum Pharmaceuticals, Inc, et al., on May 30, 2023, alleging a Class Period between March 17, 2022 and September 2022. On January 23, 2024, the court granted the defendants’ motion to dismiss as to five of the challenged statements but denied the motion to dismiss as to two specific statements. On October 25, 2024, a Spectrum stockholder (Ayoub) filed a substantially similar putative securities class action complaint asserting the same claims against the same defendants on behalf of the same alleged class as the New York Action. On October 30, 2024, Christiansen and Ayoub jointly moved for class certification and for appointment as class representatives in the New York Action. On November 4, 2024, defendants moved to disqualify Christiansen from serving as lead plaintiff and for a stay of proceedings pending appointment of a substitute lead plaintiff. On November 6, 2024, the court entered an order staying both cases pending resolution of the defendants’ motion to disqualify Mr. Christiansen as lead plaintiff. On August 4, 2025, the court entered an order granting the defendants’ motion to disqualify Christiansen from serving as lead plaintiff and reopening the lead plaintiff appointment process with applications to serve as substitute lead plaintiff due by September 24, 2025. Three individuals filed applications to serve as lead plaintiff, with one ultimately withdrawing from consideration. On January 6, 2026, the court issued an opinion and order regarding the two remaining applications, granting the application filed by Ayoub and denying the other remaining application. In addition to appointing Ayoub as lead plaintiff, the court terminated the original Ayoub case and consolidated it with the Christiansen case, which is now recaptioned Ayoub et al. v. Spectrum Pharmaceuticals, Inc. et al., Case No. 1:22-cv-10292-VEC. On January 20, 2026, the parties submitted a joint letter informing the court of their intention to mediate and subsequently scheduled mediation to take place on April 27, 2026. The court thereafter entered an order requiring the parties to submit a joint letter to the court within three business days following the conclusion of the mediation (but in any event not later than May 8, 2026) to report whether the mediation resulted in a settlement, and, if not, to propose next steps in the case. The Company intends to vigorously defend itself in this matter.

~~parties~~Enyart ~~are~~v. ~~unable~~Assertio toHoldings, ~~reach~~Inc., anet. ~~agreement~~al. ~~resolving~~In the ~~case~~Circuit atCourt of the ~~March~~Nineteenth 20Judicial ~~mediation~~Circuit, ~~the~~Lake ~~lead~~County, ~~plaintiff~~Illinois, ~~will~~Case ~~have~~No. an2024LA00000842. ~~opportunity~~On byNovember ~~April~~8, 42024, ~~2025~~this putative securities class action lawsuit was filed by an alleged former Spectrum shareholder who received Assertio shares in the Spectrum Merger, toalleging ~~amend~~that ~~certain~~Assertio ~~aspects~~and certain of its ~~complaint~~current ~~that~~and ~~were~~former ~~dismissed~~officers ~~without~~and ~~prejudice.~~directors Inviolated Sections 11, 12(a)(2), and 15 of the ~~event~~Securities Act of 1933 in connection with the ~~lead~~registration ~~plaintiff~~statement ~~exercises~~for ~~its~~the ~~option~~Assertio toshares ~~amend~~issued ~~its~~in ~~complaint~~connection with the Spectrum Merger. In general terms, the ~~parties~~complaint ~~will~~alleges ~~have~~that ~~seven~~the ~~days~~registration ~~thereafter~~statement contained misrepresentations and omissions related to ~~confer~~the onvalue ~~and~~of ~~submit~~adding aROLVEDON ~~proposed~~to ~~schedule~~Assertio’s ~~for~~portfolio ~~briefing~~of products and the ~~defendants~~risk to Assertio’s ~~anticipated~~business ~~motion~~from potential generic competition to ~~dismiss~~INDOCIN. The complaint sought compensatory damages, rescission or a rescissory measure of damages, interest, costs, attorneys’ fees, expert witness fees, and other ~~responsive~~unspecified ~~filing~~equitable relief. InOn June 24, 2025, the ~~event~~court granted the ~~lead~~defendants’ ~~plaintiff~~motion ~~does~~to ~~not~~dismiss, ~~exercise~~dismissing the complaint in its ~~option~~entirety, while granting leave to ~~amend~~re-plead with respect to certain claims. On July 18, ~~the~~2025, ~~defendants’~~Enyart ~~answer~~filed ~~will~~an beamended ~~due~~complaint. onOn ~~April~~September 2529, 2025, the defendants filed a motion to dismiss the amended complaint. ~~The~~On ~~lead~~February ~~plaintiff~~10, 2026, the court entered an order granting the defendants’s motion ~~for~~to ~~class~~dismiss ~~certification~~in isits ~~due~~entirety, onwhile ~~May~~granting 30Enyart “one final opportunity and until March 13, ~~2025~~2026, ~~and~~to ~~fact~~attempt ~~discovery~~to isreplead” ~~scheduled~~with respect to becertain ~~complete~~claims. byThe ~~December~~court also scheduled a status conference following the re-pleading deadline, which will take place on March 18, ~~2025~~2026. ~~Trial~~On March 13, 2026, Enyart filed a second amended complaint. A schedule for a motion to dismiss the second amended complaint has not yet been ~~scheduled~~established. The Company intends to vigorously defend itself in this matter.

~~Christiansen~~Assertio v.Therapeutics ~~Spectrum~~Opioid ~~Pharmaceuticals,~~Litigation Inc. et al., Case No. 1:22-cv-10292 (filed December 5, 2022 in the U.S. District Court for the Southern District of New York) (the “New York Action”). Three additional related putative securities class action lawsuits were subsequently filed by Spectrum shareholders against Spectrum and ~~certain~~Related of its former executive officers in the U.S. District Court for the Southern District of New York: Osorio-Franco v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10292 (filed December 5, 2022); Cummings v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:22-cv-10677 (filed December 19, 2022); and Carneiro v. Spectrum Pharmaceuticals, Inc., et al., Case No. 1:23-cv-00767 (filed January 30, 2023). These three New York lawsuits allege that Spectrum and certain of its former executive officers made false or misleading statements about, inter alia, the safety and efficacy of and clinical trial data for poziotinib in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Exchange Act, and seek remedies including damages, interest, costs, attorneys’ fees, and such other relief as may be determined by the Court. The Court consolidated the three New York lawsuits and entered an order designating Steven Christiansen as the lead plaintiff. Lead plaintiff Christiansen filed an amended consolidated complaint in the New York Action under the caption Christiansen v. Spectrum Pharmaceuticals, Inc, et al., on May 30, 2023, alleging a Class Period between March 17, 2022 and September 2022. On January 23, 2024, the Court granted the defendants’ motion to dismiss as to five of the challenged statements but denied the motion to dismiss as to two specific statements. On October 25, 2024, a Spectrum stockholder (Ayoub) filed a substantially similar putative securities class action complaint asserting the same claims against the same defendants on behalf of the same alleged class as the New York Action. On October 30, 2024, Christiansen and Ayoub jointly moved for class certification and for appointment as class representatives in the New York Action. On November 4, 2024, defendants moved to disqualify Christiansen from serving as lead plaintiff and for a stay of proceedings pending appointment of a substitute lead plaintiff. On November 6, 2024, the Court entered an order staying both cases pending resolution of the defendants’ motion to disqualify Mr. Christiansen as lead plaintiff, which is now fully briefed and remains pending. The Company intends to vigorously defend itself in this matter.Matters

~~Csaba~~As v.noted ~~Turgeon, et. al. (filed December 15, 2021~~ in ~~the~~Note U2.S. ~~District~~Divestitures ~~Court~~and ~~District~~Strategic ofTransactions, ~~Nevada);~~on ~~Shumacher~~May ~~v. Turgeon~~9, ~~et. al. (filed March 15~~2025, ~~2022 in~~ the ~~U.S.~~Company ~~District~~transferred ~~Court~~all ~~District~~the ofequity ~~Nevada);~~interests ~~Johnson~~in v.Assertio ~~Turgeon,~~Therapeutics ~~et.~~to ~~al.~~ATIH ~~(filed March 29~~Industries, ~~2022 in the U~~LLC.S. ~~District~~As ~~Court~~a ~~District~~result of ~~Nevada);~~that ~~Raul v. Turgeon~~divestiture, ~~et.~~neither ~~al. (filed April 28, 2022 in~~ the ~~U.S.~~Company ~~District~~nor ~~Court~~any ~~District~~ of ~~Delaware);~~its ~~and~~subsidiaries ~~Albayrak~~are v.defendants ~~Turgeon,~~in ~~et.~~any ~~al.~~opioid-related ~~(filed June 9~~litigation, ~~2022~~including in the ~~U.S.~~opioid-related ~~District~~matters ~~Court~~described ~~District~~in of“Note ~~Nevada)~~8. ~~These~~Commitments ~~putative stockholder derivative actions were filed against Spectrum (as a nominal defendant)~~ and ~~certain~~Contingencies” of ~~Spectrum’s former executive officers and directors. Following~~ the ~~decision~~Notes ~~on the motion~~ to ~~dismiss in~~ the ~~Luo~~consolidated ~~class~~financial ~~action,~~statements ~~the~~included ~~stays~~in ~~were~~Part ~~lifted by the Nevada court on October 7~~II, ~~2024.~~Item ~~The~~8 ~~defendants then requested that the plaintiffs voluntarily agree to dismiss these suits for lack~~ of ~~standing and~~ the ~~Csaba,~~Company’s ~~Schumacher,~~2024 ~~Johnson,~~Form ~~Raul and Albayrak suits have now all been dismissed by agreement on this basis~~10-K.

Enyart v. Assertio Holdings, Inc., et. al., In the Circuit Court of the Nineteenth Judicial Circuit, Lake County, Illinois, Case No. 2024LA00000842. On November 8, 2024, this putative securities class action lawsuit was filed by an alleged former Spectrum shareholder who received Assertio shares in the Spectrum Merger, alleging that Assertio and certain of its current and former officers and directors violated Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 in connection with the registration statement for the Assertio shares issued in connection with the Spectrum Merger. In general terms, the complaint alleges that the registration statement contained misrepresentations and omissions related to the value of adding ROLVEDON to Assertio’s portfolio of products. The complaint seeks compensatory damages, rescission or a recessionary measure of damages, interest, costs, attorneys’ fees, expert witness fees, and other unspecified equitable relief. On February 21, 2025, the defendants moved to dismiss the complaint. The Company intends to vigorously defend itself in this matter.82

NOTE 9. EMPLOYEE BENEFIT PLANS

The Company's 401(k) Employee Savings Plan (the “401(k) Plan") is available to U.S. employees meeting certain eligibility criteria. The Company has elected to make matching contributions in an amount equal to 100% of elective deferral contributions that are not over 5% of compensation. The Company may make discretionary matching contributions for employees.

89The Company recognized expense of $0.6 million related to its matching contributions made to the 401(k) Plan during each of the years ended December 31, 2025 and 2024. The Company's common stock is not an investment option available to participants in the 401(k) Plan.

The Company recognized expense of $0.6 million and $0.4 million related to its matching contributions made to the 401(k) Plan during the years ended December 31, 2024 and 2023, respectively. The Company's common stock is not an investment option available to participants in the 401(k) Plan.

NOTE 10. STOCK-BASED COMPENSATION

~~For~~Refer ~~the~~to ~~years~~Note ~~ended~~1. ~~December~~Organization ~~31, 2024~~ and ~~2023,~~Summary ~~stock-based compensation expense~~ of ~~$5.0 million~~Significant ~~and~~Accounting ~~$9.2 million~~Policies, ~~respectively,~~for ~~was~~further ~~recognized~~discussion inof ~~Selling, general and administrative expenses in~~ the Company’s ~~Consolidated Statements of Comprehensive Loss. The recognized tax benefits on total~~ stock-based compensation ~~expense was $1~~policies.~~2 million and $1.5 million for the years ended December 31, 2024 and 2023, respectively.~~

AsFor ofthe years ended December 31, 2025 and 2024, ~~the~~stock-based ~~Company~~compensation ~~had~~expense of $23.2 5 million and $35.8 0 million, ofrespectively, ~~total~~was ~~unrecognized~~recognized ~~compensation~~in ~~expense~~Selling, ~~related~~general toand ~~RSU~~administrative ~~and~~expenses ~~stock~~in ~~option~~the ~~grants,~~Company’s ~~respectively,~~Consolidated ~~that~~Statements ~~will~~of beComprehensive Loss. The recognized ~~over~~tax abenefits ~~weighted~~on total stock-~~average~~based ~~vesting~~compensation ~~period~~expense ofwere 1$0.678 million ~~years~~ and 2$1.002 million for the years ended December 31, 2025 and 2024, respectively.

As of December 31, 2025, the Company had $1.5 million and $2.3 million of total unrecognized compensation expense related to RSU and stock option grants, respectively, that will be recognized over a weighted-average vesting period of 1.99 years and 2.00 years, respectively.

2014 Omnibus Incentive Plan

The Company’s 2014 Omnibus Incentive Plan was adopted by the Board of Directors and approved by the shareholders in May 2014, and subsequently amended and restated through May ~~2024~~2025 (so as amended and restated, the “2014 ~~Amended~~Omnibus Plan”). The 2014 ~~Amended~~Omnibus Plan provides for the grant of stock options, stock appreciation rights, stock awards, cash awards and performance awards to the employees, non-employee directors and consultants of the Company. At December 31, ~~2024~~2025, the number of shares authorized under the 2014 ~~Amended~~Omnibus Plan was 201,~~135~~888,~~000~~997 shares, of which 7750,~~501,136~~589 were available for future issuance.

Generally, the exercise price of incentive stock options and non-statutory stock options granted under the 2014 ~~Amended~~Omnibus Plan must be the fair value of the common stock of the Company on the grant date. The term of incentive and non-statutory stock options may not exceed 10 years from the date of grant. A stock option shall be exercisable on or after each vesting date in accordance with the terms set forth in the stock option agreement. The right to exercise a stock option generally vests over three years at a rate of 33% annually or ratably in monthly installments over the vesting period.

Time-based RSUs generally vest over one or 3 years, with 100% or 33% of each award vesting annually, respectively.

Inducement Incentive Plan

Under the Company’s Inducement Incentive Plan adopted by the Board of Directors (the “Inducement Plan”), the Company grants time-based RSUs and stock options to recipients thereof as an inducement material to each respective recipient’s entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). These inducement awards are subject to such employee’s continued service relationship with the Company, with terms and conditions substantially identical to the terms and conditions of the 2014 ~~Amended~~Omnibus Plan and the award agreements pursuant to which they were granted. The time-based RSUs and options vest on an annual basis over three years beginning on the anniversary of each individual’s applicable employment commencement date. At December 31, ~~2024~~2025, the number of shares authorized under the Inducement Plan was 3254,~~820,547~~702 shares, of which ~~647~~170,~~087~~723 were available for future issuance.

Time-Based Stock Options

The following table reflects assumptions used to calculate the fair value of time-based stock option grants under the 2014 ~~Amended~~Omnibus Plan and the Inducement Plan for the years ended December 31, ~~2024~~2025 and ~~2023~~2024:

	December 31,
	2024			2023
	2025			2024
Risk-free interest rate	3.5667%	—	4.5444%	3.3856%	—	4.7954%
Dividend yield	—%			—%
Expected option term (in years)	45.05	—	6.0	4.0	—	6.0
Expected stock price volatility	~~125~~121%	—	~~138~~126%	~~120~~125%	—	~~141~~138%

The weighted-average grant date fair value of time-based stock options granted during the years ended December 31, ~~2024~~2025 and ~~2023~~2024 was $010.8353 and $412.3543 per option share, respectively. Total grant date fair value of options that vested during the years ended December 31, ~~2024~~2025 and ~~2023~~2024 was $32.35 million and $13.63 million, respectively. There were no time-based stock options exercised during the years ended December 31, 2025 and 2024.

90The following tables reflects the time-based stock option activity for the year ended December 31, 2025 (dollar amounts in thousands):

options exercised during the year ended December 31, 2024. The total intrinsic value of options exercised during the year ended December 31, 2023 was $0.7 million, and net cash received from stock options exercised during the year ended December 31, 2023 was $0.2 million.


	Shares	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Options outstanding as of December 31, 2024	491,524	$	21.58
Options granted	292,032	$	11.87
Options exercised	—	$	—
Options forfeited	(206,266)	$	13.93
Options expired	(14,023)	$	47.79
Options outstanding as of December 31, 2025	563,267	$	18.69	7.3	$	—
Options vested and expected to vest at December 31, 2025	563,267	$	18.69	7.3	$	—
Options exercisable as of December 31, 2025	259,011	$	24.74	5.5	$	—

The following tables reflects the time-based stock option activity for the year ended December 31, 2024 (dollar amounts in thousands):

	Shares	Weighted-AverageExercisePrice		Weighted-AverageRemainingContractualTerm (years)	AggregateIntrinsic Value(in thousands)
Options outstanding as of December 31, 2023	3,797,819	$	3.00
Options granted	5,814,391	$	0.93
Options exercised	—

Filing Compare · Assertio Holdings, Inc.